

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 323 806 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **17.03.93** (51) Int. Cl.⁵: **C12N 15/00, A61K 39/395, C12P 21/00, C12N 5/00, G01N 33/574**
- (21) Application number: **88810598.2**
- (22) Date of filing: **28.12.88**

The applicant has filed a statement in accordance with Rule 28(4) EPC (issue of a sample only to an expert). Accession Number(s) of the deposit(s): I-720 and I-818.

(54) **Novel chimeric antibodies.**

- (30) Priority: **05.01.88 GB 8800077**
24.08.88 GB 8820099
- (43) Date of publication of application:
12.07.89 Bulletin 89/28
- (45) Publication of the grant of the patent:
17.03.93 Bulletin 93/11
- (84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE
- (56) References cited:
EP-A- 0 125 023

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 81, June 1984;
S.CABILLY et al., pp. 3273-3277*

THE JOURNAL OF IMMUNOLOGY, vol. 141, no. 11, 01 December 1988, American Association of Immunologists (US); **C.B.BEIDLER et al.**, pp. 4053-4060*

JOURNAL OF IMMUNOLOGY, vol. 130, 1983; pp. 2302, 2308*

- (73) Proprietor: **CIBA-GEIGY AG**
Klybeckstrasse 141
CH-4002 Basel(CH)
- (72) Inventor: **Hardman, Norman, Dr.**
Gstaltenrainweg 67/3
CH-4125 Riehen(CH)
Inventor: **Gill, Laura Lee, Dr.**
Gstaltenrainweg 67
CH-4125 Riehen(CH)
Inventor: **de Winter, Ronald F.J., Dr.**
Holly Tree Cottage, Flewton End
Milton Ernest, Bedfordshire(GB)
Inventor: **Wagner, Kathrin**
Sundgauerstr. 12
CH-4055 Basle(CH)
Inventor: **Heusser, Christoph, Dr.**
Im Bertschenacker 21
CH-4103 Bottmingen(CH)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description**FIELD OF THE INVENTION**

5 This invention relates to mouse/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies, processes for the preparation of said cell lines, the use of the chimeric monoclonal antibodies and their
 10 derivatives for the diagnosis and therapy of cancer, test kits containing the chimeric monoclonal antibodies, and pharmaceutical preparations containing said antibodies.

BACKGROUND OF THE INVENTION

15 Immunoglobulins (antibodies) play an important role in the immune system of mammals. They are produced by plasma cells and consist of two identical light (L) polypeptide chains and two identical heavy (H) polypeptide chains joined by disulfide bridges, or polymers of this basic four chain unit. The light chains are of type κ or λ , the heavy chains of type μ , δ , γ , α or ϵ . Each chain consists of a variable (V) region and a constant (C) region. The V-regions, which show considerable sequence differences in antibodies with
 20 different specificity, comprise highly variable parts, so-called hypervariable or complementarity determining regions (CDRs), flanked by relatively conserved parts, so-called framework regions (FRs).

Antibodies are bifunctional molecules. On the one hand, the N-terminal variable segments of the H- and L-chain polypeptides associate in a highly specific and individual manner, generating a three-dimensional structure with a unique affinity for particular chemical motifs (epitopes) on the surface of an antigen, i.e. a
 25 molecule which is recognized as foreign by the organism and induces an immune response. Such epitopes can be small-molecular-weight molecules (haptens) or parts of macromolecular chemical structures such as proteins, carbohydrates and glycoproteins, e.g. cell-surface antigens.

The unique antigen-combining characteristics of the immunoglobulin (Ig) molecule results from genetic recombination of H- and L-chain germline genes early in B-cell differentiation, for example during
 30 embryogenesis: one of several hundred V-segments is joined to one of a small number of joining segments (J-segments) and, in the case of the H-chain locus, additional diversity segments (D-segments), forming a totally unique contiguous V-(D)-J rearranged gene segment coding for an Ig molecule with specific antigen-combining characteristics. In addition to antibody diversity caused by simple gene recombination, the precise junction at which V and J segment genes combine may vary slightly. As the joining reaction can
 35 occur between different base pairs and additional nucleotides can be added during the recombination process, several different amino acids, not coded in the germline, can be inserted at the site of each potential V-J or D-J combination. Furthermore, somatic mutation of single bases also contributes to Ig diversity.

The other key structural feature of Ig molecules is their ability to activate diverse biological pathways in
 40 the immune system. These so-called effector functions (complement binding, stimulation of phagocytosis, triggering of granule release by mast cells) reside primarily in the carboxy-terminal constant region segments of the H-chain polypeptides, giving rise to different Ig classes (IgA, IgE, IgG, etc.) which define the role of the antibody in a particular immune response.

The development of hybridoma technology has made it possible to generate continuous cell lines,
 45 mostly murine hybridomas, producing monoclonal antibodies of desired specificity which can be used to identify, isolate and characterize biologically important molecules. However, a major limitation in the use of murine-derived monoclonal antibodies as in vivo diagnostic and therapeutic agents is their immunogenicity as foreign proteins, their rather long persistence in the circulation, and the formation of damaging immune complexes. On the other hand, the treatment with human monoclonal antibodies is limited also since human
 50 hybridoma cell lines are rarely available, usually unstable and do not produce monoclonal antibodies of appropriate specificity in sufficient quantities and at reasonable costs.

A promising alternative is the modification of immunoglobulin genes by using recombinant DNA technology. One approach to decrease immunogenicity and to avoid undesired immune response, for
 55 example, is the production of chimeric antibodies with the advantages and the selectivity of murine monoclonals, yet the species specific properties of human antibodies.

The overall strategies applicable for the assembly of chimeric genes and the production of chimeric antibodies involve standard procedures of recombinant DNA technology (identification and isolation of Ig genes, insertion of the cloned genes into vectors, transfection into immortalized cell lines, expression of

chimeric proteins). Depending on the source of the genes to be combined and on the nature of the genes coding for the antigen-specific variable region, however, particular problems arise so that new and inventive steps are required to develop workable solutions.

Several research groups have attempted to engineer chimeric antibodies. Their research objectives differ in the conceptual approach, however, and the research results vary considerably with regard to the nature and characteristics of the recombinant molecules.

Chimeric antibodies of several immunoglobulin classes have been produced.

Neuberger et al. (Nature 314, 268, 1985) describe a chimeric IgE λ 1 antibody whose heavy chain is composed of a human ϵ constant region fused to a mouse variable region specific for the hapten 4-hydroxy-3-nitrophenacetyl (NP). The strategy used in the production of the chimeric antibody is to construct a chimeric gene coding for the heavy chain and to introduce this chimeric DNA segment into the J558L mouse cell line in which the expressed chimeric heavy chain is assembled with the endogenous mouse light chain to produce complete IgE molecules.

Boulianne et al. (Nature 312, 643, 1984) succeeded in linking the variable regions of the heavy and light chains from an anti-TNP mouse myeloma to human μ and κ genes, respectively. The chimeric genes were transfected into myeloma cells. The secreted IgM, however, was not as effective as the original mouse IgM and showed different binding qualities.

The generation of chimeric immunoglobulin G by joining human γ constant genes to murine variable genes has been described by various authors.

Patent application WO 87/02671 describes a chimeric antibody which binds to viral antigens, especially hepatitis B surface antigen, created from a human γ 1 region and a variable region from mouse myeloma CRL 8017. The authors also constructed a mouse/human chimeric antibody on the basis of the mouse monoclonal antibody (MAb) L6, as did Liu et al. (Proc. Natl. Acad. Sci. 84, 3439, 1987). MAb L6 [IgG2a(κ)] binds to a carbohydrate antigen found on the surface of cells derived from a variety of human carcinomas. The authors give exact data for the human colon carcinoma cell line C-3347. The γ 2a and κ constant regions of MAb L6 were substituted by human γ 1 and κ constant regions by recombining cDNA modules encoding variable or constant region domains.

Another chimeric monoclonal antibody directed to the surface antigens of human carcinomas was constructed by Sahagan et al. (J. Immunol. 137, 1066, 1986) who fused variable region exons from the IgG1 antibody of the murine hybridoma cell line B6.2 to human γ 1/ κ genes. Binding characteristics for the chimeric Ig were determined with A549.E1 human lung carcinoma cells.

Sun et al. (Proc. Natl. Acad. Sci. 84, 214, 1987) combined DNA fragments coding for the H-chain/L-chain variable regions of anti-colorectal carcinoma (ACRC) antibody, produced by mouse hybridoma 1083-17-A, with human γ 3/C κ regions.

The chimeric MAbs which are subject of the present invention are directed against carcinoembryonic antigen (CEA). CEA is a complex immunoreactive glycoprotein with a molecular weight of 180,000 found in adenocarcinomas of endodermally derived digestive system epithelia and foetal colon. The role of CEA immunoassays for diagnosis and serially monitoring cancer patients for recurrent disease or response to therapy has been widely evaluated and documented. One of the major drawbacks of the use of anti-CEA antibodies for the above purposes has been the cross-reactivity of these reagents with some apparently normal adult tissues.

Previous studies have shown that most conventional hyperimmune antisera raised against CEA using different immunogens cross-react with many different types of carcinomas as well as CEA-related antigens, e.g. non-specific cross-reacting antigen NCA, tumor-extracted CEA-related antigen TEX, various normal faecal antigens (NFA1, NFA2), biliary glycoprotein-I and others, found in normal colonic mucosa, spleen, liver, lung, sweatglands, polymorphonuclear leukocytes and monocytes of apparently normal individuals (for an overview, cf. Herberman & McIntire, "Immunodiagnosis of Cancer", Vol. 9, part 1, N.Y., 1979). This means that the antisera recognize epitopes specific for CEA alone as well as epitopes present on both CEA and CEA-related antigens; it further suggests closely related genes between CEA and CEA-related antigens as well as precursor-product relationships between some of them.

It is suggested that polyclonal antibodies (rabbit, sheep) recognize 10-15 antigenic sites in CEA (Sundblad et al., Protides Biol. Fluids 24, 435, 1976). The epitopes are predominantly located on the peptide moieties of CEA and appear to be strongly conformation dependent. Using monoclonal antibodies, at least 5 different epitopes were detected in CEA (Hedin et al., Mol. Immunol. 23, 1053, 1986).

Anti-CEA monoclonal antibodies have already been employed for the production of chimeric antibodies. In patent application EP 0 125 023, an Ig γ 1 antibody originating from hybridoma cell line CEA.66-E3 is used. The chimeric antibody is not characterized with regard to epitope specificity or cross-reactivity nor are binding or inhibition data included. The inventors describe the use of *E. coli* for the cloning of DNA

fragments and the expression of the chimeric genes. It is well established, however, that prokaryotic cells do not provide the necessary steps for biosynthesis of functional tetrameric antibodies, such as correct nascent polypeptide chain folding, glycosylation and assembly. The inventors of EP 0 125 023 describe (Proc. Natl. Acad. Sci. 81, 3273, 1984) that no detectable antibody activity is found in *E. coli* coproducing IgG H- and L-chains for the original mouse antibody when prepared following the guidance of the patent specification. The specification lists a number of possible host cells, also including mammalian cells, but these suggestions are not substantiated by the examples. The conceptual approach to the production of chimeric antibodies in the above cited patent application therefore lacks the basis for the expression of the recombinant gene constructs and thus, the secretion of active monoclonal antibodies.

OBJECT OF THE INVENTION

The object of the invention is the construction of novel chimeric monoclonal antibodies (MAbs) which

- possess murine variable and human constant region determinants,
- bind specifically to human carcinoembryonic antigen,
- are produced at a high level in immortalized mammalian cell lines,
- can be used for diagnostic and therapeutic purposes.

In view of the complex antigenic structure of the CEA molecule, the desired chimeric anti-CEA MAbs must have the following characteristics:

- high affinity for CEA,
- high percentage of binding to CEA-carrying carcinoma cells, both in vitro and in vivo.
- low percentage or absence of binding to normal tissues and cells.



DESCRIPTION OF THE INVENTION

The invention concerns chimeric monoclonal antibodies consisting of variable regions of mouse origin and human constant regions, which recognize human carcinoembryonic antigen (CEA) not present on non-specific cross-reacting antigen NCA, such as NCA₅₅ and NCA₉₅ (Buehner et al., Int. J. Cancer 33, 643, 1984), on biliary glycoprotein, or on granulocytes, and derivatives thereof.

Preferred are chimeric monoclonal antibodies and derivatives thereof with an affinity of at least 2.1×10^{10} liters/mol for human CEA.

For the production of a chimeric monoclonal antibody, a chimeric light chain and a chimeric heavy chain, each comprising a variable and a constant region, are constructed separately and are therefore distinguished in this description with special emphasis on the variable region of each chimeric construct.

The preferred chimeric monoclonal antibody of the invention and its derivatives are characterized in that they comprise light chain variable regions of the formula



(I),

wherein FR₁ is a polypeptide residue comprising 23-28 naturally occurring amino acids, FR₂ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₃ is a polypeptide residue comprising 30-34 naturally occurring amino acids and FR₄ is a polypeptide residue comprising 9-11 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges. Especially preferred are a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of formula I, wherein the polypeptide residues of the framework regions FR₁, FR₂, FR₃ and FR₄ are those preferably occurring in mammalian, especially murine, antibodies.

Most preferred are a chimeric monoclonal antibody and derivatives thereof according to the invention comprising light chain variable regions of formula I, wherein FR₁ is a polypeptide residue of the formula

A-Gly-Asp-Ile-Leu-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Leu-Ser-Val-Ser-Pro-
Gly-Glu-Arg-Val-Thr-Phe-Ser-Cys

5

(IA),

wherein A is hydrogen, acyl, or the residue Ala-Ser-Arg, Ser-Arg or Arg, particularly hydrogen,

10 FR₂ is the polypeptide residue

Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

15

(IB),

FR₃ is the polypeptide residue

20

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

25

(IC),

and FR₄ is the polypeptide residue

30

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

(ID),

35

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

The invention also relates to a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of formula I, wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of formula IA, IB, IC and ID, respectively, and wherein one or more, e.g. 1, 2, 3 or 4, single amino acids are replaced by other amino acids outside the regions CDR1L, CDR2L and CDR3L, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

The preferred chimeric monoclonal antibody of the invention and its derivatives are characterized in that they comprise heavy chain variable regions of the formula

45

FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
|----- CDR1H -----| |-----
Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
|----- CDR2H -----| |----- CDR3H -----|

50

(II),

wherein FR₅ is a polypeptide residue comprising 32-36 naturally occurring amino acids, FR₆ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₇ is a polypeptide residue comprising 32-34 naturally occurring amino acids and FR₈ is a polypeptide residue comprising 12-14 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges. Especially preferred are a chimeric monoclonal antibody and derivatives thereof comprising heavy

55

chain variable regions of formula II, wherein the polypeptide residues of the framework regions FR₆, FR₇, FR₈ and FR₉ are those preferably occurring in mammalian, especially murine, antibodies.

Most preferred are a chimeric monoclonal antibody and derivatives thereof according to the invention comprising heavy chain variable regions of formula II, wherein FR₅ is a polypeptide residue of the formula

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-
Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-
Thr-Phe-Arg

(IIA),

wherein B is hydrogen or acyl, particularly hydrogen,

FR₆ is the polypeptide residue

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

(IIB),

FR₇ is the polypeptide residue

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
Ala-Arg

(IIC),

and FR₈ is the polypeptide residue

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

The invention also relates to a chimeric monoclonal antibody and derivatives thereof comprising heavy chain variable regions of formula II, wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, and wherein one or more, e.g. 1, 2, 3 or 4, single amino acids are replaced by other amino acids outside the regions CDR1H, CDR2H and CDR3H, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

Light chain variable regions of formula IA and heavy chain variable regions of formula IIA may comprise an acyl residue, for example formyl or alkanoyl, e.g. palmitoyl, myristoyl or lower alkanoyl, such as acetyl or propionyl.

The class of an Ig molecule is defined by the H- and L-chain constant regions as pointed out above. A chimeric monoclonal antibody of the invention may be of any immunoglobulin class, i.e. IgA, IgD, IgE, IgG or IgM. A preferential chimeric monoclonal antibody according to the invention is an immunoglobulin of class G which comprises light chain human constant regions κ or λ , especially human constant regions κ , and heavy chain human constant regions γ 1, γ 2, γ 3 or γ 4, especially human constant regions γ 4.

The invention preferentially concerns a chimeric monoclonal antibody and derivatives thereof with light chain variable regions of formula I with the preferred meaning, wherein the amino acid Cys may be in the oxidized state forming S-S-bridges, light chain human constant regions κ , heavy chain variable regions of formula II with the preferred meaning, wherein the amino acid Cys may be in the oxidized state forming S-

S-bridges, and heavy chain human constant regions $\gamma 4$.

Derivatives of chimeric monoclonal antibodies according to the invention are, for example, fragments that retain their specificity for the antigenic determinants of the CEA molecule, such as the univalent fragment Fab and the divalent fragment $F(ab')_2$, conjugates of the chimeric monoclonal antibodies with enzymes, fluorescent markers, metal chelates, cytostatic or cytotoxic substances, avidin, biotin, and the like, and radioactively labelled antibodies.

Enzymes used for antibody conjugates of the invention are, for example horseradish peroxidase, alkaline phosphatase, β -D-galactosidase, glucose oxidase, glucoamylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase or glucose-6-phosphate dehydrogenase.

Fluorescent markers conjugated with chimeric antibodies are fluorescein, fluorochrome, rhodamine, and the like.

In such conjugates the antibody is bound to the enzymes or fluorescent markers directly or by the way of a spacer or linker group.

Examples for metal chelators are ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DPTA), 1,4,8,11-tetraazatetradecane, 1,4,8,11-tetraazatetradecane-1,4,8,11-tetraacetic acid, 1-oxa-4,7,12,15-tetraazaheptadecane-4,7,12,15-tetraacetic acid, or the like. Cytostatics, applicable in connection with the chimeric antibodies, are, inter alia, alkylating substances, such as mechlorethamine, triethylenephosphoramidate, cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan or triaziquone, also nitrosourea compounds, such as carmustine, lomustine, or semustine. Also used are antimetabolites, such as methotrexate, mercaptopurine, cytarabine, fluorouracil, floxuridine, or fltorafur. A further group of cytostatics includes vinblastine and vincristine, as well as certain antibiotics, such as actinomycin-D, daunorubicin (daunomycin), doxorubicin, mithramycin, streptonigrin, mitomycin and bleomycin. Further suitable cytostatics are, inter alia, procarbazine, hydroxyurea, L-asparaginase, dacarbazine, mitotane, estramustine, or podophyllotoxin. Further cytostatic agents are hormones and hormone antagonists, such as corticosteroids, e.g. prednisone, progestins, e.g. hydroxyprogesterone or medroprogesterone, estrogens, e.g. diethylstilbestrol, antiestrogens, e.g. tamoxifen, androgens, e.g. testosterone, and aromatase inhibitors, e.g. aminoglutethimide.

Conjugates of chimeric monoclonal antibodies with cytotoxic substances contain either the intact toxin or the A-chain derived from it. Toxins suitable for antibody-coupling are, among others, several lectins, such as ricin or abrin, or diphtheria toxin A, and the like.

Radioactively labelled chimeric monoclonal antibodies contain e.g. radioactive iodine (^{123}I , ^{125}I , ^{131}I), yttrium (^{90}Y), technetium ($^{99\text{m}}\text{Tc}$), or the like.

The chimeric monoclonal antibodies and derivatives thereof according to the invention are prepared by processes that are known *per se*, characterized in that mammalian cells as defined further below producing such chimeric monoclonal antibodies are multiplied according to known methods *in vitro* or *in vivo*, and, if desired, the resulting monoclonal antibodies are converted into derivatives thereof.

Multiplication *in vitro* is carried out in suitable culture media, which are the customary standard culture media, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium, optionally replenished by a mammalian serum, e.g. foetal calf serum, or trace elements and growth-sustaining supplements, e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, or the like.

As the antibody-producing cells carry a selection marker described in detail hereinbelow, the culture media may be supplemented with selective media, for example media containing G-418 or xanthine, hypoxanthine/thymidine and mycophenolic acid, in order to prevent normal cells from overgrowing the producer cells.

In vitro production allows scale-up to give large amounts of the desired antibodies. Techniques for mammalian cell cultivation under tissue culture conditions are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or immobilized or entrapped cell culture, e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges.

The cell culture supernatants are screened for the desired monoclonal antibodies, preferentially with an enzyme immunoassay, e.g. a dot-assay, or a radioimmunoassay.

For isolation of the chimeric monoclonal antibodies, the immunoglobulins in the culture supernatants are first concentrated, e.g. by precipitation with ammonium sulphate, dialysis against hygroscopic material such as PEG, filtration through selective membranes, or the like. If necessary and/or desired, the concentrated antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose or (immuno-)affinity chromatography.

Large quantities of the desired chimeric monoclonal antibodies can also be obtained by multiplying the cells *in vivo*. For this purpose, cell clones from a histocompatible and/or tolerated Ig-producing cell line are

injected into syngeneic mammals to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl pentadecane), prior to the injection. After 1-3 weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells derived from Balb/c mice that produce the desired chimeric monoclonal antibodies are injected intraperitoneally into Balb/c mice that have optionally been pre-treated with a hydrocarbon such as pristane, and, after 8-10 days, ascitic fluid is taken from these animals. The chimeric monoclonal antibodies are isolated therefrom by conventional methods as given above.

Fragments of chimeric monoclonal antibodies that retain their specificity towards human CEA, for example Fab or F(ab')₂ fragments, can be obtained from a chimeric antibody prepared as described above by methods known per se, e.g. by genetic manipulation of the appropriate Ig-coding exons, by digestion with enzymes such as papain or pepsin, and/or cleavage of disulfide bonds by chemical reduction.

Conjugates of monoclonal antibodies of the invention are prepared by methods known in the art, e.g. by reacting a monoclonal antibody prepared as described hereinbefore with the enzyme in the presence of a coupling agent, e.g. glutaraldehyde, periodate, N,N'-o-phenylenedimaleimide, N-(m-maleimidobenzoyloxy)-succinimide, N-(3-[2'-pyridyldithio]-propionoxy)-succinimide, N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide or the like. Conjugates with avidin are prepared likewise. Conjugates with biotin are prepared e.g. by reacting monoclonal antibodies with an activated ester of biotin such as the biotin N-hydroxysuccinimide ester. Conjugates with fluorescent markers are prepared in the presence of a coupling agent, e.g. those listed above, or by reaction with an isothiocyanate, preferably fluorescein-isothiocyanate. Conjugates of the chimeric antibodies of the invention with cytostatic/cytotoxic substances and metal chelates are prepared in an analogous manner.

Chimeric monoclonal antibodies radioactively labelled with iodine (¹²³I, ¹²⁵I, ¹³¹I) are obtained from the monoclonal antibodies according to the invention by iodination known per se, for example with radioactive sodium or potassium iodide and a chemical oxidising agent, such as sodium hypochlorite, chloramine T or the like, or an enzymatic oxidising agent, such as lactoperoxidase, glucose oxidase and glucose. Chimeric monoclonal antibodies according to the invention are coupled to yttrium (⁹⁰Y) for example by diethylenetriaminepentaacetic acid (DTPA)-chelation. Technetium-99m labelled chimeric antibodies are prepared by ligand exchange processes, for example by reducing pertechnetate (TcO₄⁻) with stannous ion solution, chelating the reduced technetium onto a Sephadex column and applying the antibodies to this column, or by direct labelling techniques, e.g. by incubating pertechnetate, a reducing agent such as SnCl₂, a buffer solution such as a sodium-potassium phthalate-solution, and the antibodies.

The invention also concerns recombinant DNAs comprising an insert coding for a light chain murine variable region and/or for a heavy chain murine variable region of chimeric monoclonal antibodies specific for human CEA as described hereinbefore. By definition such DNAs comprise coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

In particular the invention concerns a recombinant DNA comprising an insert coding for a light chain murine variable region specific for human CEA, originating from genomic DNA of the cell line CE 25. The cell line CE 25 was generated by the fusion of B lymphocytes of the spleen of Balb/c mice and cells from the myeloma P3-NS2/1Ag4 and produces a murine anti-CEA antibody with a κ light chain and a γ 1 heavy chain.

Preferred is a recombinant DNA comprising an insert coding for the polypeptide of formula I, optionally containing introns, especially an insert coding for the polypeptide of formula I wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of formula IA, IB, IC and ID, respectively, optionally containing introns.

An example of such a preferred recombinant DNA is a recombinant DNA comprising an insert of the formula

1 TCTAGACTGCTGTGGTCTTTTAAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT 60
 5 61 -----+-----+-----+-----+-----+-----+-----+ 120
 TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTTGGAAAGATATGCAAG
 121 -----+-----+-----+-----+-----+-----+-----+ 180
 AAGCACTATTTGGCTATTATTTGGAAAGTGCTATAATGTATTTTGATATCTCAACCTCTG
 10 181 -----+-----+-----+-----+-----+-----+-----+ 240
 AAATTCTTCTGTATGTTGGCAGATTGTAAACCTTTACAAGGCTTTCATTCTTCTCTGG
 241 -----+-----+-----+-----+-----+-----+-----+ 200
 AGAAAAATGCTTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
 15 301 -----+-----+-----+-----+-----+-----+-----+ 360
 GTGTGATATCACTTTAGTTTCATGTGTTGTTATGCTTCATGTAATGTAAAGAAAGTTAAA
 361 -----+-----+-----+-----+-----+-----+-----+ 420
 GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTGAG
 20 421 -----+-----+-----+-----+-----+-----+-----+ 480
 ATGCTCTTTATTTCAAACACTACTGAATATATCTTAGAGATTTCCTTAGACTGTGTTAAATA
 481 -----+-----+-----+-----+-----+-----+-----+ 540
 TGTAACCATTTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAAACCA
 25 541 -----+-----+-----+-----+-----+-----+-----+ 600
 ACAAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT
 601 -----+-----+-----+-----+-----+-----+-----+ 660
 TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTCTTTCTTCTAATGTCCCTGC
 30 661 -----+-----+-----+-----+-----+-----+-----+ 720
 CTCTTAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTCATGGTCCACACAAAAATAGG
 M V S T P Q F L V F L L F W I P
 MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
 35 721 -----+-----+-----+-----+-----+-----+-----+ 780
 GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGATTTTTGCTTTTCTGGATTCCA

```

      GGTAATGACTGTTTGGGTGTGGCAAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT
781  -----+-----+-----+-----+-----+-----+-----+-----+ 840
      TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTTCAGTTTAAAGAAATTGATAC
5   841  -----+-----+-----+-----+-----+-----+-----+-----+ 900
      AATAAAAGTCATTTATTTTCTAAGTTGTTTAGAAGTGACTTTCATATTCAGTGTATGA
901  -----+-----+-----+-----+-----+-----+-----+-----+ 960
                                     A S R G D I L L T Q S
10                                     AlaSerArgGlyAspIleLeuLeuThrGlnSer
      TCGACTAATGTATCTTCCATTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT
961  -----+-----+-----+-----+-----+-----+-----+-----+ 1020
      P A I L S V S P G E R V T F S C R A S Q
15      ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
      CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTCTCCTGCAGGGCCAGTCAG
1021 -----+-----+-----+-----+-----+-----+-----+-----+ 1080
      S I G T S L H W Y Q Q R T N G S P R L L
20      SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
      AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTC
1081 -----+-----+-----+-----+-----+-----+-----+-----+ 1140
      M K Y A S E S I S G I P S R F S G S G S
25      MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
      ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
1141 -----+-----+-----+-----+-----+-----+-----+-----+ 1200
      G T D F T L T I N S V E S E D I A D Y Y
30      GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
      GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
1201 -----+-----+-----+-----+-----+-----+-----+-----+ 1260
      C Q Q S H G W P F T F G S G T K L E I K
35      CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
      TGTCAACAAAGTCATGGCTGGCCATTACGTTCTGGGCTCGGGGACAAAGTTGGAAATAAAA
1261 -----+-----+-----+-----+-----+-----+-----+-----+ 1320
      CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTGGTTCTGTTTGGGTAGCTTGTGT
1321 -----+-----+-----+-----+-----+-----+-----+-----+ 1380
      GAATTTGTGATATT
40 1381 -----+----- 1395

```

(III).

45 A recombinant DNA comprising an insert of formula III wherein one or more, e.g. up to 10, single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula III from position 1069-1102, 1147-1167 and 1263-1291, respectively, is also preferential.

In particular, the invention also concerns a recombinant DNA comprising an insert coding for a heavy chain murine variable region specific for human CEA, originating from genomic DNA of the cell line CE 25.

50 Preferred is a recombinant DNA comprising an insert coding for the polypeptide of formula II, optionally containing introns, especially an insert coding for the polypeptide of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, optionally containing introns.

An example of such a preferred recombinant DNA is a recombinant DNA comprising an insert of the formula

55

AAGCTTGTCTCTGTTACATGCAAGGAGGGAACTAAACTGAGTATGGTGAATCCCTAACC
 1 -----+-----+-----+-----+-----+-----+ 60
 AAAGGGAAAAAATGAAACTACAATATGTTTCAAATGCTGTAAGTAAATCTGGTTTTTTTG
 5 61 -----+-----+-----+-----+-----+-----+ 120
 ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCCAAGAGCATGGTAT
 121 -----+-----+-----+-----+-----+-----+ 180
 AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCCATGAAAACACCTCGGCCCTGACCC
 10 181 -----+-----+-----+-----+-----+-----+ 240
 TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTGAGTTCCTCACATTGAGTGATGAGC
 241 -----+-----+-----+-----+-----+-----+ 300

 M N F G F S L I F L V L V
 MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
 15 ACTGAACACAGACACCTCACCATGAACTTCGGGTTGAGCTTGATTTTCCTTGTCCTTGTT
 301 -----+-----+-----+-----+-----+-----+ 360

 L K G
 LeuLysGly
 20 TTAAAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA
 361 -----+-----+-----+-----+-----+-----+ 420

 V Q
 ValG1
 25 TGTGGTTTGTGTTTGTAGTGACAGTTTTCCAACCAGTTATTCTCTGTTTGTAGGTGTCCA
 421 -----+-----+-----+-----+-----+-----+ 480

 C E V K L V E S G G G L V K P G G S L K
 nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
 GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA
 30 481 -----+-----+-----+-----+-----+-----+ 540

 L S C A A S G F T F R T Y A M A W V R Q
 sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgG1
 ACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGGACCTATGCCATGGCTTGGGTTGCGCA
 35 541 -----+-----+-----+-----+-----+-----+ 600

```

      T P E K R L E W V T S I S S G G T T Y Y
nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
GACTCCAGAGAAGAGGCTGGAGTGGGTCACATCCATTAGTAGTGGTGGTACCACCTACTA
601 -----+-----+-----+-----+-----+-----+ 660
5
      P D S V K G R F T I S R D N A R N I L Y
rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA
661 -----+-----+-----+-----+-----+-----+ 720
10
      L Q V S S L R S E D T A I Y Y C A R G F
rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGGTTT
721 -----+-----+-----+-----+-----+-----+ 780
15
      Y D G Y L Y V V D Y W G Q G T S L T V S
eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACCGTCTC
781 -----+-----+-----+-----+-----+-----+ 840
20
      S
rSer
CTCAGGTAAGAATGGCC
841 -----+----- 857

```

(IV).

A recombinant DNA comprising an insert of formula IV wherein one or more, e.g. up to 10, single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula IV from position 575-595, 629-680 and 776-805, respectively, is also preferential.

For the assembly of complete tetrameric immunoglobulin molecules and the expression of active antibodies, the recombinant DNA inserts coding for light and heavy chain variable regions are fused with the corresponding DNAs coding for light and heavy chain constant regions, then incorporated into hybrid vectors and transferred into appropriate host cells with the help of these hybrid vectors.

The invention therefore also concerns recombinant DNAs comprising an insert coding for a light chain murine variable region specific for human CEA fused to a human constant region κ or λ . Preferred is a recombinant DNA coding for a preferred murine variable region as described hereinbefore fused to a human constant region κ .

Likewise the invention concerns recombinant DNAs comprising an insert coding for a heavy chain murine variable specific for human CEA fused to a human constant region γ , for example $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$. Preferred is a recombinant DNA coding for a preferred murine variable region as described hereinbefore fused to a human constant region $\gamma 4$.

Furthermore the invention concerns a recombinant DNA which is a hybrid vector comprising an insert coding for a chimeric murine/human light chain as described hereinbefore and/or an insert coding for a chimeric murine/human heavy chain as described hereinbefore, a complete replicon and one or more dominant marker sequences, operationally linked to expression control sequences.

The markers allow for selection of host cells which contain the vector. Selection markers include genes which confer resistance to heavy metals, e.g. copper, antibiotics, e.g. G-418 (geneticin, a neomycin-derivative) or hygromycin, or genes which complement a genetic lesion of the host cell such as the absence of thymidine kinase, hypoxanthine phosphoryl transferase, dihydrofolate reductase or the like. In addition, hybrid vectors optionally contain signal sequences, one or more restriction sites available for the insertion of a structural gene, enhancers and/or expression control sequences. A wide variety of transcriptional and translational regulatory sequences may be employed, depending on the nature of the host. Preferred vectors are suitable for mammalian hosts and are based on viral replication systems, such as simian virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus 2, bovine papilloma virus (BPV), papovavirus BK mutant (BKV), or mouse and human cytomegalovirus (CMV). Alternatively, the vectors may contain promoters from mammalian expression products, such as actin, collagen, myosin etc., or the native promoter and control sequences which are normally associated with the immunoglobulin gene sequences. Enhancers are

transcription-stimulating DNA sequences of viral origin, e.g. derived from simian virus such as SV40, polyoma virus, bovine papilloma virus or Moloney sarcoma virus, or of genomic, especially murine origin (mouse Ig enhancer). An origin of replication is provided either by construction of the vector to include an exogenous origin, such as derived from SV40 or another viral source, or by the host cell chromosomal replication mechanism. Examples of preferred vectors are those derived from pSV-vectors in which the selectable marker is placed under the control of the SV40 early promoter, in particular pSV2gpt carrying the xanthine-guanine phosphoribosyl transferase gene, and pSV2neo, carrying the phosphotransferase gene.

The chimeric gene constructs for the light chain and for the heavy chain are sequentially or simultaneously transferred into the host cells with the help of two vectors. Alternatively, both heavy and light chains are cloned into the same hybrid vector and incorporated in a one step-procedure as a single construct into the host cells.

The recombinant DNAs coding for the desired chimeric monoclonal antibodies can be prepared, for example, by culturing a transformed host.

In particular, such DNAs can be prepared by

- a) isolating murine DNAs from a suitable hybridoma cell line, selecting the desired DNAs coding for the variable regions of monoclonal antibodies directed against human CEA using DNA probes,
- b) isolating human DNAs from a genomic library, selecting the desired DNAs coding for the constant regions of monoclonal antibodies using DNA probes,
- c) constructing chimeric mouse/human genes by incorporating the DNA of step a) and b) into appropriate hybrid vectors,
- d) transferring the obtained hybrid vectors into a recipient host, and
- e) selecting and culturing the transformed host.

The DNA according to step a) of the process described above can be obtained by isolation of genomic DNA or by preparation of cDNA from isolated mRNA. As genomic DNA constructs facilitate gene expression, the preparation and use of genomic DNA is to be preferred.

Genomic DNA from hybridoma cells is isolated by methods known in the art which include steps for disruption of the cells, e.g. by lysis in presence of detergents like Triton, extracting the DNA, e.g. by treatment with phenol and CHCl_3 /isoamyl alcohol, and DNA-precipitation. The DNA is fragmented, conveniently by one or more restriction endonucleases, e.g. XbaI, BglII, EcoRI, HindIII, BamHI, the resulting fragments are replicated on a suitable carrier, e.g. nitrocellulose membranes, and screened with a DNA probe as described in more detail hereinbelow for the presence of the DNA sequences coding for the polypeptide sequence of interest, in particular for the presence of the rearranged H- and L-chain Ig gene loci. By this procedure DNA fragments are found that contain inserts with heavy chain V, D and J regions and light chain V and J regions, respectively, together with a leader sequence and introns, if any.

Genomic human DNA according to step b) of the process described above is isolated from suitable human tissue, preferably from human placenta or human foetal liver cells, according to methods known in the art. A genomic DNA library is constructed therefrom by limited digestion with suitable restriction endonucleases, e.g. HaeIII and AluI, and incorporation into λ Charon phage, e.g. λ Charon 4a, following established procedures. The genomic DNA library is replicated, e.g. on nitrocellulose membranes, and screened with a DNA probe as described below for the DNA sequences of interest.

The DNA probe for the mouse variable regions or the human constant regions may be a synthetic DNA, a cDNA derived from mRNA coding for the desired immunoglobulin or a genomic DNA or DNA fragment of known nucleotide sequence. Preferably a genomic DNA or DNA fragment probe is used. As probes for the detection of the rearranged Ig gene loci of the variable regions of L-/H-chains, DNA fragments of known nucleotide sequences of adjacent conserved variable or constant regions are selected which constitute the Ig loci of the L-/H-chain in the mammal from which the DNA is derived, e.g. Balb/c mice. The utilization of murine DNA probes for the detection of human DNA sequences is based on sequence homologies between the murine and human DNAs. The DNA probe is isolated from suitable tissue of an appropriate mammal, e.g. Balb/c mouse liver, purified by molecular cloning in bacteriophage λ and subcloning appropriate DNA fragments in suitable plasmid vectors, such as pUC12 or pUC13, and recovering/purifying cloned DNA inserts using standard procedures. The purified probe DNA is labelled, e.g. radioactively-labelled by the well-known nick-translation technique, then hybridized with the human DNA library in buffer and salt solutions containing adjuncts, e.g. calcium chelators, viscosity regulating compounds, proteins, non-specific DNA and the like, at temperatures favoring selective hybridization.

Once a fragment has been identified which contains the desired DNA sequence, this fragment may be further manipulated to remove nonessential DNA, modified at one or both termini, and treated to remove all or a portion of intervening sequences, or the like.

The joining of the various DNA fragments in order to produce chimeric genes is performed in accordance with conventional techniques, for example, by blunt- or staggered-end ligation, restriction enzyme digestion to provide for appropriate cohesive termini, filling in cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.

5 The transfer of the recombinant DNAs, e.g. the transfer of hybrid vectors, and the selection of transformed cells is described below.

Moreover, the invention relates to host cells transformed with the recombinant DNAs described above, namely host cells which are transformed with a DNA encoding the light chain and/or a DNA encoding the heavy chain of the desired chimeric antibody.

10 The host cells of the present invention have to be capable of culture in vitro and have to be of higher eukaryotic origin to provide a suitable environment for the production of active antibodies, since the biosynthesis of functional tetrameric antibody molecules requires correct nascent polypeptide chain folding, glycosylation, and assembly. Examples of suitable host cells according to the invention are mammalian cells, e.g. COS-7 cells, Bowes melanoma cells, chinese hamster ovary (CHO) cells, embryonic lung cells L-132, and in particular mammalian cells of lymphoid origin, such as myeloma or lymphoma cells, for example Sp2/0 cells. Sp2/0 (ATCC CRL 1581) is a well-characterized, Ig non-secreting mouse cell line, derived from the fusion of mouse spleen cells with the myeloma X63-Ag8. These host cells are transfected with the chimeric H-chain gene construct alone, with the L-chain gene construct alone, or with both, either transferred with the help of two separate vectors or by using a double-construct (L-chain/H-chain) vector as indicated hereinbefore. Particularly preferred are host cells transfected with both gene constructs, which are transferred with the help of two separate vectors, secreting chimeric monoclonal antibodies with an affinity to CEA as described hereinbefore, for example cells of the cell line EFVIII/ γ 4Na 75-75/CxGa5-6 (referred to as CE75-5-6). Also particularly preferred are host cells transfected with both gene constructs, which are simultaneously transferred with the help of a double-construct vector, secreting chimeric monoclonal antibodies of the invention, for example cells of the cell line EFIX-pCEA-Ig-(γ 4;Cx) (referred to as CE 4-8-13). Further examples of host cells of the invention are cells transfected with similar recombinant plasmids which contain alternative orientations of the H- and L-chain gene constructs, incorporating additional DNA elements to facilitate high levels of expression of the chimeric monoclonal antibodies.

The host cells of the invention are genetically stable, secrete chimeric monoclonal antibodies of the invention of constant specificity and can be activated from deep-frozen cultures by thawing and recloning.

The invention also relates to processes for the preparation of host cells secreting chimeric monoclonal antibodies with specificity to CEA as described hereinbefore, characterized in that a suitable cell is transformed with one or two vectors, e.g. by electroporation, calcium treatment, microinjection or protoplast fusion.

35 Vectors are introduced into mammalian cells by transfection in the presence of helper compounds, e.g. diethylaminoethyl-dextran, dimethyl sulfoxide, glycerol, polyethylene glycol or the like, or as co-precipitates of vector DNA and calcium phosphate. Further suitable methods include direct microinjection of vector DNA into the cell nucleus, protoplast fusion and electroporation, i.e. introduction of DNA by a short electrical pulse which transiently increases the permeability of cell membranes. The subsequent selection of transfected cells can be done using a selection marker which is either covalently integrated into the expression vector or added as a separate entity. Selection markers include genes which confer resistance to antibiotics, e.g. G-418 (geneticin, a neomycin-derivative) or hygromycin, or genes which complement a genetic lesion of the host cell such as the absence of thymidine kinase, hypoxanthine phosphoribosyl transferase, dihydrofolate reductase, or the like.

45 The chimeric monoclonal antibodies and derivatives thereof according to the invention are used in a number of applications, especially for the diagnosis and therapy of cancer.

An example of diagnostic use is the qualitative and quantitative determination of human carcinoembryonic antigen, especially in biological fluids. The chimeric monoclonal antibodies and derivatives thereof may be used in any of the immunoassays known per se that utilize the binding interactions between antigen and monoclonal antibody, such as radioimmunoassays (RIA), enzyme-linked immunoassays, immunofluorescence tests, latex agglutination or haemagglutination.

50 Any of the known modifications of a RIA can be used, for example RIA in homogeneous phase, solid phase RIA or heterogeneous RIA, single RIA or double (sandwich) RIA with direct or indirect (competitive) determination of CEA. There is preferred a sandwich RIA in which a suitable carrier, for example the plastics surface of a microtitre plate or of a test tube, for example of polystyrene, polypropylene or polyvinyl chloride, glass or plastics beads, filter paper, or dextran, cellulose acetate or nitrocellulose sheets or the like, is coated with an antibody to CEA by simple adsorption or optionally after activation of the carrier, for example with glutaraldehyde or cyanogen bromide, and incubated with the test solution and a solution of an

antibody radioactively labelled with ^{125}I , the dissolved antibody recognizing another epitope of CEA than the carrier-bound antibody, and the amount of CEA is determined by measuring the radioactivity bound to the carrier. One of the two antibodies used in the sandwich RIA is a chimeric monoclonal antibody of the invention, the other one can be a known monoclonal or polyclonal anti-CEA antibody or also a chimeric antibody according to the invention.

The chimeric monoclonal antibodies according to the invention can be used as such or in the form of enzyme-conjugated derivatives in an enzyme-immunoassay. Such immunoassays include test procedures in which enzyme-labelled chimeric monoclonal antibody derivatives according to the invention or enzyme-labelled antibodies known *per se* that recognize and bind an epitope of the antibodies according to the invention are used. The amount of antigen is determined in a cascade-antigen-antibody-complex with the help of an enzymatic test.

There is preferred an ELISA (enzyme-linked immunosorbent assay) in which a carrier as described above for a RIA is coated with an anti-CEA antibody and incubated with a test solution containing CEA. After binding of CEA, a second antibody directed against CEA is added which binds to the antibody-antigen-complex. The bound antibodies are developed by a third enzyme-labelled antibody specific for the constant region of the second antibody. The amount of CEA is determined by an enzyme-substrate reaction. One of the antibodies used in the test is a chimeric monoclonal antibody of the invention, the other one can be a known monoclonal or polyclonal anti-CEA antibody or also a chimeric antibody according to the invention. The labelled antibody is, for example, an alkaline phosphatase-labelled goat-anti-human IgG antibody.

There is also preferred an ELISA in which a carrier coated with an antibody is incubated with a test solution containing CEA and with a solution of an antibody that is conjugated with an enzyme, the dissolved antibody recognizing a different CEA-epitope than does the carrier-bound antibody. One of the antibodies used in the test is a chimeric monoclonal antibody of the invention, the other one is a known monoclonal or polyclonal anti-CEA antibody.

The invention relates also to test kits for the determination of human CEA containing chimeric monoclonal antibodies to human CEA and/or derivatives thereof and, optionally, adjuncts.

Test kits according to the invention for a radioimmunoassay contain, for example, a suitable carrier, optionally freeze-dried or concentrated solutions of one or more monoclonal antibodies, solutions of a radioactively labelled monoclonal antibody or of radioactively labelled human CEA, standard solutions of human CEA, buffer solutions and, optionally, detergents for preventing non-specific adsorption and aggregate formation, pipettes, reaction vessels, calibration curves and the like. One or more of the monoclonal antibodies of the test kit are chimeric monoclonal antibodies of the invention.

Test kits according to the invention for an enzyme-immunoassay contain, for example, a suitable carrier, optionally freeze-dried or concentrated solutions of one or more monoclonal antibodies, optionally freeze-dried or concentrated solutions of an enzyme-labelled monoclonal antibody, of enzyme-labelled human CEA, of a polyclonal anti-human CEA serum and/or of enzyme-labelled monoclonal or polyclonal antibodies that recognize and bind the anti-human CEA antibody, enzyme substrates in solid or dissolved form, standard solutions of human CEA, buffer solutions, detergents, pipettes, reaction vessels, calibration curves, colour scale tables and the like. One or more of the monoclonal antibodies of the test kit are chimeric monoclonal antibodies of the invention.

In addition, based on their reduced immunogenicity, the chimeric monoclonal antibodies and their derivatives are useful in therapy, for passive immunization without negative immune reactions such as serum sickness or anaphylactic shock, for localization and *in vivo* imaging of tumors, for specific treatment of diseased cells, e.g. site-directed delivery of cytotoxins, immuno-modulators or other pharmaceutically active molecules where local concentration of the active agent is an important factor, or the like. For *in vivo* imaging, the chimeric antibody is radiolabelled or conjugated with a metal chelate complexed with a radionuclide, e.g. iodine, yttrium, technetium, or the like, and radioscanning techniques may be used to detect primary and metastatic tumors. To that end, the radioactive antibody is injected e.g. intravenously and the patient scanned with a gamma imager at regular intervals. Tumors expressing CEA will take up more radioactive antibodies than other tissue and will be clearly recognized by the gamma imaging camera. Preferentially monoclonal antibodies labelled with ^{131}I are used for radioscanning in amounts of 3 to 8 μg representing 15 to 30 μCi per kg body weight. For biocidal activity in the treatment of cancer, the chimeric antibodies are used as derivatives conjugated to cytostatic or cytotoxic substances as described hereinbefore, e.g. ricin A, as radiolabelled derivatives, or else delivered in liposomes containing biocidal reagents. The therapeutic dose for mammals is between approximately 1 mg and 5 mg per kg body weight for monoclonal antibodies themselves, and between 0.1 mg and 5 mg per kg body weight for conjugates with cytotoxic drugs, depending on the status of the patient and the mode of application. Alternatively, the chimeric antibodies can be used in combination with components of the host immune system, e.g.

complement, due to the presence of the native constant region. In vitro, the subject chimeric antibodies can be used in conjunction with complement to remove particular CEA-presenting cells from a mixture of cells.

The invention also relates to pharmaceutical preparations containing a chimeric monoclonal antibody or derivatives thereof with a high specificity for CEA as disclosed hereinbefore. The pharmaceutical preparations contain, for example, chimeric monoclonal antibodies or derivatives thereof in an effective amount together or in admixture with inorganic or organic, solid or liquid pharmaceutically acceptable carriers.

Preferred are pharmaceutical preparations for parenteral application. Preparations for intramuscular, subcutaneous or intravenous application are e.g. isotonic aqueous solutions or suspensions, optionally prepared shortly before use from lyophilized or concentrated preparations. The pharmaceutical preparations may be sterilized and contain adjuvants e.g. for conserving, stabilizing, wetting, emulsifying or solubilizing the ingredients, salts for the regulation of the osmotic pressure, buffer and/or compounds regulating the viscosity, e.g. sodium carboxycellulose, dextran, polyvinylpyrrolidone or gelatine. They are prepared by methods known in the art, e.g. by conventional mixing, dissolving or lyophilizing, and contain from approximately 0.01 % to approximately 50 % of active ingredients. The preparations for injections are processed, filled into ampoules or vials, and sealed under aseptic conditions according to methods known in the art.

The following examples illustrate the invention.

Figure legends

Symbols for restriction sites: A - AluI, B - BamHI, Bg - BglII, E - EcoRI, H - HindIII, Hh - HhaI, P - PstI, Sa - Sall, Sp - SphI, X - XbaI, Xm - XmnI

V: variable region Ig gene segment

J: joining segment

D: diversity segment

L: leader sequence

Boxes indicate the position of the rearranged V-region and its leader peptide coding segment (black boxes), and the position of J-segments (open boxes).

Figure 1:

A) G: germline configuration of the mouse L-chain Ig gene locus showing the position of J-segments and the origin of the J-region probe

L2 and L2.5: restriction maps of the CE 25 hybridoma-specific rearranged L-chain Ig genes deduced from Southern blot analysis (Example 3)

plasmid pCEA-L2a: cloned segment of the L2 gene

(B) G: germline configuration of the mouse H-chain Ig gene locus showing the position of J-segments and the origin of the J-region probe

H2 and H8: restriction maps of the CE 25 hybridoma-specific rearranged H-chain Ig genes deduced from Southern blot analysis (Example 3)

The plasmid pH8a1 is not shown, but it is constructed in an analogous manner to pCEA-L2a and contains the XbaI/XbaI segment of the H8 gene.

[E]: EcoRI sites in the cloned H8 gene that cannot be detected by Southern blot analysis of CE 25 hybridoma DNA

Figure 2:

Detection of L2- and H8-specific mRNA transcripts in CE 25 hybridoma cells by Northern blot analysis (Example 6):

RNA blots of 25 and 50 µg of P3-NS2/1Ag4-cell RNA (NS) and CE 25 hybridoma-cell RNA (CE 25)

(a) using an L2 L-chain gene segment

(b) using an H8 H-chain gene segment.

Figure 3:

Scheme for construction of the chimeric mouse/human L-chain gene pCEA-C_xGa (Examples 8.1 and 8.2)

Symbols: see above.

Figure 4:

Scheme for construction of the chimeric mouse/human H-chain gene pCEA- γ 4Na (Examples 8.3 and 8.4)

5 Symbols: see above.

Figure 5:

Scheme for the construction of pM1HuCx-1a

10 (Examples 10.1 and 10.2)

Symbols: see above; restriction sites placed in brackets are eliminated during the various cloning procedures.

Figure 6:

15

Scheme for the construction of the chimeric double-construct pCEA(H+L)2neo holding both mouse/human (γ 4; κ) anti-CEA, H- and L-chain Ig genes

Symbols: see above; restriction sites placed in brackets are eliminated during the various cloning procedures.

20

Figure 7:

Binding of the chimeric monoclonal antibody secreted by CE 4-8-13 to CEA

OD: optical density.

25

Abbreviations

	bp	base pairs
	CDR	complementarity determining region
30	ddNTP	dideoxynucleotide triphosphate (N = adenine, cytosine, guanine or thymine)
	dNTP	deoxynucleotide triphosphate (N = adenine, cytosine, guanine or thymine)
	DMEM	Dulbecco's minimal essential medium (Dulbecco & Vogt, J. Exp. Med. <u>99</u> , 167, 1954)
	DTT	dithiothreitol
	EDTA	ethylenediaminetetraacetic acid
35	FCS	foetal calf serum
	HEPES	N-2-hydroxyethyl piperazine-N'-2'-ethanesulphonic acid
	HAT	hypoxanthine/aminopterin/thymidine
	HT	hypoxanthine/thymidine
	Ig	immunoglobulin
40	kb	kilobase (pairs)
	MOPS	γ -morpholino propanesulphonic acid
	NZ-amine	NZ-amine (10 g/l); NaCl (5 g/l); yeast extract (5 g/l, Difco); casamino acids (1 g/l, Difco)
		MgSO ₄ · 7H ₂ O (2 g/l), pH 7.5 with NaOH
	PBS	phosphate buffered saline (Dulbecco & Vogt, J. Exp. Med. <u>99</u> , 167, 1954)
45	PBS-CM	PBS without MgCl ₂ and CaCl ₂
	RIA	radioimmunoassay
	SDS	sodium dodecylsulphate
	20 x SET	3 M NaCl, 20 mM EDTA, 0.4 M Tris-HCl, pH 7.8
	SSC	0.15 M NaCl, 0.015 M sodium citrate
50	TE buffer	1 mM EDTA, 10 mM Tris-HCl, pH 8.0
	Tris	Tris (hydroxymethyl)aminomethane

Example 1: Preparation of hybridoma cell line CE 2555 1.1 Purification of carcinoembryonic antigen (CEA)

Colon carcinoma liver metastases obtained from autopsies (within 6 h of death) are extracted with saline. 1 vol. of tissue is first homogenized in 3 vol. of 0.02M phosphate buffer pH 7.4 at 4 °C for 10 min in

a Sorvall Omnimixer® at 8,000 rpm. The crude homogenate is then centrifuged at 8,000 g for 15 min at 4°C. The clear supernatant is applied to an immunoadsorbent consisting of a pool of the known anti-CEA monoclonal antibodies MAb 35 and MAb 115 (Haskell et al., Cancer Res. 43, 3857, 1983; Buchegger et al., J. Exp. Med. 158, 413, 1983) and MAb 73 (Buchegger et al., Immunol. Letters 5, 85, 1982) coupled to
 5 CNBr-activated Sepharose®. CEA is eluted with 2M ammonium thiocyanate.

1.2 Immunization of Balb/c mice

Balb/c mice two months of age are immunized with CEA by injecting intraperitoneally 15 µg of saline-extracted purified CEA with complete Freund's adjuvant. After 4 months, a series of booster injections
 10 comprising 15, 50 and 150 µg of the same saline CEA preparation without Freund's adjuvant given intraperitoneally 5, 4 and 3 days before fusion, respectively.

1.3 Cell fusion

Cell fusion is accomplished using 1.5×10^8 spleen cells of immunized mice and 1.5×10^7 cells from the mouse myeloma P3-NS2/1Ag4 according to conventional previously described methods (Koehler & Milstein, Nature 256, 495, 1975). After washing, the cells are resuspended in 48 ml of standard Dulbecco's minimum essential medium (Gibco No. 0422501). 3×10^6 normal mouse peritoneal exudate cells per fusion
 20 are added as feeder cells. The cells are distributed into 96 x 0.5 ml Costar wells and fed 3 times per week with standard HAT selection medium for 3-6 weeks. When the growth of hybridoma cells becomes visible, the supernatants are screened as described in Example 1.4. Positive hybridomas, for example the cell line CE25 described in Example 1.5, are recloned and stored.

25 1.4 Antibody detection in hybridoma supernatants

Culture fluids of growing hybridomas are tested for the presence of anti-CEA antibody by a modification of the assay of Farr (J. Infect. Dis. 103, 239, 1958) as described previously (Accolla et al., Proc. Natl. Acad. Sci. 77, 563, 1980). 1:10 (v/v) dilutions of cell culture supernatants are incubated in duplicate with ¹²⁵I-
 30 labelled CEA in 0.02M Tris-HCl buffer, pH 7.4. CEA bound to antibodies is precipitated at 4°C by adding cold, saturated ammonium sulphate solution in the presence of normal human serum.

1.5 Hybridoma storage and processing

Hybridoma CE 25 secreting anti-CEA antibody MAb CE 25 can be grown in culture, frozen at -80°C or in liquid nitrogen and recultivated. The cells are cloned by the method of limiting dilution and expanded by forming ascites in Balb/c mice primed with pristane. Cell line CE 25 was deposited at the "Collection
 35 Nationale de Cultures de Microorganismes" of the Institut Pasteur, Paris, on December 15, 1987, under the number I-719.

40 Example 2: Isolation of DNA from the hybridoma cell lines CE 25, P3-NS2/1Ag4 and Balb/c mouse kidney cells

CE 25 hybridoma cells (5×10^7) are grown in suspension culture at 37°C in DMEM (Seromed) + 10 % FCS (Seromed), 1 mM sodium pyruvate (Seromed), 2 mM glutamine (Seromed), 50 µM 2 mercaptoethanol and 100 µg/ml of gentamycin (Seromed) in a humidified atmosphere of air and 7.5 % CO₂, in 175 cm³ tissue culture flasks (Falcon 3028). Cells are harvested by centrifugation, flash-frozen in liquid nitrogen and kept frozen as a pellet at -80°C in a clean, sterile plastic capped tube.

The frozen cells are resuspended in 10 ml of PBS to which is added 90 ml of 0.3 M sucrose, 5 mM MgCl₂, 0.1 % (w/v) Triton-X-100, 10 mM Tris-HCl, pH 7.5, at 4°C in a clean, sterile 100 ml plastic beaker. Cells are lysed by mixing, and nuclei collected by centrifugation (10 min, 10,000 rpm, 4°C, Sorvall RC-5 centrifuge, SS-34 rotor). The supernatant is removed and the nuclear pellet resuspended in 4.5 ml of 75 mM NaCl, 24 mM EDTA, pH 8.0. Distilled water (100 µl), SDS (250 µl of a 10 % (w/v) solution in distilled water), and 100 µl of proteinase K solution (Boehringer; 10 mg/ml solution in distilled water) are
 55 added and mixed gently. The mixture is incubated at 37°C overnight.

The solution is extracted by mixing with an equal volume of redistilled phenol saturated with 20 mM Tris-HCl, pH 8.0, at 0°C. The aqueous phase is recovered after centrifugation (10,000 rpm, room temperature, Sorvall RC-5 Centrifuge, SS-34 Rotor) and extracted twice with an equal volume of

CHCl₃/isoamyl alcohol (24:1, v/v). DNA is precipitated by the addition of one-tenth volume of 3 M NaOAc, pH 5.0, followed by two volumes of absolute ethanol at room temperature. The precipitated DNA is lifted from the ethanolic solution, placed in 1 ml of TE buffer and dissolved overnight at 4°C. The yield of DNA is approximately 0.5 mg.

DNA from cell line P3-NS2/1Ag4 is obtained likewise.

For preparations of DNA from Balb/c mouse kidney tissue, fresh mouse kidney is flash-frozen in liquid nitrogen, ground to a fine powder in a clean, sterile pestle and mortar in the presence of liquid nitrogen, and DNA extracted from an amount of tissue equivalent to 5×10^7 cells, following the procedure described above.

Example 3: Analysis of rearranged Ig H- and L-chain gene loci in CE 25 cells

Hybridoma CE 25 contains H- and L-chain Ig gene loci derived from the P3-NS2/1Ag4 cell used as fusion partner for the generation of the hybridoma. The P3-NS2/1Ag4 cell line is derived from the MOPC-21 myeloma (Storb et al., *Nucleic Acids Res.* 8, 4681, 1980). These 'endogenous' rearranged loci are distinguished from CE 25-specific rearranged genes by the following procedures:

3.1 Source and preparation of probe DNA fragments

The probe DNA segment used for the detection of the Balb/c mouse germline H-chain J-region DNA segment is an approximately 1750 bp BglII/XbaI segment of Balb/c mouse liver DNA, corresponding to nucleotide positions 1130-2881 of the published germline H-chain Ig locus (Newell et al., *Science* 209, 1128, 1980; EMBL data base entry MUSIGCD07).

The probe DNA segment used for the detection of the Balb/c mouse germline L-chain J-region segment is an approximately 2240 bp HindIII/XbaI segment of Balb/c mouse liver DNA, corresponding to nucleotide positions 659-2900 of the published germline L-chain Ig locus (Max et al., *Proc. Natl. Acad. Sci.* 76, 3450, 3454, 1979; EMBL data base sequence entry MUSIGKJC2).

DNA probes are purified by molecular cloning of Balb/c mouse liver DNA in bacteriophage λ , subcloning appropriate DNA fragments in pUC12- or pUC13-plasmid vectors, and recovering/purifying cloned DNA inserts using standard procedures (Maniatis et al., "Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982).

DNA probes are prepared from 300 ng of purified DNA fragments by nick-translation in the presence of α -³²P-dCTP, E. coli DNA polymerase-I and DNaseI, using the standard published procedure (Rigby et al., *J. Mol. Biol.* 113, 237, 1977). Labelled probe DNA is separated from unincorporated label using Sephadex® G50 (Pharmacia) chromatography with a 10 x 0.5 cm separation column and an elution buffer containing 150 mM NaCl, 10 mM EDTA, 0.1 % (w/v) SDS, 50 mM Tris-HCl, pH 7.5.

3.2 Gel electrophoresis of DNA

Samples of DNA (5 μ g) from (a) the P3-NS2/1-Ag4 myeloma used as parental fusion partner in the generation of the CE 25 hybridoma, (b) the CE 25 hybridoma, and (c) Balb/c mouse kidney cells, prepared as described in Example 2, are digested to completion using the restriction enzymes XbaI, BglII, EcoRI + HindIII, BamHI, EcoRI or HindIII (Boehringer) under conditions recommended by the manufacturer. DNA fragments are separated by flat-bed agarose gel electrophoresis using 10 x 20 x 0.5 cm 0.5 % (w/v) agarose (Biorad, standard low M_r) gels and electrophoresis buffer containing 25 mM disodium-EDTA, 90 mM Tris-base, 90 mM boric acid, pH 8.3. Fragments of bacteriophage λ digested either with HindIII or with EcoRI are pooled and radioactively labelled using Klenow DNA polymerase I fragment (Boehringer) in the presence of dNTPs and α -³²P-dNTPs using a published procedure (Maniatis et al., "Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982). These are included in separate lanes of the agarose gel to provide a range of labelled DNA marker fragments of known size. After separation of DNA fragments by electrophoresis they are transferred by blotting at room temperature to nitrocellulose membrane using the published Southern procedure (Southern, *J. Mol. Biol.* 98, 503, 1975) with some minor modifications as follows. After electrophoresis excess agarose is trimmed from the edges of the gel, after which it is soaked at room temperature in 500 ml of 0.25 M HCl solution for 30 min, followed by soaking in 500 ml of 1.5 M NaCl, 0.5 M NaOH for 60 min to denature the DNA. The gel is rinsed briefly with distilled water and then soaked for 60 min in neutralising solution (3 M NaCl, 0.3 M Tris-HCl, pH 7.5). DNA fragments are then transferred overnight to a nitrocellulose membrane (Schleicher & Schuell, 0.45 μ m pore size) by the published procedure referred to above using a solution containing 3 M NaCl, 0.3 M sodium citrate, pH 6.8.

The nitrocellulose membrane containing the blotted DNA fragments is air-dried and baked at 80 °C for 2 h under vacuum. After baking, excess dried salts are removed by soaking the membrane in 0.75 M NaCl, 0.075 M sodium citrate, pH 6.8, before hybridizing with radioactively-labelled DNA probes.

3.3 DNA hybridization

Nitrocellulose filters prepared as described in Example 3.2 are prehybridized in heat-sealed plastic bags for 4 h at 65 °C in 20 ml of prehybridization solution containing 0.2 ml of 10 % (w/v) SDS, 0.4 ml of 5 % (w/v) sodium pyrophosphate, 0.4 ml of herring sperm DNA (5 mg/ml in distilled water) sheared by passage through an 18 gauge hypodermic needle, 5 ml of Denhardt's solution (Denhardt, BBRC 23, 641, 1966; 0.2 % (w/v) bovine serum albumin, 0.02 % (w/v) polyvinylpyrrolidone, 0.02 % (w/v) Ficoll-400 in 20 x SET buffer (3 M NaCl, 20 mM EDTA, 0.4 M Tris-HCl, pH 7.8)) and 14 ml of distilled water.

The DNA hybridization mixture contains 10⁷ cpm of radioactively-labelled DNA probe, 10 ml of prehybridization solution, prepared as described above, and 10 % (w/v) dextran sulphate (Sigma). The mixture is heated at 100 °C for 20 min to denature the DNA. For hybridization, the prehybridization mixture is removed from the plastic bag and replaced by the hybridization mixture. After excluding air-bubbles the bag is resealed and incubated overnight at 65 °C. To remove non-specifically bound DNA from the membrane, the hybridization mixture and membrane are removed from the plastic bag. The membrane is placed in a bath containing 500 ml of 5 x SSC, 0.1 % (w/v) sodium pyrophosphate and washed for 15 min at 65 °C. The membrane is then washed sequentially at 65 °C for 30 min in 500 ml of solution containing 4 x SSC, 3 x SSC, 2 x SSC and finally 1 x SSC, all containing 0.1 % (w/v) sodium pyrophosphate. The membrane is air-dried, sealed in a clean, thin polythene bag, and autoradiographed at -70 °C using Kodak X-ray film (X-omat TM AR) and image intensifying screens, for up to three days.

The results are summarized in Table 1 below and illustrated in Figure 1:

Table 1

Size of CE 25 hybridoma-specific genomic DNA fragments showing homology with murine H-chain and L-chain Ig J-region DNA probes						
DNA probe	restriction enzyme used/size of fragments in kb					
	XbaI	BglII	EcoRI/HindIII	BamHI	EcoRI	HindIII
H-chain	8.0*	21.0	5.6	10.8	7.5	6.3
	2.1	20.0	2.1	8.3	2.5	2.9
L-chain	2.5	1.8	2.1	6.4	20.0	9.5
	2.0*	1.2	1.9	4.5	18.0	1.9

* fragments encoding functional H- and L-chain V-region H8 and L2 segments of the CE 25 antibody

By comparison with the parental fusion partner cell line P3-NS2/1Ag4, the CE 25 hybridoma contains two additional rearranged H-chain Ig gene loci and two additional rearranged L-chain Ig gene loci. These are referred to as H2 and H8 (Fig. 1B), and L2 and L2.5 (Fig. 1A), respectively, from the sizes of the mouse genomic DNA fragments detected in XbaI restriction digests by Southern blotting using mouse Ig-specific DNA probes.

Example 4: Molecular cloning of functionally-rearranged H- and L-chain Ig genes of the CE 25 hybridoma

4.1 Preparation of size-selected DNA fractions containing CE 25 hybridoma-specific rearranged H- and L-chain Ig loci

CE 25 hybridoma DNA (50 µg) is digested to completion with XbaI, extracted with an equal volume of CHCl₃/redistilled phenol (1:1, v/v, saturated with 20 mM Tris-HCl, pH 8.0), followed by extraction with an equal volume of CHCl₃ to remove traces of phenol. DNA is precipitated by the addition of 0.1 vol. of 3 M NaOAc, pH 5.0 and 2.5 vol. of absolute ethanol at -20 °C. The DNA pellet is recovered, dissolved in 150 µl of TE buffer and applied to a 12 ml, 5-24 % (w/v) NaCl gradient in TE buffer in a polyallomer tube for the Beckman SW41 rotor. Gradients are centrifuged for 4.5 h at 37,000 rpm at 25 °C, and fractionated from the

bottom. DNA fractions (300 μ l) corresponding to (a) 1.5-2.5 kb-long DNA fragments, and (b) 6.0-9.0 kb-long DNA fragments, are collected, pooled and precipitated using 2.5 vol. of absolute ethanol at -20 °C. DNA from pooled fractions (a) and (b) are recovered by centrifugation, dried under vacuum and dissolved in TE buffer to concentrations of 50 ng/ μ l and 200 ng/ μ l, respectively.

4.2 DNA ligations and packaging into bacteriophage particles

DNA samples (1 μ l) from fractions (a) and (b) as described above are ligated overnight at 4 °C with 0.8 μ g of λ -OngC/XbaI-digested bacteriophage DNA arms (Stratagene Inc., San Diego, USA) in 5 μ l of a solution containing 10 mM DTT, 1 mM ATP, 10 mM MgCl₂, 20 mM Tris-HCl, pH 7.6, in the presence of 5 units of T4 DNA ligase (Boehringer). Ligation mixtures are packaged using Gigapack 'PLUS' (Stratagene Inc., San Diego, USA) and plated on *E. coli* K12/VCS257 (prepared by growth on NZ-amin/0.4 % (w/v) maltose) using NZ-amin growth medium, according to the manufacturer's instructions, at a density of approximately 250 pfu/cm² using standard microbiological procedures. Plates are incubated overnight at 37 °C.

The L2 and L2.5 rearranged L-chain Ig gene loci are detected in library (a) by Benton & Davis hybridization screening (Science 196, 180, 1977) using the nick-translated ³²P-labelled mouse L-chain Ig DNA probe described in Example 3.1. Positively-hybridizing plaques are plaque-purified, picked using the tip of a sterile pasteur pipette, and the phage resuspended in 1 ml of phage buffer (100 mM NaCl, 8 mM MgSO₄·7H₂O, 0.01 % (w/v) gelatin, 5 mM Tris-HCl, pH 7.5). Phage lysates (10 ml) are prepared by adsorbing 20 μ l of phage suspension to a 100 μ l volume of cells taken from an overnight culture of *E. coli* K12/VCS257, grown in NZ-amin medium supplemented with 0.4 % (w/v) maltose. The mixture is diluted to 10 ml with fresh NZ-amin medium in sterile 50 ml Falcon tubes and grown overnight at 37 °C with vigorous shaking. CHCl₃ (20 μ l) is added and shaking continued at 37 °C for 30 min. Recombinant bacteriophage DNA is prepared from the lysates using a published procedure devised by Blattner et al. (Science 202, 1279, 1978). DNA obtained after the final ethanol precipitation step is dissolved in 100 μ l of TE buffer. Yields of phage DNA are approximately 100 μ g.

Samples of DNA (1 μ g) from each positively-hybridizing recombinant bacteriophage are digested to completion using the restriction endonuclease XbaI. An L2 gene segment is identified as a 2 kb XbaI restriction fragment when the digested recombinant DNA samples are analysed by 1 % (w/v) agarose gel electrophoresis. The approximately 2.0 kb L2 gene segment is cut from the agarose gel, purified by phenol/CHCl₃ extraction and recovered by ethanol precipitation. The purified DNA fragment is then subcloned in both orientations into the pUC12 plasmid cloning vector, linearized by XbaI digestion. All procedures are standard methods (Maniatis et al., "Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982). Restriction mapping of these plasmid subclones using the restriction endonucleases XbaI, BglII, PstI, HindIII and BamHI confirms that the structure of the cloned L2 gene segment corresponds to that of the original genomic L2 gene segment, deduced from Southern blotting of CE 25 hybridoma DNA as described in Example 3. Plasmids containing the cloned L2 gene segment in either orientation are designated pCEA-L2a and pCEA-L2b. A restriction map of pCEA-L2a is shown in Fig. 1A.

Library (b) is used as a source of the H8 rearranged H-chain Ig gene segment using the same procedure. Screening of recombinant phage for H-chain gene loci is achieved by hybridizing with the H-chain-specific radioactively-labelled DNA probe described in Example 3.1. Positively-hybridizing recombinant phages are plaque-purified, DNA is isolated and digested using XbaI as described above. An H8 gene sequence is identified as an approximately 8 kb restriction fragment when separated from cloning vector DNA by digestion with XbaI followed by 1 % (w/v) agarose gel electrophoresis. The H8 gene is subcloned in both orientations into the plasmid vector pUC12, linearized by digestion using XbaI. Restriction mapping of the DNA subclones using the enzymes XbaI, PstI, HindIII and BamHI confirms that the structure of the cloned H8 gene segment corresponds to that of the genomic H8 rearranged H-chain Ig locus, deduced from Southern blotting of CE 25 hybridoma DNA using an H-chain-specific radioactively-labelled DNA probe as described in Example 3. These H8 DNA subclones are designated pH8a1 and pH8b1. A restriction map of the pH8a1 XbaI insert DNA fragment is shown in Fig. 1B.

4.3 Nucleotide sequence analysis of the L2 and H8 gene segments

Nucleotide sequencing of the L2 and H8 gene loci in pCEA-L2(a or b) and pH8(a1 or b1) is performed using the published Sanger dideoxynucleotide chain-termination method (Sanger et al., Proc. Natl. Acad. Sci. 74, 5463, 1977). Recombinant plasmid DNAs are cut using appropriate restriction endonucleases and DNA fragments to be sequenced recovered by 1 % (w/v) gel electrophoresis. DNA fragments are then

cloned and sequenced in M13 bacteriophage vectors with the Amersham M13 Cloning System, using the instructions supplied (Amersham International PLC, UK).

The L2 gene segment is sequenced from the 5'-XbaI restriction site to nucleotide 1395, located 3' to the rearranged L-chain V-J4 region. The nucleotide sequence is the one given in formula III.

5 This data confirms the restriction map of the cloned L2 gene in this region (Fig. 1A) and defines the sequence of the first exon encoding the N-terminal residues of the L-chain leader peptide (beginning with methionine at position 733 in the sequence), an intervening sequence (nucleotides 781-987), and the coding sequence of the remainder of the leader peptide and the rearranged L2 V-region ending in a proline residue located at the V-J4 region (nucleotides 988-1284). Nucleotides 1285-1395 correspond to the known mouse
10 α -chain Ig germline sequence (between 1725-1836 of the EMBL data bank sequence entry MUSIGKJC2). Nucleotides 680-1284 correspond to a known mouse germline L-chain V-region (L7, Pech et al., Nature 291, 668, 1981) except for 7 changes in the V-region coding sequence, which may arise by somatic mutation. This data defines the amino acid coding sequence of the rearranged L2 L-chain gene encompassing the leader peptide, the three framework regions and complementarity determining regions CDRLs 1-3
15 (nucleotide residues 1069-1102, 1147-1167, 1263-1291) including the in-frame V-J4 junction.

The H8 H-chain gene segment is sequenced from the internal HindIII restriction site to nucleotide 857 located 3' to the rearranged H-chain V-D-J region. The nucleotide sequence is the one given in formula IV.

This data confirms the restriction map of this region of the H8 gene (Fig. 1B) and defines the sequence of the first exon encoding the N-terminal 16 amino acid residues of the leader peptide (beginning with
20 methionine at position 322 in the sequence), an intervening sequence (nucleotides 368-473) and the coding sequence of the remainder of the leader peptide and the H8 V-region up to a serine residue (nucleotides 474-844). Nucleotide residues 797-857 correspond to the mouse H-chain Ig germline sequence (between 2291-2352 of the EMBL data bank sequence entry MUSIGCD007) except for three nucleotide changes which affect the predicted coding sequence of the J-region of the H-chain polypeptide. The first 796
25 nucleotide residues of the sequence are homologous to, but not identical to, known mouse H-chain V-region, as deduced from a search of the available sequence data in the Genbank, NBRF or EMBL libraries. This sequencing data defines the amino acid coding sequence encompassing the leader peptide, the three framework regions and CDRHs 1-3 (nucleotides 575-595, 629-680, 776-805), the origin of the H-chain diversity (D) segment (which originates either from DSP2.3, DSP2.4 or DSP2.6 of the mouse H-chain Ig
30 germline locus) and the in-frame V-D-J4 junction of the rearranged H8 H-chain gene of hybridoma CE 25.

Example 5: Comparison between nucleotide sequences of expressed H-and L-chain Ig mRNAs and nucleotide sequences of rearranged H-and L-chain genes from the mouse hybridoma CE 25

35 5.1 Extraction of total cellular RNA

Total RNA is extracted using the LiCl/urea method described by Auffray & Rougeon (Eur. J. Biochem. 107, 303, 1980) as modified by Le Meur et al. (Cell 23, 561, 1981). CE 25 hybridoma cells (5×10^7) are grown and prepared as described in Example 2. Cell pellets are thawed directly in the tube in the presence
40 of 5 ml of LiCl/urea (3 M LiCl, 6 M urea, 200 μ g/ml heparin, 0.1 % SDS, 10 mM NaOAc, pH 5.0). Subsequent steps are described in the published procedures. The method yields approximately 50 μ g of total cellular RNA. Final purified material is stored under 70 % (v/v) ethanol at -80°C at a known concentration.

45 5.2 Nucleotide sequencing of expressed H- and L-chain Ig mRNAs

Nucleotide sequencing of mRNA from the CE 25 hybridoma is accomplished directly in total cellular RNA preparations utilising specific radioactively-labelled oligonucleotide primers. These primer oligonucleotides are synthesized chemically using a published procedure (Rink et al., Nuc. Acids Res. 12,
50 6369, 1984).

(a) Sequencing of mouse C α -containing mRNA is achieved using a specific oligonucleotide primer of composition HO-5'-dGGGAAGATGGATACAGTTGG-3'-OH. This sequence is complementary to codons 3-12 of the published mouse C α coding sequence (Altenburger et al., Nuc. Acids Res. 9, 971, 1981).

(b) Sequencing of mouse IgG1-specific mRNA is achieved using a specific oligonucleotide primer of
55 composition HO-5'-dGGCCAGTGGATAGAC-3'-OH. This sequence is complementary to codons 7-11 of the CH1 domain (first constant region exon) of the mouse Ig γ 1 H-chain coding sequence (Honjo et al., Proc. Natl. Acad. Sci. 18, 559, 1979).

Both oligonucleotides are radioactively-labelled at the 5'-end in the presence of γ - ^{32}P -ATP (Amersham) using T4-polynucleotide kinase (Pharmacia), to a specific activity of 2×10^6 dpm/pmol. Labelling and separation of radioactively-labelled oligonucleotides from unincorporated γ - ^{32}P -ATP using Sephadex G50 (Pharmacia) chromatography is carried out using a published procedure (Qu et al., Nuc. Acids Res. 11, 5903, 1983).

For sequencing, samples (25 μg) of stored RNA under ethanol are recovered by centrifugation at 4°C for 30 min using an Eppendorf centrifuge, and resuspended in TE buffer containing 10^6 dpm of 5'-end-labelled primer. This mixture is aliquoted into 5 x 1 ml Eppendorf tubes containing 1 μl of annealing buffer, 5 units of reverse transcriptase (Genofit SA, Geneva), 1 μl of dNTP mixture and 1 μl of either ddATP (200 μM), ddGTP (100 μM), ddCTP (80 μM) or ddTTP (200 μM) solution in distilled water in a final volume of 5 μl (all from Amersham International, UK). The fifth reaction tube contains no ddNTPs and is used to monitor the integrity of the mRNA. Reaction mixtures are incubated at 37°C for 30 min for primer (a), or at 42°C for 30 min for primer (b). Buffers and mixtures are as follows: annealing buffer for primer (a): 60 mM MgCl_2 , 0.4 M KCl, 0.5 M Tris-HCl, pH 8.3; annealing buffer for primer (b): 60 mM MgCl_2 , 0.6 M NaCl, 0.5 M Tris-HCl, pH 8.3; dNTP mixture: 2 mM concentration of each of dNTPs in distilled water, except for that corresponding to the ddNTP used in the particular sequencing reaction, which is used at a concentration of 0.5 mM.

Sequencing reactions are stopped by the addition of 20 μl of distilled water and 30 μl of 0.6 M NaOH to each tube. RNA is hydrolysed by incubation overnight at 37°C. Reaction mixtures are neutralized by the addition of 8.4 μl of 3 M acetic acid, and DNA precipitated by addition of 2.5 vols. of absolute ethanol in the presence of 0.3 M NaOAc, pH 5.0. The DNA pellets are dried in air at 60°C and resuspended in 2 μl of sequencing dye mixture and electrophoresed on 6 % polyacrylamide/urea DNA sequencing gels using standard materials and procedures (Sanger et al., Proc. Natl. Acad. Sci. 74, 5463, 1977).

The sequence of the L-chain mRNA specifically expressed in mouse hybridoma CE 25 is

```

      1160              1180              1200
mRNA:  ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
      3'-GACCCTAGGGAAGGTCCAAATCACCGTCACCTAGT
      1220              1240              1260
mRNA:  GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
      CCCTGTCTAAATGAGAATGGTAGTTATCACACCTCAGACTTCTATAACGTCTAATAATG
      1280              1300              1320
mRNA:  TGTCACAAAGTCATGGCTGGCCATTCACGTTTCGGCTCGGGACAAAGTTGGAAATAAAA
      ACAGTTGTTTCAGTACCGACCGGTAAGTGCAAGCCGAGCCCCTGTTTCAACCTTTATTTT
      CG
mRNA:  GCccgactacgacgtggttgacataggtagaaggg-5'
      |----- primer -----|

```

The sequence runs 3'-5' and is complementary to the portion of the cloned and sequenced L2 L-chain Ig gene isolated from CE 25 hybridoma DNA from nucleotide 1166-1322 (cf. Example 4.3).

The sequence of the H-chain mRNA specifically expressed in mouse hybridoma CE 25 is

```

5      614      634      654
mRNA:  TCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTACATCCATTAGTAGTGGTGGTACCAC
      3'-ACCTCAGCCAGTGTAGGTAATCATCACCACCATGGTG
10      674      694      714
mRNA:  CTACTATCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACAT
      GATGATAGGTCTGTACACACTTCCCGGCTAAGTGGTAGAGGTCTCTATTACGGTCCTTGT
15      734      754      774
mRNA:  CCTGTACCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAG
      GGACATGGACGTTCACTCGTCAGACTCCAGACTCCTGTGCCGGTAAATAATGACACGTTT
20      794      814      834
mRNA:  AGGTTTCTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCAC
      TCCAAAGATACTACCAATGGAGATACAACACCTGATGACCCAGTTCCTTGGAGTGAGTG
      854
mRNA:  CGTCTCCTCAGGTAAGAATGGCC
      GCAGA-5'

```

The sequence runs 3'-5' and is complementary to the portion of the cloned and sequenced H8 H-chain Ig gene isolated from CE 25 hybridoma DNA from nucleotide 618-839 (cf. Example 4.3). It does not include the sequence complementary to the primer binding site.

Example 6: Specific transcription of L2- and H8-specific mRNA transcripts in CE 25 hybridoma cells by Northern blot analysis

Total cellular RNA from either CE 25 hybridoma cells or from P3-NS2/1Ag4 cells is prepared as described in Example 5. Samples of RNA (25 and 50 µg) are recovered by centrifugation from the ethanol used for storage, after which they are resuspended in 20 µl of solution containing 2.2 M formaldehyde, 50 % (v/v) formamide, 1 mM EDTA, 40 % (w/v) sucrose, 50 mM γ-morpholino propanesulphonic acid (MOPS) pH 7.0, and 0.5 % (w/v) xylene cyanol and 0.5 % (w/v) bromocresol green, used as marker dyes for monitoring the progress of electrophoresis. After mixing, samples are loaded on to 1 % (w/v) agarose gels using an electrophoresis buffer containing 1 mM EDTA, 2.2 M formaldehyde, 50 mM MOPS, pH 7.0. Gels are pre-electrophoresed for 30 min before use.

After electrophoresis, excess agarose is trimmed from the sides of the gel, which is then soaked in 20 x SSC buffer for 5 min. RNA is transferred to nitrocellulose membrane by the standard Northern blot procedure (Maniatis et al., "Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982). After overnight transfer, the membrane is air-dried and baked for 2 h at 80 °C under vacuum. Before hybridization, the membrane is prehybridized in 20 ml of a solution containing 50 % (v/v) formamide, 5 x SSC buffer, 5 x Denhardt's solution (described in Example 3.3), 10 mM EDTA, 0.1 % (w/v) SDS, 50 mM sodium phosphate, pH 6.8 and 2 ml of sheared herring sperm DNA (5 mg/ml in distilled water, Example 3.3). Incubation is carried out in a heat-sealed plastic bag at 42 °C for 8 h. For hybridization, the prehybridization mixture is removed from the plastic bag and replaced with hybridization solution similar to prehybridization solution but containing 2 x Denhardt's solution instead of 5 x Denhardt's solution, and 2 x 10⁷ cpm of nick-translated ³²P-labelled denatured hybridization probe DNA. The radioactively-labelled DNA probe specific for the rearranged L2 Ig L-chain gene segment is the plasmid pCEA-L2a (Fig. 1A & Fig. 3). The radioactively-labelled DNA specific for the rearranged H8 H-chain gene segment is the plasmid pH8a1 (Fig. 1B). Preparation of nick-translated probe DNA is described in Example 3.1. After hybridization for 16 h at 42 °C, the membrane is removed from the plastic bag and washed twice for 1 h at 42 °C in hybridization mixture without DNA probe, then once in 2 x SSC, 0.1 % (w/v) SDS also at 42 °C, followed by two washes in 0.1 x SSC, 0.1 % (w/v) SDS, both at room temperature. The membrane is then air-dried, placed in a thin plastic bag and exposed to Kodak X-omat TM AR diagnostic film at -70 °C using an image intensifying screen.

The results of the Northern blot analysis are shown in Fig. 2.

Example 7: Molecular cloning of constant region segments of the human Ig gene loci7.1 Human DNA library

A human DNA library is constructed in the bacteriophage λ vector Charon 4a, by limited digestion of human foetal liver DNA with restriction endonucleases HaeIII and AluI using published procedures (Lawn et al., Cell 15, 1157, 1978). Approximately 1×10^5 independent recombinant phages are plated on *E. coli* K12/803 and screened by nucleic acid hybridization for the presence of human C α L-chain sequences and for human Ig γ 4 H-chain sequences, as described below.

7.2 Isolation of human C α -containing DNA segment

A nick-translated 32 P-labelled mouse Ig L-chain DNA probe is prepared corresponding to that described in Example 3.1, and used to screen recombinant phage using the procedure described in Example 4.2. DNA is isolated from plaque-purified positively-hybridizing plaques using a standard published procedure (Blattner et al., Science 202, 1279, 1978). A 2.5 kb EcoRI DNA fragment encompassing the human C α coding segment (Hieter et al., J. Biol. Chem. 257, 1516, 1982) is isolated in this manner and subcloned in both orientations into the plasmid vector pBR322, linearized using EcoRI. These plasmids are referred to as pDA13b and pDA14a, respectively. A restriction map of pDA14a is constructed and is shown in Fig. 3.

7.3 Isolation of human γ 4 H-chain-containing DNA segment

A nick-translated 32 P-labelled mouse IgG H-chain DNA probe corresponding to the XbaI/HhaI fragment of the mouse γ 2b gene locus is used to screen recombinant phage as described previously (Takahashi et al., Cell 29, 671, 1982). One DNA clone (#188) contains the human γ 4 gene locus as determined by restriction mapping and by nucleotide sequence analysis using the Gilbert-Maxam procedure (Proc. Natl. Acad. Sci. 74, 560, 1977). The portion of clone #188 that is sequenced corresponds exactly to that of the published human γ 4 gene between nucleotides 27-98 (EMBL data base sequence entry HUMIGCD2). An approximately 3 kb HindIII/EcoRI DNA restriction fragment, including the 4 exons of the γ 4 gene locus, is subcloned into the plasmid vector pUC12 cleaved using HindIII/EcoRI. The plasmid is designated p γ 4/1. The HindIII site in p γ 4/1 is found in the γ 4 gene locus of Balb/c mouse DNA (nucleotide position 1 of EMBL data base sequence entry HUMIGCD2; Ellison et al., DNA 1, 11, 1981). The EcoRI site is derived from the EcoRI cloning site in the Charon 4a bacteriophage λ cloning vector at the end of clone #188. A restriction map of p γ 4/1 is shown in Fig. 4.

Example 8: Construction of chimeric mouse/human (γ 4; α) anti-CEA H- and L-chain Ig genes and insertion of these genes into separate vectors

Chimeric constructs holding chimeric mouse/human anti-CEA H- and L-chain genes, respectively, are constructed and are sequentially transferred into host cells with the help of two expression vectors as described in the following (examples 8 and 9).

Unless otherwise stated experimental procedures are those described in Maniatis et al. ("Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982).

8.1 Molecular cloning of a mouse DNA segment containing the L-chain Ig enhancer element

An approximately 475 bp AluI DNA restriction fragment containing the mouse L-chain Ig enhancer of RNA transcription (Picard & Schaffner, Nature 307, 80, 1984; nucleotides 3691-4164 of the Balb/c mouse L-chain Ig locus, EMBL data base sequence entry MUSIGKJC2) is cloned by blunt-end ligation into the pUC12 plasmid vector linearized using the restriction endonuclease SmaI. Ligated DNA is transformed into competent *E. coli* K12/803, and clones are selected after overnight growth on nutrient agar (Oxoid) plates containing 50 μ g/ml of ampicillin. Of the two orientations of insert DNA possible a clone is selected containing the plasmid pEL22, the restriction map of which is shown in Fig. 3. pEL22 contains the 475 bp mouse AluI DNA fragment in the same orientation as in the mouse genome, with its 3' end adjacent to the EcoRI site in the pUC12 vector. Its orientation is determined by nucleotide sequencing with the Sanger sequencing protocol described in Example 4.3, using the modifications for direct sequencing of plasmid DNA molecules (Chen & Seeburg, DNA 4, 165, 1985). The sequencing primer used is the Amersham reverse sequencing primer (Cloning and Sequencing Handbook, Amersham International PLC, UK).

8.2 The chimeric L-chain gene (pCEA-C $\times$ Ga)

The scheme for the construction of pCEA-C $\times$ Ga is shown in Fig. 3. Plasmid pDA14a (Example 7.2) and plasmid pEL22 (Example 8.1) are digested to completion with restriction endonuclease EcoRI. The 2.5 kb EcoRI DNA fragment insert of pDA14a is separated from vector sequences by 1 % (w/v) agarose gel electrophoresis and recovered by ethanol precipitation after phenol/CHCl₃ extraction (Example 3.2). Equimolar amounts of EcoRI-cut pEL22 and pDA14a 2.5 kb DNA insert are ligated together overnight at 4°C using T4 DNA ligase (Boehringer) and transformed into competent *E. coli* K12/803. Ampicillin-resistant colonies are selected by plating on nutrient agar plates containing 50 μ g/ml of ampicillin and incubating overnight at 37°C. Single colonies are selected and plasmid DNA is prepared from 5 ml mini-cultures according to the procedure described by Ish-Horowicz & Burke (Nucleic Acids Res. 9, 2989, 1981). Digestion of recombinant plasmids using the restriction endonuclease XbaI is used to determine the orientation of the 2.5 kb EcoRI fragment with respect to the transcriptional enhancer-containing element of pEL22. A clone containing these fragments in the desired orientation is selected and plasmid DNA isolated. The corresponding recombinant plasmid is referred to as pKY14a. DNA of pKY14a is partially digested using the restriction endonuclease XbaI, extracted with phenol/CHCl₃ and recovered by ethanol precipitation. After recovery, the DNA is treated with Klenow DNA polymerase-I fragment (Boehringer) in the presence of dNTPs to perform a filling-in reaction on the XbaI-cleaved DNA termini. Flush-ended DNA fragments are blunt-end ligated in the presence of T4 DNA ligase (Boehringer), transformed into competent *E. coli* K12/803, and plasmid DNA mini-preparations made from individual ampicillin-resistant clones, as described above. Restriction mapping of recombinant plasmids by terminal digestion using HindIII + XbaI is used to identify a plasmid recombinant (pXba5.5) containing a deleted XbaI restriction site at the position indicated in parentheses in Fig. 3.

The complete DNA insert (approximately 3 kb) of pXba5.5 is isolated by partial digestion of the plasmid with EcoRI followed by complete digestion with Sall, separation from vector DNA sequences by 1 % (w/v) agarose gel electrophoresis, followed by phenol/CHCl₃ extraction and ethanol precipitation as described above. The approximately 2 kb insert DNA fragment of pCEA-L2a is similarly recovered after terminal digestion with EcoRI/Sall. The recovered DNA fragments are quantified. The eukaryotic plasmid vector pSV2gpt (Mulligen & Berg, Science 209, 1422, 1980) is digested to completion using EcoRI and DNA similarly extracted with phenol/CHCl₃, recovered after ethanol precipitation and quantified. Equimolar amounts of EcoRI-cut pSV2gpt, the 2 kb EcoRI/Sall mouse DNA fragment of pCEA-L2a, and the 3 kb Sall/EcoRI mouse DNA fragment of pXba5.5 are ligated together in a three-way ligation reaction in the presence of T4 DNA ligase (Boehringer). Recombinant plasmids are again selected as described above and those with the correct orientation of DNA fragments characterized by restriction mapping. One recombinant designated pCEA-C $\times$ Ga contains the DNA fragments in the orientation shown in Fig. 3. The selectable marker gene (gpt) derived from pSV2gpt and the resulting chimeric mouse/human L-chain Ig gene have the same transcriptional polarity.

8.3 Molecular cloning of a mouse DNA segment containing the H-chain Ig enhancer element

A 1.6 kb HindIII/EcoRI DNA segment from the Balb/c mouse genome (nucleotide positions 1963-3559, EMBL data bank sequence entry MUSIGCD07) is treated with Klenow DNA polymerase-I fragment (Boehringer) in the presence of dNTPs in order to generate a blunt-ended, double-stranded DNA molecule. The DNA is extracted with phenol/CHCl₃ and recovered after ethanol precipitation. Double-stranded HindIII DNA linkers are added by ligation in the presence of T4 DNA ligase (Boehringer) and the extraction/precipitation procedure repeated. The DNA fragment is then treated with restriction endonucleases HindIII + XbaI, and the smaller of the two XbaI/HindIII fragments generated (approximately 670 bp) is isolated after separation from the other by 1 % (w/v) agarose gel electrophoresis. This fragment is cloned in an XbaI/HindIII-cleaved pUC13 plasmid vector using procedures described in Example 8.2. The resulting plasmid, referred to as pDA4 (Fig. 4), contains the mouse H-chain Ig enhancer of transcription.

8.4 The chimeric H-chain gene (pCEA- γ 4Na)

The mouse Ig enhancer-containing fragment of pDA4 is recovered after cleavage with EcoRI + HindIII by agarose gel electrophoresis/phenol-CHCl₃ extraction/ethanol precipitation. The 3 kb EcoRI/HindIII DNA insert of p γ 4/1 is similarly isolated. The two fragments are ligated together with pBR322 plasmid vector DNA linearized by digestion with EcoRI. After transformation into *E. coli* K12/803, recombinants are selected and plasmid DNA mini-preparations made. Restriction mapping using EcoRI, HindIII and PstI leads to the

identification of recombinant clones containing the desired DNA fragments. One of these clones is designated pDA16a (Fig. 4). The approximately 3.7 kb insert DNA fragment of pDA16a is recovered after terminal digestion using restriction endonucleases XbaI and EcoRI, followed by agarose gel electrophoresis/phenol-CHCl₃ extraction/ethanol precipitation. The approximately 1.7 kb EcoRI/XbaI fragment of pH8a1, containing the rearranged V-D-J4 H-chain segment of the H8 gene is similarly purified. The two fragments are quantified and ligated together in equimolar amounts in a three-way ligation reaction with pSV2neo (Southern & Berg, J. Mol. App. Genet. 1, 327, 1982) linearized using EcoRI restriction endonuclease in the presence of T4 DNA ligase (Boehringer). After transformation into *E. coli* K12/803, recombinants are selected as described above and characterized by restriction mapping using the restriction endonucleases EcoRI, HindIII, PstI and XbaI. A recombinant with the desired orientation of DNA fragments is designated pCEA-γ4Na. In this plasmid the selectable marker gene (neo) derived from the vector pSV2neo has the same transcriptional polarity as the mouse/human chimeric H-chain Ig gene.

Example 9: Transfection and expression of chimeric mouse/human Ig genes pCEA-CxGa and pCEA-γ4Na in mouse lymphoid cells

Sp2/0 (ATCC CRL 1581) is a well-characterized mouse cell line of lymphoid origin. It is an Ig non-secreting variant of a cell line obtained from the fusion of a mouse spleen cell with the myeloma X63-Ag8, a subline of the myeloma MOPC-21 (Koehler & Milstein, Eur. J. Immunol. 6, 511, 1976; Shulman et al., Nature 276, 270, 1978). Sp2/0 cells grown in supplemented DMEM as described in Example 2 are harvested by gentle centrifugation (130 g, 4°C) in 50 ml sterile tubes (Falcon 2070) and washed/resuspended in PBS-CM (Seromed) at a concentration of approximately 1×10^8 cells/ml at 4°C. Cells are kept on ice for up to 30 min.

9.1 Transfection of Sp2/0 with the chimeric H-chain Ig gene pCEA-γ4Na

Transfection of the chimeric H-chain gene construct (pCEA-γ4Na) is achieved by addition of 20 µg of supercoiled pCEA-γ4Na DNA in 50 µl of TE buffer to 1×10^7 Sp2/0 cells in 200 µl of PBS-CM in a sterile plastic tube, on ice. The cells are drawn into the barrel of a TA750 electro-transfection apparatus (Kruess GmbH, Hamburg, W. Germany) and subjected to one electrical pulse of 3500 V/cm for 10 µs, using the cylindrical electroporation chamber provided by the manufacturers, pre-cooled by drawing sterile, ice-cold PBS-CM into the barrel of the apparatus before use. Cells are expelled gently into a clean, sterile cryotube (Nunc) and kept on ice for 10 min, after which they are incubated at room temperature for a further 20 min after dilution (1:3; v/v) with growth medium (see above). Cells are then distributed into 96 wells in two 48-well tissue culture clusters (Costar) at a cell density of approximately 1×10^5 cells/well in 1 ml of DMEM growth medium containing 15 % FCS, 1 mM sodium pyruvate, 10 mM Hepes, 1 mM glutamine, 100 µM gentamycin (Gibco), 5 ng/ml insulin + 5 ng/ml transferrin + 5 pg/ml selenium (CR-ITS premix., Collaborative Res. Inc.), 56 µg/ml folic acid (Seromed), 36 µg/ml L-asparagine (Calbiochem), 116 µg/ml L-arginine HCl (Calbiochem). After incubation for 48 h at 37°C in a humidified atmosphere containing 7.5 % CO₂ (Heraeus Cytoperm incubator), transfected cells are selected by addition of 1 mg/ml of G418-sulphate (Geneticin, Gibco 066-1811). Medium and drug are changed every 2 days. Cells are screened for the expression of human IgG after 14 days using the "dot" assay described in Example 9.2.

9.2 Selection of transfectants containing intracellular human Ig H-chain polypeptide

No H-chain Ig protein is expected to be detected in the medium of Sp2/0 cells transfected with the chimeric H-chain gene construct alone, because H-chains are only secreted after they become associated with L-chains, but Sp2/0 cells do not contain functional L-chain polypeptide. Confirmation of expression of intracellular H-chain polypeptides in cells transfected with the chimeric Ig H-chain gene pCEA-γ4Na is performed as follows. Transfected cells (1×10^5) are collected from culture medium by gentle centrifugation, washed with PBS and resuspended in 10 µl of H₂O. Cells are ruptured by three rounds of freezing in dry ice and thawing at 37°C. Cell debris is removed by centrifugation at 5'000 g (Eppendorf Microcentrifuge) at room temperature. The intracellular heavy chain expression is analysed by a procedure described by Towbin & Gordon (J. Immun. Meth. 72, 313, 1984) by dotting samples (1 µl) of the supernatant on to acetate cellulose membrane (Millipore HAWAG, 0.45 µm pore size). After blocking non-specific binding by incubating membranes in RIA-buffer (1 % BSA (Fluka Fraction V, 05480), 0.2 % Na₂S₂O₃ (Merck), 0.1 % phenol red (Seromed) in PBS) at 37°C for 20 min, they are washed in PBS and then incubated for 2 h at 37°C in developing serum containing goat-anti-human IgG (alkaline phosphatase-labelled, Tago) at a

dilution of 1:1000 in RIA-buffer. Membranes are washed 6x in PBS followed by 6x in H₂O after which they are incubated at room temperature for 15 min in substrate buffer consisting of a 1:1 mixture of the following two solutions prepared immediately before use: (a) 1 mg/ml of Fast Blue B salt (Fluka, 44660) in H₂O; (b) 1 mg/ml of 2-naphthylphosphate, monosodium salt (Fluka, 71100) in 60 mM borate buffer, pH 9.7. The reaction is stopped by incubating membranes in methanol:acetic acid:water (5:1:5, v/v). Viable cells, corresponding to those giving strong colour signal signifying alkaline phosphatase activity (thus expressing high levels of intracellular human IgG heavy chain), are cloned. From several such cloned cell lines, one (EFVIII/γ4Na75-75) is chosen for a second round of transfection with the chimeric L-chain gene construct plasmid pCEA-C_xGa.

9.3 Transfection of EFVIII/γ4Na75-75 with the chimeric L-chain Ig gene pCEA-C_xGa

Cells of EFVIII/γ4Na75-75 or any other cell line prepared according to Example 9.2 are expanded by growth in the medium described in Example 2. Approximately 1×10^7 cells are collected by gentle centrifugation, and washed/resuspended in 200 μl of PBS-CM on ice. Cells are then transfected using 10 μg of supercoiled pCEA-C_xGa DNA, and transfectants plated in tissue culture clusters using the procedure described in Example 9.2. After growth for 60 h transfected cells are selected using growth medium containing 0.125 μg/ml of mycophenolic acid (Calbiochem, 475913, from Behring Diagnostics), 250 μg/ml of xanthine, and a 1:45 dilution of hypoxanthine/thymidine (HT, 50x conc., Boehringer, 623091). The concentration of mycophenolic acid is increased to 0.5 μg/ml within the following 14 day growth period, keeping the amount of HT and xanthine constant. After this period, cell culture medium from wells of tissue culture clusters is assayed for secreted human IgG, as described in Example 9.4.

9.4 Antibody detection assay and determination of level of secreted human IgG in transfected cells

Flat-bottomed micro-ELISA plates (Immulon, Dynatech, M129A) are coated either with 1 μg/well of goat-anti-human α antibody (Tago, 060401) or with 500 ng/well of purified human carcinoembryonic antigen (Tu241, a gift from Prof. J.-P. Mach, Department of Biochemistry, University of Lausanne), by incubation overnight at 4°C. After washing with PBS, non-specific binding is blocked by incubating with RIA-buffer (Example 9.2) for 20 min at 37°C in a humidified chamber, followed by further washing with PBS. Cell supernatants (50 μl) are added and incubated for 2 h at 37°C. After washing with PBS, bound chimeric antibody is developed using alkaline phosphatase-labelled goat-anti-human IgG antibody (Tago, 902002) at the recommended dilution (1:1000) in RIA-buffer. Plates are incubated for 2 h at 37°C. Plates are washed several times with PBS before addition of 150 μl of substrate buffer which consists of 2 tablets of phosphatase substrate (p-nitrophenylphosphate, Sigma, 104R) in 10 ml of substrate buffer (800 ml of H₂O, 97 ml of diethanolamine, 130 ml of 1 M HCl, 200 mg of NaN₃, 200 mg of MgCl₂·6H₂O, pH adjusted to 9.7. After incubation for 15 min at 37°C the colour reaction is stopped by addition of 50 μl of 1 M NaOH. E₄₀₅₋₄₉₅ measured using a Titertek Multiscan MC. Viable cells from parallel wells having high levels of secreted human IgG are cloned. One of several such clones is designated EFVIII/γ4Na75-75/C_xGa5-6 (referred to as CE 75-5-6) and was deposited at the "Collection Nationale de Cultures de Microorganismes" of the Institut Pasteur, Paris, on Dec. 15, 1987, under the number I-720.

For quantitation of the amount of chimeric antibody (γ4;_x) secreted by CE 75-5-6, several standard human IgG4_x myeloma proteins (from Dr. F. Skvaril, Institute of Cancer Research, Berne) are used. Based on this test the transfectoma CE 75-5-6 secretes 1 μg/ml of chimeric antibody into the culture medium after 6 days growth.

Example 10: Construction of chimeric mouse/human (γ4;_x) anti-CEA H- and L-chain genes and insertion of these genes into a double-construct vector

Chimeric constructs containing chimeric mouse/human anti-CEA H- and L-chain-genes, respectively, are constructed and are transferred into host cells with the help of a single vector comprising chimeric H- as well as L-chain genes as described in the following examples 10 and 11. Unless otherwise stated experimental procedures are those described in Maniatis et al. ("Molecular Cloning: A laboratory manual", Cold Spr. Harbour, N.Y., 1982).

10.1 Molecular cloning of a mouse DNA segment containing the L-chain Ig enhancer element (mouse Ig L-chain-ΔC_x precursor)

The mouse C_x gene is deleted from the germline sequences by isolating a 2 kb PstI/XmnI and a 1.1 kb XmnI/BamHI fragment from pLCEA/14A. (Walfield et al., Nucl. Acids Res. 8, 4689, 1980). This plasmid contains the mouse NS2 C_x light chain gene, rearranged at the J2 joining segment, on a 7.0 kb BamHI/BamHI restriction fragment. This fragment is equivalent to the 7.0 kb BamHI/BamHI fragment derived from MOPC21/NS-1n as described by Walfield et al. (see above). The exact sequence of the 3.9 kb PstI/BamHI fragment is given in the EMBL data base entry MUSIGKJC2, nucleotide positions 2368-6258.

The cloning of these two fragments into the vector pUC12, double-restricted with PstI and BamHI, creates a recombinant plasmid designated pM1ΔC_x. The resultant cloned fragment contains germline sequences from the mouse immunoglobulin light chain locus starting at the PstI site, 268 bp downstream of the J5 joining segment, through to the BamHI site, 3884 bp downstream of the PstI site. Nucleotide positions below are indicated relative to the first base of this PstI recognition sequence. The fragment includes the mouse Ig C_x enhancer sequences at 1542-1666 in its original germline configuration. The mouse C_x coding region has been deleted between positions 2021 and 2754 using existing XmnI sites at these positions, recreating an XmnI site at the junction of the deleted C_x gene. The total PstI/BamHI fragment measures 3152 bp and now has a unique XmnI site at the site of the deleted mouse C_x gene at position 2017-2026, for cloning purposes. A restriction map of pM1ΔC_x is shown in Figure 5.

10.2 The chimeric L-chain gene (pMceaC_x^h-1a)

The human C_x coding sequences are isolated from plasmid pDA14a, a pBR322 recombinant, containing a 2.5 kb EcoRI/EcoRI fragment within which is located the ca. 320 bp human C_x coding region. This plasmid has been described in Example 7.2 and a restriction map is shown in figures 3 and 5. A 724 bp SphI/HhaI fragment is purified and the 3' protruding ends trimmed with bacteriophage T4 DNA-polymerase. The fragment starts 106 bp 5' and extends 296 bp 3' of the human C_x coding region. It includes also the polyadenylation site which lies 177 bp 3' of the C_x coding sequence.

pM1ΔC_x contains two XmnI sites, one at the junction of the deleted mouse C_x sequences and one in the β-lactamase coding sequence derived from pUC12, which confers resistance to ampicillin. pM1ΔC_x is partially restricted to ampicillin. pM1ΔC_x is partially restricted with XmnI and the linear form gel-purified. 50 % of this material is restricted at the XmnI site in the β-lactamase coding sequence, 50 % is restricted at the required former mouse C_x location.

Insertion of the human C_x fragment in the first XmnI site results in a recombinant plasmid without a functional β-lactamase gene, hence only recombinants are found which contain the human C_x fragment at the position of the former mouse C_x region. Two orientations are possible. The recombinant plasmid containing the human C_x fragment in the correct orientation, N-terminus closest to the mouse enhancer region, is identified by restriction analysis of the recombinant plasmids with restriction endonuclease Aval. This plasmid is designated pM1HuC_x-1a.

The mouse CEA light chain sequences are isolated from the recombinant plasmid pCEA-L2a. This plasmid contains an 1.9 kb XbaI/XbaI fragment coding for the functional variable part of the mouse anti-CEA light chain and is described previously (Example 4.2). A restriction map is shown in Figs. 1A, 3 and 6.

By partial XbaI restriction followed by total EcoRI restriction, the mouse anti-CEA light chain variable segment is isolated on a 1.9 kb EcoRI/XbaI fragment. This fragment has an extra 24 bp derived from the pUC12 polylinker, including restriction sites for BamHI, SmaI and SacI. These sites lie 5' of the mouse variable anti-CEA coding region. In the final genomic construct they are positioned at the junction of the recombinant fragment and the expression vector.

The 1.9 kb EcoRI/XbaI fragment is joined to the 3.8 kb PstI/BamHI fragment from pM1HuC_x-1a described above, containing the mouse Ig C_x enhancer and the human C_x coding region. For cloning purposes it is isolated as an XbaI/EcoRI fragment using the XbaI site 18 bp downstream of the PstI site and the EcoRI site in the pUC12 polylinker, which adds 18 bp downstream of the BamHI site including SmaI and SacI restriction sites. These polylinker sequences are positioned at the second junction of recombinant fragment and expression vector.

The two fragments are joined and cloned into the expression vector pSV2gpt, restricted with EcoRI, in a three way ligation. Two orientations of the fragment, relative to the gpt gene, are isolated, either both gpt and mouse variable anti-CEA-human C_x in the same transcriptional orientation (orientation a) or in opposite transcriptional orientation (orientation b). Both orientations are identified by double restriction with restriction

endonucleases HindIII and PstI. They are designated pMceaC_x^h-1a and pMceaC_x^h-1b. Their DNA insert contains the full coding region of the mouse variable anti-CEA-human C_x constant immunoglobulin light chain in the original mouse genomic configuration. The fragment is recovered as a single EcoRI/EcoRI fragment of ca. 5.7 kb.

10.3 The chimeric H-chain gene (pCEA-γ4Na)

The chimeric H-chain gene pCEA-γ4Na is constructed as described in examples 8.3 and 8.4.

10.4 The chimeric double-construct holding both mouse/human (γ4;x) anti-CEA H- and L-chain lg genes (pCEA(H+L)2neo)

Both the mouse anti-CEA-human constant chimeric light and heavy chain are contained on a single EcoRI/EcoRI fragment, the light chain on a 5.7 kb fragment in pMceaC_x^h-1a, the heavy chain on a 5.3 kb EcoRI/EcoRI fragment in pCEA-γ4Na.

By joining the light and heavy chain EcoRI/EcoRI fragments and destroying the EcoRI site at the junction, a double gene construct is created where all coding sequences and regulatory sequences for the mouse/human (γ4;x) anti-CEA H- and L-chain lg genes are located on an 11.0 kb EcoRI/EcoRI fragment.

pMceaC_x^h-1a and pCEA-γ4Na are partially restricted with EcoRI followed by filling in of the 5' overhang with the large fragment of *E. coli* DNA polymerase I (Klenow fragment). The linear form of each plasmid is gel purified followed by double restriction with restriction endonucleases EcoRI and HpaI. This releases the chimeric fragment from the pSV2gpt or pSV2neo vector, respectively, since the only restriction sites for HpaI are in the two vectors. Only one of the EcoRI 5' ends of each fragment is a blunt end. The other end remains a 'sticky' 5'-EcoRI overhang. The two fragments are ligated together in a 1:1 ratio with bacteriophage T4 ligase to form concatemeric molecules. A certain number of the light chain fragments are joined to a blunt-end of a heavy chain fragment. Total restriction with EcoRI produces a certain number of 11.0 kb EcoRI/EcoRI fragments of which a third part is a light chain joined to a heavy chain mouse/human (γ4;x) anti-CEA chimeric fragment. The remaining two thirds consist of heavy-heavy and light-light chain dimers which are presumably not clonable.

Gel purification of the ca. 11.0 kb EcoRI/EcoRI fragments followed by cloning into the pSV2neo or pSV2gpt expression vector, restricted with EcoRI, and transformation to competent *E. coli* K12/803 results in a number of recombinant plasmids. These are screened by colony hybridization to the 1.9 kb XbaI/XbaI fragment coding for the mouse anti-CEA variable light chain sequences, isolated from plasmid pCEA-L2a (Example 4.2). DNA is prepared from positive colonies and recombinant plasmids having both the heavy and light chain mouse/human (γ4;x) anti-CEA chimeric DNA fragments are identified by restriction enzyme analysis with restriction endonucleases EcoRI, XmnI and PstI. One recombinant plasmid obtained this way is designated pCEA(H+L)2neo. The anti-CEA light and heavy chain chimeric fragments are arranged in opposite transcriptional orientation. The anti-CEA heavy chain fragment is in the same transcriptional orientation as the neo gene in pSV2neo. The EcoRI site at the junction of the anti-CEA light and heavy chain chimeric fragments is destroyed but the expected XmnI site, which is created by joining two blunted EcoRI sites, is not present. From this double chimeric gene construct the mouse/human (γ4;x) anti-CEA light and heavy chain coding and regulatory sequences are isolated as a single ca. 11.0 kb EcoRI/EcoRI fragment. A restriction map of pCEA(H+L)2neo is shown in Figure 6.

Example 11: Transfection and expression of the chimeric mouse/human (γ4;x) anti-CEA lg H- and L-chain double gene construct pCEA(H+L)2neo in mouse lymphoid cells

Transfection of the chimeric mouse/human (γ4;x) anti-CEA lg gene double-construct pCEA(H+L)2neo is achieved by isolation of the coding regions of the mouse/human (γ4;x) anti-CEA H- and L-chains on a single ca. 11.0 kb EcoRI/EcoRI DNA fragment from pCEA(H+L)2neo. 15 μg of this fragment are mixed with 1.5 μg pSV2neo, linearized with EcoRI, in 50 μl of TE buffer and subsequently transfected to Sp2/0 mouse lymphoid cells, exactly as described in example 9 for the chimeric mouse/human (γ4;x) anti-CEA single lg gene constructs.

Selection for neomycin resistance, antibody detection and determination of level of secreted IgG in transfected cells are carried out exactly as described in Example 9.2 and 9.3, respectively. One clonal cell line isolated in this manner and selected for high expression of the chimeric monoclonal antibody is designated EFIX-pCEA-Ig-(γ4;C_x) 4-8-13 (referred to as CE 4-8-13) and was deposited at the "Collection Nationale de Cultures de Microorganismes" of the Institut Pasteur, Paris, on Nov. 22, 1988, under the

number I-818.

The transfectoma CE 4-8-13 secretes 10 µg/ml of chimeric antibody into the culture medium after 6 days growth, as determined by the procedures described in example 9.4.

5 Example 12: Characterization of the chimeric monoclonal antibody

The binding of the chimeric monoclonal antibody ($\gamma 4;x$) to CEA is determined by the ELISA test described in Example 9.4 for the selection of chimeric antibodies. With the chimeric anti-CEA MAb secreted by the cell line CE 4-8-13, less than 8 ng/ml of the MAb is required to result in an optical density of 0.1 in the test (see Figure 7). For competition tests, purified CEA antigen and a purified Ig fraction from mouse ascites fluid generated from the CE 25 hybridoma are used. Methods used are based on published procedures (Voller et al., "Manual of Clinical Immunology", 1976, 506). The binding of the chimeric antibody to purified CEA in the ELISA test is inhibited either by soluble CEA or with purified murine CE 25 antibody. Over 99 % of secreted chimeric monoclonal antibody can be absorbed on immobilized CEA antigen. Whereas the parental CE 25 hybridoma produces a murine ($\gamma 1;x$) antibody when developed using goat-anti-mouse IgG₁ (alkaline phosphatase labelled), CE 75-5-6 and CE 4-8-13 do not.

The above immunological tests demonstrate that the antibody secreted by cell lines CE 75-5-6 and CE 4-8-13:

- (a) bind to the CEA antigen;
- (b) possess human constant region ($\gamma 4;x$) determinants and lack corresponding determinants of mouse origin;
- (c) are inhibited by the corresponding murine antibody produced by hybridoma CE 25;
- (d) bind specifically to the CEA antigen, since their binding is inhibited by soluble CEA;
- (e) are produced at high levels in transfectomas containing the chimeric H- and L-chain Ig genes as described above (1 µg/ml by CE 75-5-6; 10 µg/ml by CE 4-8-13).

Example 13: Isolation and purification of chimeric monoclonal antibodies for diagnostic/therapeutic purposes

13.1 In vitro synthesis

A cell line as described above synthesizing the chimeric monoclonal antibodies is grown on the glass beads of a packed bed column. The preculture for this column is prepared as follows: The cells from 4 confluent 175 cm² tissue culture flasks are used to inoculate one Nunc stapler. The adherent cells are detached from the flask by rinsing the confluent cell layer with a trypsin/Versene solution made up of equal volumes of trypsin solution (Gibco, 0.5 g/l) and Versene (Gibco, 1:5000). 4×10^6 cells are suspended in 400 ml of modified conditioned DMEM medium (DMEM_{med} = DMEM containing in addition 1 mM Na-pyruvate, 2 mM glutamine, 50 µM 2-mercaptoethanol, 10 mM HEPES and, if not indicated otherwise, 10 % FCS). The volume of the suspension is brought to 500 ml by adding fresh DMEM_{med}. 500 ml cell suspension are transferred to a Nunc stapler and incubated at 37 °C in an atmosphere of air containing 10 % CO₂. Four, seven and ten days after inoculation, additional medium (3 x 500 ml) is added. Fourteen days after inoculation the cells are harvested and used to inoculate the packed bed reactor. The conditioned medium is first removed from the stapler. 500 ml trypsin/Versene solution is added to the stapler and the entire cell layer is soaked with this solution. Free trypsin/Versene solution is poured off and the cell layer is left in contact with remaining trypsin/Versene for 5 min. 500 ml conditioned medium is added back to the cells. The cells are detached by shaking the stapler thoroughly. An additional 1.5 l of conditioned medium are added to the stapler and the entire suspension is then transferred to the packed bed reactor. The reactor consists of a 10 l cylindrical glass vessel filled with boro-silicate glass beads of 2 mm diameter. The medium is circulated through the reactor by an external pump at a rate of 45 l/h. The dissolved oxygen concentration and the pH of the circulating medium is measured and controlled continuously. Pure oxygen is used to keep the minimal dissolved oxygen level above 10 % saturation and CO₂ and 1.0 NaOH are used to control the pH between 7.0 and 7.3. The liquid volume in the reactor and the external circuit is 5 l. The system is kept in a water bath at 37 °C. After inoculation the cells are allowed to grow in a DMEM_{med} medium containing 10 % serum. As soon as the glucose level in the medium drops below 1 g/l continuous exchange of medium is initiated at a rate of 2 l/day. When the level of dissolved oxygen decreases to 20 % the serum concentration in the feed medium is lowered to 1.25 %. Two days later the exchange ratio is increased by 1 l/day. On subsequent days the exchange rate is increased further until a maximum value of 5 l/day is reached. From this time onward the outflowing medium is collected for the isolation and purification of the chimeric antibody.

13.2 Isolation and purification of chimeric monoclonal antibodies

The culture medium is filtered using a Minitan ultrafiltration system (Millipore Corp., Bedford, Mass.), through a 0.1 μ m cassette filter (type VVLPOMPO4, Millipore). The filtrate is concentrated 10-fold using the Minitan ultrafiltration system fitted with 30,000 MW cut-off filter cassettes (type PTTKOMPO4, Millipore). The concentrated retentate is then prepared for chromatography on protein-A Sepharose by addition of glycine and NaCl to a final concentration of 1.5 M glycine and 3 M NaCl and the pH adjusted to 8.6 with 5 M NaOH. After passing the culture medium concentrate through a column containing protein-A Sepharose CL-4B (Pharmacia, Uppsala, Sweden), unbound material is washed from the column with binding buffer (1.5 M glycine, 3 M NaCl, pH 8.9 with NaOH) and the column eluted with a stepwise gradient of decreasing pH consisting of 100 mM citric acid adjusted to pH 3.0, 4.0, 5.0 and 6.0 with 5 M NaOH as described in the Pharmacia application note (Separation News Vol. 13, No. 5). The highest concentration of chimeric antibody is determined by an ELISA test to elute at pH 4.0.

15 Example 14: Determination of CEA with an enzyme-linked immunosorbent assay (ELISA)

14.1 Labelling of chimeric monoclonal antibodies with alkaline phosphatase

1.4 mg of a chimeric monoclonal antibody in 1.4 ml of PBS are coupled for 2 h with a solution containing 5 mg of alkaline phosphatase (Sigma P6774, type VII-T) according to the standard method of Voller et al. (Bull. World Health Organ. 53, 55, 1976) using glutaraldehyde (0.2 % v/v). The conjugate is transferred into 5 ml of Tris buffer 0.05 M, pH 8.0, containing 1 mM $MgCl_2$, 1 % BSA and 0.02 % NaN_3 . The solution is kept in the dark at 4 °C.

25 14.2 Assay procedure

Polypropylene microtitre plates (Dynatech) are coated over a period of 2 h at 37 °C and overnight at 4 °C with 150 μ l of a solution of the chimeric monoclonal antibody secreted by cell line CE 75-5-6 or CE 4-8-13 (10 μ g/ml) in a buffer pH 8.6 (carbonate-buffered 0.9 % saline containing 0.02 % sodium azide). The plates are washed five times with PBS, and protein-reactive sites still present are saturated by incubation for 1 h at 37 °C with 250 μ l of a buffer pH 7.4 (0.2 % gelatine and 0.2 % NaN_3 in PBS). Plates coated in this manner can be kept at 4 °C in this buffer for a few days.

50 μ l of a dilution series of a test solution or a standard solution containing purified human CEA, 50 μ l of buffer pH 7.4 and 50 μ l of a solution of the phosphatase-labelled monoclonal anti-CEA antibody MAb 35 (Haskell et al., Cancer Res. 43, 3857, 1983) recognizing a different CEA-epitope than the chimeric antibody (Example 14.1) diluted 1:100 with buffer pH 7.4 are mixed and incubated in the wells of the microtiter plates for 2 h at 37 °C and for 30 minutes at 4 °C. The plates are washed five times with PBS, then incubated for 30 min at 37 °C with 150 μ l of a solution of p-nitrophenyl phosphate (1 mg/ml in 10 % diethanolamine buffer, 0.5 mM $MgCl_2$, pH 9.8). By measuring the optical density at 405 nm, the amount of released p-nitrophenol is determined, which is proportional to the amount of the bound enzyme phosphatase and hence proportional to the amount of human CEA in the test solution.

The test can also be carried out by using the enzyme-labelled chimeric monoclonal antibody secreted by cell line CE 75-5-6 or CE 4-8-13 and coating the microtitre plates with the monoclonal anti-CEA antibody MAb 35 recognizing a different CEA-epitope than the chimeric antibody.

45 14.3 Test kit for ELISA

A test kit for the assay described in Example 14.2 contains:
polypropylene microtiter plates,
20 ml of the chimeric monoclonal anti-CEA antibody secreted by cell line CE 75-5-6 or CE 4-8-13 (10 μ g/ml) in carbonate-buffered saline (0.9 % NaCl, 0.42 % $NaHCO_3$, 0.0072 % Na_2CO_3 , 0.02 % NaN_3),
1 ml of the alkaline phosphatase-coupled monoclonal anti-CEA antibody MAb 35 recognizing a different CEA-epitope than the chimeric antibody (0.3 mg antibody per ml) in Tris-buffer (0.05 M, 1 mM $MgCl_2$, 1 % BSA, 0.02 % NaN_3 , pH 8.0),
2 ml of standard solution containing 5 μ g purified human CEA,
300 ml of PBS,
300 ml of buffer pH 7.4 (0.2 % gelatine and 0.2 % NaN_3 in PBS)
50 ml of p-nitrophenyl phosphate (1 mg/ml) in diethanolamine buffer (10 %, 0.5 mM $MgCl_2$, 0.02 % NaN_3 ,

adjusted to pH 8.9 with HCl),
calibration curve,
colour intensity scale,
instruction manual.

5

Example 15: Pharmaceutical preparation for parenteral application

120 mg chimeric monoclonal antibody prepared according to Example 13 are dissolved in 5 ml physiological saline. The solution is passed through a bacteriological filter, and the filtrate filled in an ampoule under aseptic conditions. The ampoule is preferentially stored in the cold, e.g. at -20 °C.

10

Claims



Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

15 1. A chimeric monoclonal antibody consisting of variable regions of mouse origin and human constant regions, which recognizes epitopes of human carcinoembryonic antigen (CEA) not present on non-specific cross-reacting antigen NCA₅₅ and NCA₉₅, on biliary glycoprotein, or on granulocytes, and derivatives thereof.

20 2. A chimeric monoclonal antibody and derivatives thereof according to claim 1 with an affinity of at least 2.1×10^{10} liters/mol for human CEA.

3. A chimeric monoclonal antibody and derivatives thereof according to claim 1 or 2 comprising light chain variable regions of the formula

25



30

(I),

wherein FR₁ is a polypeptide residue comprising 23-28 naturally occurring amino acids, FR₂ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₃ is a polypeptide residue comprising 30-34 naturally occurring amino acids and FR₄ is a polypeptide residue comprising 9-11 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.


35

4. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-3 comprising light chain variable regions of formula I, wherein the polypeptide residues of the framework regions FR₁, FR₂, FR₃ and FR₄ are those preferably occurring in murine antibodies.

40

5. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-4 comprising light chain variable regions of formula I, wherein FR₁ is a polypeptide residue of the formula

45



50

(IA),

wherein A is hydrogen, acyl, or the residue Ala-Ser-Arg, Ser-Arg or Arg,

55

FR₂ is the polypeptide residue

Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

(IB),

FR₃ is the polypeptide residue

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

(IC),

and FR_4 is the polypeptide residue

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

(ID),

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

6. A chimeric monoclonal antibody and derivatives thereof according to claim 3 comprising light chain variable regions of formula I, wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of formula IA, IB, IC and ID, respectively, wherein one or more single amino acids are replaced by other amino acids outside the regions CDR1L, CDR2L and CDR3L, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.
7. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-6 comprising heavy chain variable regions of the formula

FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-

|----- CDR1H -----| |----- FR6 -----|

Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈

|----- CDR2H -----| |----- CDR3H -----|

(II),

wherein FR₅ is a polypeptide residue comprising 32-36 naturally occurring amino acids, FR₆ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₇ is a polypeptide residue comprising 32-34 naturally occurring amino acids and FR₈ is a polypeptide residue comprising 12-14 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

8. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-7 comprising heavy chain variable regions of formula II, wherein the polypeptide residues of the framework regions FR₅, FR₆, FR₇ and FR₈ are those preferably occurring in murine antibodies.
9. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-8 comprising heavy chain variable regions of formula II, wherein FR₅ is a polypeptide residue of the formula

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-
Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-
Thr-Phe-Arg

(IIA),

wherein B is hydrogen or acyl,

FR₆ is the polypeptide residue

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

(IIB),

FR₇ is the polypeptide residue

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
Ala-Arg

(IIC),

and FR₈ is the polypeptide residue

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

10. A chimeric monoclonal antibody and derivatives thereof according to claim 7 comprising heavy chain variable regions of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, wherein one or more single amino acids are replaced by other amino acids outside the regions CDR1H, CDR2H and CDR3H, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.
11. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-10 comprising light chain human constant regions κ or λ .
12. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-11 comprising heavy chain human constant regions γ 1, γ 2, γ 3 or γ 4.
13. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-12 comprising light chain human constant regions κ and heavy chain human constant regions γ 4.
14. A chimeric monoclonal antibody and derivatives thereof according to any of the claims 1-13 with light chain variable regions of formula I wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of the formula IA, IB, IC and ID, respectively, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges, a light chain human constant region κ , a heavy chain variable region of formula II

wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges and a heavy chain human constant region γ 4.

- 5 15. A derivative of a chimeric monoclonal antibody according to any of the claims 1-14 which is a fragment.
16. A derivative of a chimeric monoclonal antibody according to any of the claims 1-14 which is a conjugate with an enzyme, a fluorescent marker, a metal chelate, a cytostatic or cytotoxic substance, avidin or biotin.
- 10 17. A derivative of a chimeric monoclonal antibody according to any of the claims 1-14 which is radioactively labelled.
- 15 18. A process for the preparation of chimeric monoclonal antibodies and derivatives thereof according to claim 1, characterized in that mammalian cells producing such chimeric monoclonal antibodies are multiplied in vitro and, if desired, the resulting chimeric monoclonal antibodies are converted into derivatives thereof.
- 20 19. A process for the preparation of chimeric monoclonal antibodies and derivatives thereof according to claim 1, characterized in that mammalian cells producing such chimeric monoclonal antibodies are multiplied in vivo and, if desired, the resulting chimeric monoclonal antibodies are converted into derivatives thereof.
- 25 20. A recombinant DNA comprising an insert coding for a light chain murine variable region and/or for a heavy chain murine variable region of chimeric monoclonal antibodies according to claim 1.
- 30 21. A recombinant DNA according to claim 20 comprising an insert coding for a light chain murine variable region specific for human CEA which originates from genomic DNA of the cell line CE 25, having the deposit accession number CNCM I-719.
- 35 22. A recombinant DNA according to claim 20 or 21 comprising an insert coding for the polypeptide of formula I, optionally containing introns.
- 40 23. A recombinant DNA according to any of the claims 20-22 comprising an insert coding for the polypeptide of formula I wherein FR₁, FR₂, FR₃ and FR₄ are polypeptides of formula IA, IB, IC and ID, respectively, optionally containing introns.
- 45
- 50
- 55

24. A recombinant DNA according to any of the claims 20-23 comprising an insert of the formula

```

      TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT
1  -----+-----+-----+-----+-----+-----+-----+ 60
5
      TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTGGAAAGATATGCAAG
61 -----+-----+-----+-----+-----+-----+-----+ 120
      AAGCACTATTTGGCTATTATTTGGAAAGTGCTATAATGTATTTTGATATCTCAACCTCTG
121 -----+-----+-----+-----+-----+-----+-----+ 180
10
      AAATTCTTCTGTATGTTGGCAGATTGTAAACCTTTACAAGGCTTTCATTCTCTTCTCTGG
181 -----+-----+-----+-----+-----+-----+-----+ 240
      AGAAAAATGCTTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
241 -----+-----+-----+-----+-----+-----+-----+ 200
15
      GTGTGATATCACTTTAGTTTCATGTGTTGTTATGCTTCATGTAATGTTAAGAAAGTTAAA
301 -----+-----+-----+-----+-----+-----+-----+ 360
      GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTTGAG
361 -----+-----+-----+-----+-----+-----+-----+ 420
20
      ATGCTCTTTATTTCAAACACTGAATATATCTTAGAGATTCTTTAGACTGTGTTAAATA
421 -----+-----+-----+-----+-----+-----+-----+ 480
      TGTAACCATTTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA
481 -----+-----+-----+-----+-----+-----+-----+ 540
25
      ACAAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT
541 -----+-----+-----+-----+-----+-----+-----+ 600
      TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTTCTTTCTTCTAATGTCCCTGC
601 -----+-----+-----+-----+-----+-----+-----+ 660
30
      CTCTTAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTCATGGTCCACACAAAAATAGG
661 -----+-----+-----+-----+-----+-----+-----+ 720
      M V S T P Q F L V F L L F W I P
      MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
35
      GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGATTTTTGCTTTTCTGGATTCCA
721 -----+-----+-----+-----+-----+-----+-----+ 780

```

781 GCTAATGACTGTTTGGGTGTGGCAAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT 840
 5 841 TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTTCAGTTTAAAGAAATTGATAC 900
 AATAAAAGTCATTTATTTTCTAAGTTGTTTAGAAGTGACTTTTCATATTCAGTGTTATGA
 901 960
 10 A S R G D I L L T Q S
 AlaSerArgGlyAspIleLeuLeuThrGlnSer
 TCGACTAATGTATCTTCCATTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT
 961 1020
 15 P A I L S V S P G E R V T F S C R A S Q
 ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
 CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTTCTCCTGCAGGGCCAGTCAG
 1021 1080
 20 S I G T S L H W Y Q Q R T N G S P R L L
 SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
 AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAATGGTTCTCCAAGGCTTCTC
 1081 1140
 25 M K Y A S E S I S G I P S R F S G S G S
 MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
 ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
 1141 1200
 30 G T D F T L T I N S V E S E D I A D Y Y
 GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
 GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
 1201 1260
 35 C Q Q S H G W P F T F G S G T K L E I K
 CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
 TGTCAACAAAGTCATGGCTGGCCATTACGTTTCGGCTCGGGGACAAAGTTGGAATAAAA
 1261 1320
 CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTGGTTCTGTTTGGGTAGCTTGTGT
 1321 1380
 40 GAATTTGTGATATTT
 1381 1395
 (III).

- 45 25. A recombinant DNA according to claim 22 comprising an insert of formula III wherein one or more single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula III from position 1069-1102, 1147-1167 and 1263-1291, respectively.
- 50 26. A recombinant DNA according to claim 20 comprising an insert coding for a heavy chain murine variable region specific for human CEA which originates from genomic DNA of the cell line CE 25, having the deposit accession number CNCM I-719.
27. A recombinant DNA according to claim 20 or 26 comprising an insert coding for the polypeptide of formula II, optionally containing introns.
- 55 28. A recombinant DNA according to claim 20, 26 or 27 comprising an insert coding for the polypeptide of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, optionally containing introns.

29. A recombinant DNA according to any of the claims 20, 26-28 comprising an insert of the formula

```

5      1  AAGCTTGTTCCTGTTACATGCAAGGAGGGAACTAACTGAGTATGGTGAATCCCTAACC 60
      61  AAAGGGAAAAAATGAACTACAATATGTTTCAAATGCTGTAAGTCAAATCTGGTTTTTTG 120
      121  ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCAGAGCATGGTAT 180
      181  AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCATGAAAACACCTCGGCCCTGACCC 240
      241  TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTTGAGTTCTCACATTGAGTGATGAGC 300
      301  M N F G F S L I F L V L V
          MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
      361  ACTGAACACAGACACCTCACCATGAACTTCGGGTTGAGCTTGATTTTCCTTGTCCTTGTT 360
      361  L K G
          LeuLysGly
      421  TTTAAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA 420
      421  V Q
          ValG1
      481  TGTGGTTTGTGTTTGTAGTGACAGTTTTCCAACCAGTTATTCTCTGTTTGTAGGTGTCCA 480
      481  C E V K L V E S G G G L V K P G G S L K
          nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
      541  GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA 540
      541  L S C A A S G F T F R T Y A M A W V R Q
          sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgG1
      601  ACTCTCCTGTGCAGCCTCTGGGTTCACTTCAGGACCTATGCCATGGCTTGGGTTGCCCA 600
      601  T P E K R L E W V T S I S S G G T T Y Y
          nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
      660  GACTCCAGAGAAGAGGCTGGAGTGGGTCACATCCATTAGTAGTGGTGGTACCACCTACTA 660

```

P D S V K G R F T I S R D N A R N I L Y
 rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
 TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA
 5 661 -----+-----+-----+-----+-----+ 720
 L Q V S S L R S E D T A I Y Y C A R G F
 rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
 CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGCCATTATTACTGTGCAAGAGGTTT
 10 721 -----+-----+-----+-----+-----+ 780
 Y D G Y L Y V V D Y W G Q G T S L T V S
 eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
 CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACC GTCTC
 15 781 -----+-----+-----+-----+-----+ 840
 S
 rSer
 CTCAGGTAAGAATGGCC
 20 841 -----+----- 857

(IV).

- 25 30. A recombinant DNA according to claim 27 comprising an insert of formula IV wherein one or more single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula IV from position 575-595, 629-680 and 776-805, respectively.
- 30 31. A recombinant DNA according to claim 20 comprising an insert coding for a light chain murine variable region fused to a human constant region κ or λ .
32. A recombinant DNA according to claim 31 comprising an insert of formula III fused to a human constant region κ .
- 35 33. A recombinant DNA according to claim 20 comprising an insert coding for a heavy chain murine variable region fused to a human constant region $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$.
34. A recombinant DNA according to claim 33 comprising an insert of formula IV fused to a human constant region $\gamma 4$.
- 40 35. A recombinant DNA according to claim 20 which is a hybrid vector comprising an insert coding for a chimeric murine/human light chain according to claim 31 and/or a chimeric murine/human heavy chain according to claim 33, a complete replicon and one or more dominant marker sequences, operationally linked to expression control sequences.
- 45 36. A recombinant DNA according to claim 20 which is a hybrid vector comprising an insert coding for a chimeric murine/human light chain according to claim 32 and/or a chimeric murine/human heavy chain according to claim 34, a complete replicon and one or more dominant marker sequences, operationally linked to expression control sequences.
- 50 37. A recombinant DNA which is a hybrid vector according to claim 35 or 36 suitable for mammalian hosts.
38. A recombinant DNA which is a hybrid vector according to claim 35, 36 or 37 wherein the vector is derived from plasmid pSV.
- 55 39. A recombinant DNA which is a hybrid vector according to claim 38 wherein the vector is derived from plasmid pSV2gpt or from plasmid pSV2neo.

40. A process for the preparation of recombinant DNAs according to claim 20 comprising culturing a transformed host.

41. A process according to claim 40 comprising the steps of

- a) isolating murine DNAs from a suitable hybridoma cell line, selecting the desired DNAs coding for the variable regions of monoclonal antibodies directed against human CEA using DNA probes,
- b) isolating human DNAs from a genomic library, selecting the desired DNAs coding for the constant regions of monoclonal antibodies using DNA probes,
- c) constructing chimeric mouse/human genes by incorporating the DNAs of step a) and b) into appropriate hybrid vectors,
- d) transferring the obtained hybrid vectors into a recipient host, and
- e) selecting and culturing the transformed host.

42. A host cell which is transformed with recombinant DNAs according to any of the claims 31-39.

43. A host cell according to claim 42 which is a mammalian cell of lymphoid origin.

44. A host cell according to claim 42 which is a cell derived from the Ig non-secreting mouse hybridoma cell line Sp2/0 (ATCC CRL 1581).

45. A host cell according to claim 42 or 44 which is transformed with one or two vectors according to any of the claims 36-39.

46. A host cell according to claim 45 which is a cell of the cell line EFVIII/ γ 4Na75-75/C α Ga5-6 (CE 75-5-8, having the deposit accession number CNCM I-720).

47. A host cell according to claim 45 which is a cell of the cell line EFIX-pCEA-Ig-(γ 4;C α) (CE 4-8-13, having the deposit accession number CNCM I-818).

48. A host cell according to claim 42 characterized in that it secretes chimeric monoclonal antibodies according to claim 1.

49. A process for the preparation of a host cell according to claim 42 or 48, characterized in that a suitable cell is transformed with one or two vectors by electroporation, calcium treatment, microinjection or protoplast fusion.

50. Chimeric monoclonal antibodies and derivatives thereof according to claim 1 for use in a method for the treatment of humans and for diagnosis.

51. The use of chimeric monoclonal antibodies and derivatives thereof according to claim 1 for the in vitro diagnosis of cancer.

52. The use of chimeric monoclonal antibodies and derivatives thereof according to claim 1 for the qualitative and quantitative in vitro determination of human CEA.


53. The use according to claim 51 of chimeric monoclonal antibodies and derivatives thereof in a radioimmunoassay or an enzyme-immunoassay.

54. Test kits for the qualitative and quantitative determination of human CEA containing chimeric monoclonal antibodies according to claim 1 and/or derivatives thereof and, optionally, other monoclonal or polyclonal antibodies and/or adjuncts.

55. A pharmaceutical composition containing a chimeric monoclonal antibody or derivatives thereof according to claim 1.


Claims for the following Contracting States : ES, GR

1. A process for the preparation of a chimeric monoclonal antibody consisting of variable regions of mouse origin and human constant regions, which recognizes epitopes of human carcinoembryonic antigen (CEA), not present on non-specific cross-reacting antigen NCA₆₅ and NCA₉₅, on biliary glycoprotein, or on granulocytes, and derivatives thereof, characterized in that mammalian cells producing such chimeric monoclonal antibodies are multiplied in vivo or in vitro and, if desired, the resulting chimeric monoclonal antibodies are converted into derivatives thereof.
2. A process according to claim 1 for the preparation of a chimeric monoclonal antibody and derivatives thereof with an affinity of at least 2.1×10^{10} liters/mol for human CEA.
3. A process according to claim 1 or 2 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of the formula



wherein FR₁ is a polypeptide residue comprising 23-28 naturally occurring amino acids, FR₂ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₃ is a polypeptide residue comprising 30-34 naturally occurring amino acids and FR₄ is a polypeptide residue comprising 9-11 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.


4. A process according to any of the claims 1-3 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of formula I, wherein the polypeptide residues of the framework regions FR₁, FR₂, FR₃ and FR₄ are those preferably occurring in murine antibodies.
5. A process according to any of the claims 1-4 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of formula I, wherein FR₁ is a polypeptide residue of the formula



(IA),

wherein A is hydrogen, acyl, or the residue Ala-Ser-Arg, Ser-Arg or Arg,

FR₂ is the polypeptide residue



(IB),

FR₃ is the polypeptide residue

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

(IC).

and FR_4 is the polypeptide residue

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

(ID),

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

- 20 6. A process according to claim 3 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain variable regions of formula I, wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of formula IA, IB, IC and ID, respectively, wherein one or more single amino acids are replaced by other amino acids outside the regions CDR1L, CDR2L and CDR3L, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

7. A process according to any of the claims 1-6 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising heavy chain variable regions of the formula

30 FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
 |----- CDR1H -----| |-----
 Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
 |----- CDR2H -----| |----- CDR3H -----|

(II),

wherein FR₅ is a polypeptide residue comprising 32-36 naturally occurring amino acids, FR₆ is a polypeptide residue comprising 14-16 naturally occurring amino acids, FR₇ is a polypeptide residue comprising 32-34 naturally occurring amino acids and FR₈ is a polypeptide residue comprising 12-14 naturally occurring amino acids, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

8. A process according to any of the claims 1-7 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising heavy chain variable regions of formula II, wherein the polypeptide residues of the framework regions FR₅, FR₆, FR₇ and FR₈ are those preferably occurring in murine antibodies.

9. A process according to any of the claims 1-8 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising heavy chain variable regions of formula II, wherein FR₅ is a polypeptide residue of the formula

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-
Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-
Thr-Phe-Arg

(IIA),

wherein B is hydrogen or acyl,

FR₅ is the polypeptide residue

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

(IIB),

FR₇ is the polypeptide residue

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
Ala-Arg

(IIC),

and FR₈ is the polypeptide residue

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.

10. A process according to claim 7 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising heavy chain variable regions of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, wherein one or more single amino acids are replaced by other amino acids outside the regions CDR1H, CDR2H and CDR3H, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges.
11. A process according to any of the claims 1-10 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain human constant regions κ or λ .
12. A process according to any of the claims 1-11 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising heavy chain human constant regions γ 1, γ 2, γ 3 or γ 4.
13. A process according to any of the claims 1-12 for the preparation of a chimeric monoclonal antibody and derivatives thereof comprising light chain human constant regions κ and heavy chain human constant regions γ 4.
14. A process according to any of the claims 1-13 for the preparation of a chimeric monoclonal antibody and derivatives thereof with light chain variable regions of formula I wherein FR₁, FR₂, FR₃ and FR₄ are polypeptide residues of the formula IA, IB, IC and ID, respectively, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges, a light chain human constant region κ , a heavy chain

variable region of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, and wherein the amino acid Cys may be in the oxidized state forming S-S-bridges and a heavy chain human constant region γ 4.

- 5 15. A process according to any of the claims 1-14 for the preparation of a derivative of a chimeric monoclonal antibody, characterized in that the monoclonal antibody is cleaved enzymatically or chemically into a fragment.
- 10 16. A process according to any of the claims 1-14 for the preparation of a derivative of a chimeric monoclonal antibody, characterized in that the monoclonal antibody is conjugated with an enzyme, a fluorescent marker, a metal chelate, a cytostatic or cytotoxic substance, avidin or biotin.
- 15 17. A process according to any of the claims 1-14 for the preparation of a derivative of a chimeric monoclonal antibody, characterized in that the monoclonal antibody is radioactively labelled.
- 20 18. A process for the preparation of a recombinant DNA comprising an insert coding for a light chain murine variable region and/or for a heavy chain murine variable region of chimeric monoclonal antibodies prepared by a process according to claim 1, characterized in that said process comprises culturing a transformed host.
- 25 19. A process according to claim 18 for the preparation of a recombinant DNA, characterized in that said process comprises the steps of
 - a) isolating murine DNAs from a suitable hybridoma cell line, selecting the desired DNAs coding for the variable regions of monoclonal antibodies directed against human CEA using DNA probes,
 - 30 b) isolating human DNAs from a genomic library, selecting the desired DNAs coding for the constant regions of monoclonal antibodies using DNA probes,
 - c) constructing chimeric mouse/human genes by incorporating the DNAs of step a) and b) into appropriate hybrid vectors,
 - d) transferring the obtained hybrid vectors into a recipient host, and
 - 35 e) selecting and culturing the transformed host.
- 40 20. A process according to claim 18 or 19 for the preparation of a recombinant DNA comprising an insert coding for a light chain murine variable region specific for human CEA which originates from genomic DNA of the cell line CE 25, having the deposit accession number CNCM I-719
- 45 21. A process according to claim 18, 19 or 20 for the preparation of a recombinant DNA comprising an insert coding for the polypeptide of formula I, optionally containing introns.
- 50 22. A process according to any of the claims 18-21 for the preparation of a recombinant DNA comprising an insert coding for the polypeptide of formula I wherein FR₁, FR₂, FR₃ and FR₄ are polypeptides of formula IA, IB, IC and ID, respectively, optionally containing introns.
- 55 23. A process according to any of the claims 18-22 for the preparation of a recombinant DNA comprising an insert of the formula

TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT

1 -----+-----+-----+-----+-----+-----+-----+ 60

5 61 TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTGGAAAGATATGCAAG 120
 AAGCACTATTTGGCTATTATTTGGAAAGTGCTATAATGTATTTGATATCTCAACCTCTG
 121 180
 10 181 AAATTCTTCIGTAIGTTGGCAGATTGIAAACCTTTACAAGGCTTTCATTCTCTTCTCTGG 240
 AGAAAAATGTCTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
 241 200
 15 301 GTGTGATATCACTTTAGTTTCATGTGTTGTTATGCTTCATGTAATGTTAAGAAAGTTAAA 360
 GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTGAG
 361 420
 20 421 ATGCTCTTTATTTCAAACACTACTGAATATATCTTAGAGATTTCTTTAGACTGTGTAAATA 480
 TGTAACCATTAAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA
 481 540
 25 541 ACAAAGGATAAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT 600
 TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTCTTTCTTCTAATGTCCCTGC
 601 660
 30 661 CTCTTAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTCATGGTCCACACAAAAATAGG 720
 M V S T P Q F L V F L L F W I P
 MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
 GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGTATTTTGTCTTCTGGATTCCA
 721 780
 35 781 GGTAAATGACTGTTTGGGTGTGGCAAAAAAGTGGAGATGTTATTTAAATACAAAAATTTTCT 840
 TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTCAGTTTAAAGAAATTGATAC
 841 900
 40 901 AATAAAAGTCATTTATTTTCTAAGTTGTTTAGAAGTGACTTTCATATTCAGTGTTATGA 960
 A S R G D I L L T Q S
 AlaSerArgGlyAspIleLeuLeuThrGlnSer
 45 961 TCGACTAATGTATCTTCCATTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT 1020
 P A I L S V S P G E R V T F S C R A S Q
 ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
 50 1021 CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTCTCCTGCAGGGCCAGTCAG 1080
 S I G T S L H W Y Q Q R T N G S P R L L
 SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
 55 1081 AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTC 1140

M K Y A S E S I S G I P S R F S G S G S
 MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
 5 ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
 1141 -----+-----+-----+-----+-----+ 1200
 G T D F T L T I N S V E S E D I A D Y Y
 GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
 10 GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
 1201 -----+-----+-----+-----+-----+ 1260
 C Q Q S H G W P F T F G S G T K L E I K
 CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
 15 TGTCAACAAAGTCATGGCTGGCCATTACGTTTCGGCTCGGGGACAAAGTTGGAAATAAAA
 1261 -----+-----+-----+-----+-----+ 1320
 CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTTGGTTCGTTTGGGTAGCTTGTGT
 1321 -----+-----+-----+-----+-----+ 1380
 GAATTTGTGATATTT
 20 1381 -----+----- 1395
 (III).

- 25 24. A process according to claim 21 for the preparation of a recombinant DNA comprising an insert of formula III wherein one or more single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula III from position 1069-1102, 1147-1167 and 1263-1291, respectively.
- 30 25. A process according to claim 18 for the preparation of a recombinant DNA comprising an insert coding for a heavy chain murine variable region specific for human CEA which originates from genomic DNA of the cell line CE 25, having the deposit accession number CNCM I-719.
- 35 26. A process according to claim 18 or 25 for the preparation of a recombinant DNA comprising an insert coding for the polypeptide of formula II, optionally containing introns.
27. A process according to claim 18, 25 or 26 for the preparation of a recombinant DNA comprising an insert coding for the polypeptide of formula II wherein FR₅, FR₆, FR₇ and FR₈ are polypeptide residues of formula IIA, IIB, IIC and IID, respectively, optionally containing introns.
- 40 28. A process according to any of the claims 18, 25-27 for the preparation of a recombinant DNA comprising an insert of the formula

1 AAGCTTGTCTGTTCACATGCAAGGAGGGAACTAACTGAGTATGGTGAATCCCTAACC 60
 5 61 AAAGGGAAAAAATGAACTACAATATGTTTCAAATGCTGTAAGTGAATCTGGTTTTTTTG 120
 121 ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTAGTCCAACCCAGAGCATGGTAT 180
 10 181 AGCAGGAAGACATGCAAATAAGTCTTCTCTGCCCCATGAAAACACCTCGGCCCTGACCC 240
 241 TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTGAGTTCCTCACATTCAAGTGATGAGC 300
 15 M N F G F S L I F L V L V
 MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
 301 ACTGAACACAGACACCTCACCATGAAGTTCGGGTTGAGCTTGATTTTCCTTGTCTTGT 360
 L K G
 LeuLysGly
 20 361 TTTAAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA 420
 V Q
 ValG1
 25 421 TGTGGTTTGTGTTTGTAGTGACAGTTTTCCAACCAGTTATTCTCTGTTGTAGGTGTCCA 480
 C E V K L V E S G G G L V K P G G S L K
 nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
 30 481 GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA 540
 L S C A A S G F T F R T Y A M A W V R Q
 sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgG1
 35 541 ACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGGACCTATGCCATGGCTTGGGTTCCGCA 600
 T P E K R L E W V T S I S S G G T T Y Y
 nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
 40 601 GACTCCAGAGAAGAGGCTGGAGTGGGTACATCCATTAGTAGTGGTGGTACCACCTACTA 660
 P D S V K G R F T I S R D N A R N I L Y
 rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
 45 661 TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA 720
 L Q V S S L R S E D T A I Y Y C A R G F
 rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
 50 721 CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGGTTT 780
 Y D G Y L Y V V D Y W G Q G T S L T V S
 eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
 55 781 CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACCGTCTC 840

S
rSer
CTCAGGTAAGAATGGCC
841 -----+----- 857

(IV).

10

29. A process according to claim 26 for the preparation of a recombinant DNA comprising an insert of formula IV wherein one or more single nucleotides are replaced by other nucleotides outside the nucleotide sequences of formula IV from position 575-595, 629-680 and 776-805, respectively.

15

30. A process according to claim 18 for the preparation of a recombinant DNA comprising an insert coding for a light chain murine variable region fused to a human constant region κ or λ .

20

31. A process according to claim 30 for the preparation of a recombinant DNA comprising an insert of formula III fused to a human constant region κ .

32. A process according to claim 18 for the preparation of a recombinant DNA comprising an insert coding for a heavy chain murine variable region fused to a human constant region $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$.

25

33. A process according to claim 32 for the preparation of a recombinant DNA comprising an insert of formula IV fused to a human constant region $\gamma 4$.

30

34. A process according to claim 18 for the preparation of a recombinant DNA which is a hybrid vector comprising an insert coding for a chimeric murine/human light chain prepared by a process according to claim 31 and/or a chimeric murine/human heavy chain prepared by a process according to claim 33, a complete replicon and one or more dominant marker sequences, operationally linked to expression control sequences.

35

35. A process according to claim 18 for the preparation of a recombinant DNA which is a hybrid vector comprising an insert coding for a chimeric murine/human light chain prepared by a process according to claim 32 and/or a chimeric murine/human heavy chain prepared by a process according to claim 34, a complete replicon and one or more dominant marker sequences, operationally linked to expression control sequences.

40

36. A process according to claim 34 or 35 for the preparation of a recombinant DNA which is a hybrid vector suitable for mammalian hosts.

37. A process according to claim 34, 35 or 36 for the preparation of a recombinant DNA which is a hybrid vector wherein the vector is derived from plasmid pSV.

45

38. A process according to claim 37 for the preparation of a recombinant DNA which is a hybrid vector wherein the vector is derived from plasmid pSV2gpt or from plasmid pSV2neo.

50

39. A host cell which is transformed with recombinant DNAs prepared by a process according to any of the claims 30-38.

40. A host cell according to claim 39 which is a mammalian cell of lymphoid origin.

55

41. A host cell according to claim 39 which is a cell derived from the Ig non-secreting mouse hybridoma cell line Sp2/0 (ATCC CRL 1581).


42. A host cell according to claim 39 or 41 which is transformed with one or two vectors prepared by a process according to any of the claims 35-38.

43. A host cell according to claim 42 which is a cell of the cell line EFVIII/ γ 4Na75-75/C $\times$ Ga5-6 (CE 75-5-6, having the deposit accession number CNCM I-720).
44. A host cell according to claim 42 which is a cell of the cell line EFIX-pCEA-Ig-(γ 4;C $\times$) (CE 4-8-13, having the deposit accession number CNCM I-818).
45. A host cell according to claim 39 characterized in that it secretes chimeric monoclonal antibodies prepared by a process according to claim 1.
46. A process for the preparation of a host cell according to claim 39 or 45, characterized in that a suitable cell is transformed with one or two vectors by electroporation, calcium treatment, microinjection or protoplast fusion.
47. A process for the preparation of a pharmaceutical composition containing a chimeric monoclonal antibody or derivatives thereof prepared by a process according to claim 1, characterized in that the monoclonal antibody is mixed with a pharmaceutical carrier.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Chimärer monoklonaler Antikörper, bestehend aus variablen Regionen des Maus-Origin und humanen konstanten Regionen, der Epitope von menschlichem Carcinoembryonal-Antigen (CEA) erkennt, die nicht vorhanden sind auf den nicht-spezifisch kreuzreagierenden Antigenen NCA₅₅ und NCA₉₅, auf billärem Glycoprotein oder auf Granulocyten, und Derivaten davon.
2. Chimärer monoklonaler Antikörper und Derivate davon nach Anspruch 1 mit einer Affinität von wenigstens $2,1 \times 10^{10}$ Liter/Mol für Human-CEA.
3. Chimärer monoklonaler Antikörper und Derivate davon nach Anspruch 1 oder 2, umfassend die variable Regionen der leichten Ketten der Formel



- worin FR₁ ein Polypeptidrest ist, umfassend 23-28 natürlich vorkommende Aminosäuren, FR₂ ist ein Polypeptidrest, umfassend 14-16 natürlich vorkommende Aminosäuren, FR₃ ist ein Polypeptidrest, umfassend 30-34 natürlich vorkommende Aminosäuren und FR₄ ist ein Polypeptidrest, umfassend 9-11 natürlich vorkommende Aminosäuren, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.
4. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 3, umfassend die variable Regionen der leichten Kette der Formel I, worin die Polypeptidreste der Gerüstregionen FR₁, FR₂, FR₃ und FR₄ solche sind, die vorzugsweise in Maus-Antikörpern auftreten.
5. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 4, umfassend die variable Regionen der leichten Kette der Formel I, worin FR₁ ein Polypeptidrest ist der Formel

A-Gly-Asp-Ile-Leu-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Leu-Ser-Val-Ser-Pro-
Gly-Glu-Arg-Val-Thr-Phe-Ser-Cys

5

(IA),

worin A Wasserstoff, Acyl oder der Rest Ala-Ser-Arg, Ser-Arg oder Arg ist,
FR₂ ist der Polypeptidrest

10

Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

15

(IB),

FR₃ ist der Polypeptidrest

20

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

25

(IC),

und FR₄ ist der Polypeptidrest

30

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

(ID),

35

und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

6. Chimärer monoklonaler Antikörper und Derivate davon nach Anspruch 3, umfassend variable Regionen der leichten Kette der Formel I, worin FR₁, FR₂, FR₃ und FR₄ entsprechende Polypeptidreste der Formel IA, IB, IC und ID sind, worin eine oder mehrere einzelne Aminosäuren durch andere Aminosäuren außerhalb der Regionen CDR1L, CDR2L und CDR3L ersetzt sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

40

7. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 6, umfassend variable Regionen der schweren Kette der Formel

45

FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
|----- CDR1H -----| |-----
50 Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
|----- CDR2H -----| |----- CDR3H -----|

(II),

55

worin FR₅ ein Polypeptidrest ist, bestehend aus 32-36 natürlich vorkommenden Aminosäuren, FR₆ ist ein Polypeptidrest, bestehend aus 14-16 natürlich vorkommenden Aminosäuren, FR₇ ist ein Polypeptidrest, bestehend aus 32-34 natürlich vorkommenden Aminosäuren und FR₈ ist ein Polypeptidrest, bestehend aus 12-14 natürlich vorkommenden Aminosäuren, und worin die Aminosäure Cys in

oxidiertem Zustand S-S-Brücken bilden kann.

8. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 7, umfassend variable Regionen der schweren Kette der Formel II, worin die Polypeptidreste der Gerüstregionen FR₅, FR₆, FR₇ und FR₈ solche sind, die vorzugsweise in Maus-Antikörpern auftreten.

9. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 8, umfassend variable Regionen der schweren Kette der Formel II, worin FR₅ ein Polypeptidrest der Formel

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-
Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-
Thr-Phe-Arg

(IIA),

ist, worin B Wasserstoff oder Acyl ist,
FR₆ ist der Polypeptidrest

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

(IIB),

FR₇ ist der Polypeptidrest

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
Ala-Arg

(IIC),

und FR₈ ist der Polypeptidrest

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

10. Chimärer monoklonaler Antikörper und Derivate davon nach Anspruch 7, umfassend variable Regionen der schweren Kette der Formel I, worin FR₅, FR₆, FR₇ und FR₈ entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, worin eine oder mehrere einzelne Aminosäuren durch andere Aminosäuren außerhalb der Regionen CDR1H, CDR2H und CDR3H ersetzt sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

11. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 10, umfassend die konstanten Regionen κ oder λ der humanen leichten Kette.

12. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 11, umfassend die konstanten Regionen γ 1, γ 2, γ 3 oder γ 4 der humanen schweren Kette.

13. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 12, umfassend die konstanten Regionen α der humanen leichten Kette und die konstanten Regionen γ^4 der humanen schweren Kette.
- 5 14. Chimärer monoklonaler Antikörper und Derivate davon nach einem der Ansprüche 1 bis 13 mit variablen Regionen der leichten Kette der Formel I, worin FR_1 , FR_2 , FR_3 und FR_4 entsprechende Polypeptidreste der Formel IA, IB, IC und ID sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann, einer konstanten Region α der humanen leichten Kette, einer variablen Region der schweren Kette der Formel II, worin FR_5 , FR_6 , FR_7 und FR_8 entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann, und einer konstanten Region γ^4 der humanen schweren Kette.
- 10
15. Derivat eines chimären monoklonalen Antikörpers nach einem der Ansprüche 1 bis 14, das ein Fragment ist.
- 15 16. Derivat eines chimären monoklonalen Antikörpers nach einem der Ansprüche 1 bis 14, das ein Konjugat ist mit einem Enzym, einem fluoreszierenden Marker, einem Metallchelat, einer cytostatischen oder cytotoxischen Substanz, Avidin oder Biotin.
- 20 17. Derivat eines chimären monoklonalen Antikörpers nach einem der Ansprüche 1 bis 14, das radioaktiv markiert ist.
18. Verfahren zur Herstellung von chimären monoklonalen Antikörpern und von Derivaten davon nach Anspruch 1, dadurch gekennzeichnet, daß Säugerzellen, die solche chimären monoklonalen Antikörper produzieren, in vitro vermehrt werden und gewünschtenfalls die erhaltenen chimären monoklonalen Antikörper in Derivate davon umgewandelt werden.
- 25 19. Verfahren zur Herstellung eines chimären monoklonalen Antikörpers und von Derivaten davon nach Anspruch 1, dadurch gekennzeichnet, daß Säugerzellen, die solche chimären monoklonalen Antikörper produzieren, in vivo vermehrt werden und gewünschtenfalls die erhaltenen chimären monoklonalen Antikörper in Derivate davon umgewandelt werden.
- 30 20. Rekombinante DNA, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus und/oder eine variable Region der schweren Kette der Maus eines chimären monoklonalen Antikörpers nach Anspruch 1 kodiert.
- 35 21. Rekombinante DNA nach Anspruch 20, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus kodiert, die spezifisch ist für Human-CEA, das aus genomischer DNA der Zelllinie CE 25 herrührt, mit der Hinterlegungsnummer CNCM I-719.
- 40 22. Rekombinante DNA nach Anspruch 20 oder 21, umfassend ein Insert, das für das Polypeptid der Formel I kodiert, das gegebenenfalls Introns enthält.
- 45 23. Rekombinante DNA nach einem der Ansprüche 20 bis 22, umfassend ein Insert, das für das Polypeptid der Formel I kodiert, worin FR_1 , FR_2 , FR_3 und FR_4 entsprechende Polypeptide der Formel IA, IB, IC und ID sind, das gegebenenfalls Introns enthält.
- 50
- 55

24. Rekombinante DNA nach einem der Ansprüche 20 bis 23, umfassend ein Insert der Formel

```

      TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT
5      1  -----+-----+-----+-----+-----+-----+-----+ 60
      TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTGGAAAGATATGCAAG
      61  -----+-----+-----+-----+-----+-----+-----+ 120
      AAGCACTATTGGCTATTATTTGGAAAGTGCTATAATGTATTTTGATATCTCAACCTCTG
10     121 -----+-----+-----+-----+-----+-----+-----+ 180
      AAATTCTTCTGTATGTTGGCAGATTGTAAACCTTTACAAGGCTTTCATTCTCTTCTCTGG
      181 -----+-----+-----+-----+-----+-----+-----+ 240

```

15

20

25

30

35

40

45

50

55

AGAAAAATGCTTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
 241 -----+-----+-----+-----+-----+-----+ 200
 GTGTGATATCACTTTATGTTTCATGTGTTGTTATGCTTCAATGTTAAGAAAGTTAAA
 5 301 -----+-----+-----+-----+-----+-----+ 360
 GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTGAG
 361 -----+-----+-----+-----+-----+-----+ 420
 ATGCTCTTTTATTTCAAACACTACTGAATATATCTTAGAGATTTCTTTAGACTGTGTTAAATA
 10 421 -----+-----+-----+-----+-----+-----+ 480
 TGTAACCAITTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA
 481 -----+-----+-----+-----+-----+-----+ 540
 ACAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT
 15 541 -----+-----+-----+-----+-----+-----+ 600
 TATAAGCAACATGAAGACAGTATGATTTCATAAGTTTTTCTTTCTTCTAATGTCCCTGC
 601 -----+-----+-----+-----+-----+-----+ 660
 CTCTTAGAGTATTATAAGAAGATCTTTCTAGGATGTGTCATGGTCCACACAAAAATAGG
 20 661 -----+-----+-----+-----+-----+-----+ 720
 M V S T P Q F L V F L L F W I P
 MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
 GAAAGTGTGAAGATGGTATCCACACCTCAGTTCTTGTATTTTGTCTTTCTGGATTCCA
 25 721 -----+-----+-----+-----+-----+-----+ 780
 GGTAATGACTGTTTGGGTGTGGCAAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT
 781 -----+-----+-----+-----+-----+-----+ 840
 TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTCAGTTTAAAGAAATTGATAC
 30 841 -----+-----+-----+-----+-----+-----+ 900
 AATAAAAGTCATTTATTTTTCTAAGTTGTTTAGAAGTGACTTTCATATTCAGTGTTATGA
 901 -----+-----+-----+-----+-----+-----+ 960
 A S R G D I L L T Q S
 AlaSerArgGlyAspIleLeuLeuThrGlnSer
 TCGACTAATGTATCTTCCATTTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT
 35 961 -----+-----+-----+-----+-----+-----+ 1020
 P A I L S V S P G E R V T F S C R A S Q
 ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
 40 1021 -----+-----+-----+-----+-----+-----+ 1080
 CCAGCCATCCTGCTGTGAGTCCAGGAGAAAGAGTCACTTTCCTGCAGGGCCAGTCAG
 S I G T S L H W Y Q Q R T N G S P R L L
 SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
 45 1081 -----+-----+-----+-----+-----+-----+ 1140
 AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAATGGTCTCTCAAGGCTTCTC
 M K Y A S E S I S G I P S R F S G S G S
 MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
 50 1141 -----+-----+-----+-----+-----+-----+ 1200
 ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
 G T D F T L T I N S V E S E D I A D Y Y
 GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
 55 1201 -----+-----+-----+-----+-----+-----+ 1260
 GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC

5 C Q Q S H G W P F T F G S G T K L E I K
 CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
 1261 TGTCAACAAAGTCATGGCTGGCCATTACGTTCTGGGCTCGGGGACAAAGTTGGAAATAAAA
 1320
 1321 CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTTGGTTCTGTTTGGGTAGCTTGTGT
 1380
 10 GAATTTGTGATATTT
 1381 1395
 (III).

- 15
25. Rekombinante DNA nach Anspruch 22, umfassend ein Insert der Formel III, worin ein oder mehrere Nukleotide durch andere Nukleotide ersetzt sind außerhalb der Nukleotidsequenzen der Formel III von Position 1069-1102, 1147-1167 und 1263-1291.
- 20
26. Rekombinante DNA nach Anspruch 20, umfassend ein Insert, das für eine variable Region der schweren Kette der Maus kodiert, die spezifisch ist für Human-CEA, das aus der genomischen DNA der Zelllinie CE 25 herrührt, mit der Hinterlegungsnummer CNCM I-719.
- 25
27. Rekombinante DNA nach Anspruch 20 oder 26, umfassend ein Insert, das für das Polypeptid der Formel II kodiert, das gegebenenfalls Introns enthält.
28. Rekombinante DNA nach einem der Ansprüche 20, 26 oder 27, umfassend ein Insert, das für das Polypeptid der Formel II kodiert, worin FR₅, FR₆, FR₇ und FR₈ entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, das gegebenenfalls Introns enthält.
- 30
29. Rekombinante DNA nach einem der Ansprüche 20, 26 bis 28, umfassend ein Insert der Formel

35 AAGCTTGTCTGTTTACATGCAAGGAGGGAAACTAAACTGAGTATGGTGAATCCCTAACC
 1 60
 AAAGGGAAAAAATGAACTACAATATGTTTCAAATGCTGTAAGTGAATCTGGTTTTTTG
 61 120
 ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCAGAGCATGGTAT
 40 121 180

45

50

55

181 AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCATGAAAACACCTCGGCCCTGACCC 240
 5 -----+-----+-----+-----+-----+-----+-----+-----+
 241 TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTTGAGTTCCTCACATTCAGTGATGAGC 300
 -----+-----+-----+-----+-----+-----+-----+-----+
 M N F G F S L I F L V L V
 MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
 10 301 ACTGAACACAGACACCTCACCATGAACTTCGGGTTTCTGCTTTCCTTGTCTTGT 360
 -----+-----+-----+-----+-----+-----+-----+-----+
 L K G
 LeuLysGly
 15 361 TTAAAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA 420
 -----+-----+-----+-----+-----+-----+-----+-----+
 V Q
 ValG1
 20 421 TGTGGTTTGTGTTTGTAGTGACAGTTTCCACCAGTTATTCTCTGTTTGTAGGTGTCCA 480
 -----+-----+-----+-----+-----+-----+-----+-----+
 C E V K L V E S G G G L V K P G G S L K
 nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
 25 481 GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA 540
 -----+-----+-----+-----+-----+-----+-----+-----+
 L S C A A S G F T F R T Y A M A W V R Q
 sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgG1
 30 541 ACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGGACCTATGCCATGGCTTGGGTTCCGCCA 600
 -----+-----+-----+-----+-----+-----+-----+-----+
 T P E K R L E W V T S I S S G G T T Y Y
 nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
 35 601 GACTCCAGAGAAGAGGCTGGAGTGGGTTCACATCCATTAGTAGTGGTGGTACCACCTACTA 660
 -----+-----+-----+-----+-----+-----+-----+-----+
 P D S V K G R F T I S R D N A R N I L Y
 rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
 40 661 TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA 720
 -----+-----+-----+-----+-----+-----+-----+-----+
 L Q V S S L R S E D T A I Y Y C A R G F
 rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
 45 721 CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGGTTT 780
 -----+-----+-----+-----+-----+-----+-----+-----+
 Y D G Y L Y V V D Y W G Q G T S L T V S
 eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
 50 781 CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACCGTCTC 840
 -----+-----+-----+-----+-----+-----+-----+-----+
 S
 rSer
 55 841 CTCAGGTAAGAATGGCC 857
 -----+-----+-----+-----+-----+-----+-----+-----+

(IV).

30. Rekombinante DNA nach Anspruch 27, umfassend ein Insert der Formel IV, worin ein oder mehrere Nukleotide durch andere Nukleotide ersetzt sind außerhalb der Nukleotidsequenzen der Formel IV von Position 575-595, 629-680 und 776-805.
31. Rekombinante DNA nach Anspruch 20, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus fusioniert mit einer konstanten Region κ oder λ kodiert.
32. Rekombinante DNA nach Anspruch 31, umfassend ein Insert der Formel III, fusioniert mit einer humanen konstanten Region κ .
33. Rekombinante DNA nach Anspruch 20, umfassend ein Insert, das für eine variable Region der schweren Kette der Maus fusioniert mit einer konstanten Region $\gamma 1$, $\gamma 2$, $\gamma 3$ oder $\gamma 4$ kodiert.
34. Rekombinante DNA nach Anspruch 33, umfassend ein Insert der Formel IV fusioniert mit einer humanen konstanten Region $\gamma 4$.
35. Rekombinante DNA nach Anspruch 20, die ein Hybridvektor ist, umfassend ein Insert, kodierend für eine chimäre Maus/Human-leichte Kette nach Anspruch 31 und/oder eine chimäre Maus/Human-schwere Kette nach Anspruch 33, ein vollständiges Replikon und eine oder mehrere dominante Markersequenzen, gegebenenfalls an Expressionssteuerungssequenzen gebunden.
36. Rekombinante DNA nach Anspruch 20, die ein Hybridvektor ist, umfassend ein Insert, kodierend für eine chimäre Maus/Human-leichte Kette nach Anspruch 32 und/oder eine chimäre Maus/Human-schwere Kette nach Anspruch 34, ein vollständiges Replikon und eine oder mehrere dominante Markersequenzen, gegebenenfalls an Expressionssteuerungssequenzen gebunden.
37. Rekombinante DNA, die ein Hybridvektor ist, nach Anspruch 35 oder 36, geeignet für Säuger-Wirte.
38. Rekombinante DNA, die ein Hybridvektor ist, nach Anspruch 35, 36 oder 37, worin der Vektor aus dem Plasmid pSV abgeleitet ist.
39. Rekombinante DNA, die ein Hybridvektor ist, nach Anspruch 38, worin der Vektor aus dem Plasmid pSV2gpt oder aus dem Plasmid pSV2neo abgeleitet ist.
40. Verfahren zur Herstellung von rekombinanten DNAs nach Anspruch 20, gekennzeichnet durch Kultivieren eines transformierten Wirtes.
41. Verfahren nach Anspruch 40, umfassend die Stufen
 - a) Isolieren von Maus-DNAs aus einer geeigneten Hybridoma-Zelllinie, Selektieren der gewünschten DNAs, die für die variablen Regionen von monoklonalen Antikörpern kodieren, die gegen Human-CEA gerichtet sind, unter Verwendung von DNA-Sonden,
 - b) Isolieren von Human-DNAs aus einer genomischen Bibliothek, Selektieren der gewünschten DNAs, die für die konstanten Regionen monoklonaler Antikörper kodieren, unter Verwendung von DNA-Sonden,
 - c) Konstruieren der chimären Maus/Human-Gene durch Einbringen der DNAs von Stufe a) und b) in entsprechende Hybridvektoren,
 - d) Transferieren der erhaltenen Hybridvektoren in einen Rezipienten-Wirt, und
 - e) Selektieren und Kultivieren des transformierten Wirtes.
42. Wirtszelle, transformiert mit rekombinanten DNAs nach einem der Ansprüche 31 bis 39.
43. Wirtszelle nach Anspruch 42, die eine Säugerzelle lymphoiden Ursprunges ist.
44. Wirtszelle nach Anspruch 42, die eine Zelle ist, abgeleitet aus der Ig nicht-sekretierenden Maus-Hybridom-Zelllinie Sp2/O (ATCC CRL 1581).

45. Wirtszelle nach Anspruch 42 oder 44, die mit einem oder zwei Vektoren nach einem der Ansprüche 36 bis 39 transformiert ist.
46. Wirtszelle nach Anspruch 45, die eine Zelle der Zelllinie EFVIII/ γ 4Na 75-75/CxGa5-8 ist (CE 75-5-8 mit der Hinterlegungsnummer CNCM I-720).
47. Wirtszelle nach Anspruch 45, die eine Zelle der Zelllinie EFIX-pCEA-Ig-(γ 4;Cx) ist (CE 4-8-13 mit der Hinterlegungsnummer CNCM I-818).
48. Wirtszelle nach Anspruch 42, dadurch gekennzeichnet, daß sie chimäre monoklonale Antikörper nach Anspruch 1 sekretiert.
49. Verfahren zur Herstellung einer Wirtszelle nach Anspruch 42 oder 48, dadurch gekennzeichnet, daß eine geeignete Zelle mit einem oder zwei Vektoren durch Elektroporation, Calciumbehandlung, Mikroinjektion oder Protoplastenfusion transformiert wird.
50. Chimäre monoklonale Antikörper und Derivate davon nach Anspruch 1 zur Verwendung in einer Methode für die Behandlung von Menschen und zur Diagnose.
51. Verwendung von chimären monoklonalen Antikörpern und Derivaten davon nach Anspruch 1 für die in vitro-Diagnose von Krebs.
52. Verwendung von chimären monoklonalen Antikörpern und Derivaten davon nach Anspruch 1 zur qualitativen und quantitativen in vitro-Bestimmung von Human-CEA.
53. Verwendung nach Anspruch 51 von chimären monoklonalen Antikörpern und Derivaten davon in einem Radioimmunoassay oder einem Enzym-Immunoassay.
54. Test-Ausrüstung für die qualitative und quantitative Bestimmung von Human-CEA, enthaltend chimäre monoklonale Antikörper nach Anspruch 1 und/oder Derivate davon und gegebenenfalls andere monoklonale oder polyklonale Antikörper und/oder Begleitstoffe.
55. Pharmazeutische Zusammensetzung, enthaltend einen chimären monoklonalen Antikörper oder Derivate davon nach Anspruch 1.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung eines chimären monoklonalen Antikörpers, bestehend aus variablen Regionen des Maus-Origin und humanen konstanten Regionen, der Epitope von menschlichem Carcinoembryonal-Antigen (CEA) erkennt, die nicht vorhanden sind auf den nicht-spezifisch kreuzreagierenden Antigenen NCA₅₅ und NCA₉₅, auf biliärem Glycoprotein oder auf Granulocyten, und Derivaten davon, dadurch gekennzeichnet, daß Säugerzellen, die solche chimären monoklonalen Antikörper produzieren, in vitro vermehrt werden und gewünschtenfalls die erhaltenen chimären monoklonalen Antikörper in Derivate davon umgewandelt werden.
2. Verfahren nach Anspruch 1 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon mit einer Affinität von wenigstens $2,1 \times 10^{10}$ Liter/Mol für Human-CEA.
3. Verfahren nach Anspruch 1 oder 2 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die variablen Regionen der leichten Ketten der Formel

FR₁-Arg-Ala-Ser-Gln-Ser-Ile-Gly-Thr-Ser-Leu-His-FR₂-
 |----- CDR1L -----|

5 Tyr-Ala-Ser-Glu-Ser-Ile-Ser-FR₃-Gln-Gln-Ser-His-Gly-Trp-Pro-Phe-Thr-FR₄,
 |----- CDR2L -----| |----- CDR3L -----|
 (I),

10 worin FR₁ ein Polypeptidrest ist, umfassend 23-28 natürlich vorkommende Aminosäuren, FR₂ ist ein Polypeptidrest, umfassend 14-16 natürlich vorkommende Aminosäuren, FR₃ ist ein Polypeptidrest, umfassend 30-34 natürlich vorkommende Aminosäuren und FR₄ ist ein Polypeptidrest, umfassend 9-11 natürlich vorkommende Aminosäuren, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

15 4. Verfahren nach einem der Ansprüche 1 bis 3 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die variablen Regionen der leichten Kette der Formel I, worin die Polypeptidreste der Gerüstregionen FR₁, FR₂, FR₃ und FR₄ solche sind, die vorzugsweise in Maus-Antikörpern auftreten.

20 5. Verfahren nach einem der Ansprüche 1 bis 4 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die variablen Regionen der leichten Kette der Formel I, worin FR₁ ein Polypeptidrest ist der Formel

25 A-Gly-Asp-Ile-Leu-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Leu-Ser-Val-Ser-Pro-
 Gly-Glu-Arg-Val-Thr-Phe-Ser-Cys

30 (IA),

worin A Wasserstoff, Acyl oder der Rest Ala-Ser-Arg, Ser-Arg oder Arg ist,
 FR₂ ist der Polypeptidrest

35 Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

40 (IB),

FR₃ ist der Polypeptidrest

45 Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
 Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

50 (IC),

und FR₄ ist der Polypeptidrest

55

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

5

(ID).

und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

- 10 6. Verfahren nach Anspruch 3 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend variablen Regionen der leichten Kette der Formel I, worin FR₁, FR₂, FR₃ und FR₄ entsprechende Polypeptidreste der Formel IA, IB, IC und ID sind, worin eine oder mehrere einzelne Aminosäuren durch andere Aminosäuren außerhalb der Regionen CDR1L, CDR2L und CDR3L ersetzt sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.
- 15 7. Verfahren nach einem der Ansprüche 1 bis 6 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die variablen Regionen der schweren Kette der Formel

20 FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
 |----- CDR1H -----| |-----
 Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
 |----- CDR2H -----| |----- CDR3H -----|

(II).

25

worin FR₅ ein Polypeptidrest ist, bestehend aus 32-36 natürlich vorkommenden Aminosäuren, FR₆ ist ein Polypeptidrest, bestehend aus 14-16 natürlich vorkommenden Aminosäuren, FR₇ ist ein Polypeptidrest, bestehend aus 32-34 natürlich vorkommenden Aminosäuren und FR₈ ist ein Polypeptidrest, bestehend aus 12-14 natürlich vorkommenden Aminosäuren, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann.

8. Verfahren nach einem der Ansprüche 1 bis 7 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend variablen Regionen der schweren Kette der Formel II, worin die Polypeptidreste der Gerüstregionen FR₅, FR₆, FR₇ und FR₈ solche sind, die vorzugsweise in Maus-Antikörpern auftreten.
9. Verfahren nach einem der Ansprüche 1 bis 8 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die variablen Regionen der schweren Kette der Formel II, worin FR₅ ein Polypeptidrest der Formel

40

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Arg

(IIA).

50

ist, worin B Wasserstoff oder Acyl ist,
FR₆ ist der Polypeptidrest

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

55

(IIB).

FR₇ ist der Polypeptidrest

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
 Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
 Ala-Arg

(IIC),

und FR₈ ist der Polypeptidrest

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

und worin die Aminosäure Cys in oxidiertem Zustand sein kann, S-S-Brücken bildend.

10. Verfahren nach Anspruch 7 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend schwere Kette-variable Regionen der Formel II, worin FR₅, FR₆, FR₇ und FR₈ entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, worin eine oder mehrere einzelne Aminosäuren durch andere Aminosäuren außerhalb der Regionen CDR1H, CDR2H und CDR3H ersetzt sind, und worin die Aminosäure Cys in oxidiertem Zustand sein kann, S-S-Brücken bildend.

11. Verfahren nach einem der Ansprüche 1 bis 10 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die konstanten Regionen κ oder λ der humanen leichten Kette.

12. Verfahren nach einem der Ansprüche 1 bis 11 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die konstanten Regionen $\gamma 1$, $\gamma 2$, $\gamma 3$ oder $\gamma 4$ der humanen schweren Kette.

13. Verfahren nach einem der Ansprüche 1 bis 12 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon, umfassend die konstanten Regionen κ der humanen leichten Kette und die konstanten Regionen $\gamma 4$ der humanen schweren Kette.

14. Verfahren nach einem der Ansprüche 1 bis 13 zur Herstellung eines chimären monoklonalen Antikörpers und Derivaten davon mit variablen Regionen der leichten Kette der Formel I, worin FR₁, FR₂, FR₃ und FR₄ entsprechende Polypeptidreste der Formel IA, IB, IC und ID sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann, einer konstanten Region κ der humanen leichten Kette, einer variablen Region der schweren Kette der Formel II, worin FR₅, FR₆, FR₇ und FR₈ entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, und worin die Aminosäure Cys in oxidiertem Zustand S-S-Brücken bilden kann, und einer konstanten Region $\gamma 4$ der humanen schweren Kette.

15. Verfahren nach einem der Ansprüche 1 bis 14 zur Herstellung eines Derivates eines chimären monoklonalen Antikörpers, dadurch gekennzeichnet, daß der monoklonale Antikörper enzymatisch oder chemisch in ein Fragment gespalten wird.

16. Verfahren nach einem der Ansprüche 1 bis 14 zur Herstellung eines Derivates eines chimären monoklonalen Antikörpers, dadurch gekennzeichnet, daß der monoklonale Antikörper konjugiert wird mit einem Enzym, einem fluoreszierenden Marker, einem Metallchelate, einer cytostatischen oder cytotoxischen Substanz, Avidin oder Biotin.

17. Verfahren nach einem der Ansprüche 1 bis 14 zur Herstellung eines Derivates eines chimären monoklonalen Antikörpers, dadurch gekennzeichnet, daß der monoklonale Antikörper radioaktiv markiert

ist.

18. Verfahren zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus und/oder eine variable Region der schweren Kette der Maus der nach einem Verfahren gemäß Anspruch 1 hergestellten chimären monoklonalen Antikörper kodiert, dadurch gekennzeichnet, daß das Verfahren das Kultivieren eines transformierten Wirtes umfaßt.
19. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, dadurch gekennzeichnet, daß das Verfahren die Stufen umfaßt
 - a) Isolieren von Maus-DNAs aus einer geeigneten Hybridom-Zelllinie, Selektieren der gewünschten DNAs, die für die variablen Regionen von monoklonalen Antikörpern kodieren, die gegen Human-CEA gerichtet sind, unter Verwendung von DNA-Sonden,
 - b) Isolieren von Human-DNAs aus einer genomischen Bibliothek, Selektieren der gewünschten DNAs, die für die konstanten Regionen monoklonaler Antikörper kodieren, unter Verwendung von DNA-Sonden,
 - c) Konstruieren der chimären Maus/Human-Gene durch Einbringen der DNAs von Stufe a) und b) in entsprechende Hybridvektoren,
 - d) Transferieren der erhaltenen Hybridvektoren in einen Rezipienten-Wirt, und
 - e) Selektieren und Kultivieren des transformierten Wirtes.
20. Verfahren nach Anspruch 18 oder 19 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus kodiert, die spezifisch ist für Human-CEA, das aus genomischer DNA der Zelllinie CE 25 herrührt, mit der Hinterlegungsnummer CNCM I-719.
21. Verfahren nach Anspruch 18, 19 oder 20 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für das Polypeptid der Formel I kodiert, das gegebenenfalls Introns enthält.
22. Verfahren nach einem der Ansprüche 18 bis 21 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für das Polypeptid der Formel I kodiert, worin FR_1 , FR_2 , FR_3 und FR_4 entsprechende Polypeptide der Formel IA, IB, IC und ID sind, das gegebenenfalls Introns enthält.
23. Verfahren nach einem der Ansprüche 18 bis 22 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel

TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT
1 -----+-----+-----+-----+-----+ 60
5 TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTGGAAAGATATGCAAG
61 -----+-----+-----+-----+-----+ 120
AAGCACTATTTGGCTATTATTTGGAAAGTGCTATAATGTATTTTGATACTCAACCTCTG
121 -----+-----+-----+-----+-----+ 180
10 AAATTCTTCTGTATGTTGCCAGATTGTAAACCTTTACAAGGCTTTCATTCTCTTCTCTGG
181 -----+-----+-----+-----+-----+ 240
AGAAAAATGTCTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
241 -----+-----+-----+-----+-----+ 200
15 GTGTGATATCACTTTAGTTTCATGTGTTGTTATGCTTCATGTAATGTTAAGAAAGTTAAA
301 -----+-----+-----+-----+-----+ 360
GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTTGAG
361 -----+-----+-----+-----+-----+ 420
20 ATGCTCTTTATTTCAAACACTACTGAATATATCTTAGAGATTCTTTAGACTGTGTTAAATA
421 -----+-----+-----+-----+-----+ 480
TGTAACCATTTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA
481 -----+-----+-----+-----+-----+ 540
25 ACAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT
541 -----+-----+-----+-----+-----+ 600
TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTCTTTCTTCTAATGTCCCTGC
601 -----+-----+-----+-----+-----+ 660
30 CTCITAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTCATGGTCCACACAAAAATAGG
661 -----+-----+-----+-----+-----+ 720


```

      M V S T P Q F L V F L L F W I P
      MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
5  721  -----+-----+-----+-----+-----+-----+ 780
      GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGTATTTTTCCTTTTCTGGATTCCA
      GGTAAATGACTGTTTGGGTGTGGCAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT
      781  -----+-----+-----+-----+-----+-----+ 840
      TGCTTTATTTTGAAGCCAATGTCACATGGGAATTGACTTTCAGTTTAAAGAAATTGATAC
10  841  -----+-----+-----+-----+-----+-----+ 900
      AATAAAAGTCATTIATTTTCTAAGTTGTTTAGAAGTGACTTTCATATTCAGTGTTATGA
      901  -----+-----+-----+-----+-----+-----+ 960
      A S R G D I L L T Q S
      AlaSerArgGlyAspIleLeuLeuThrGlnSer
15  961  -----+-----+-----+-----+-----+-----+ 1020
      TCGACTAATGTATCTTCCATTTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT
      P A I L S V S P G E R V T F S C R A S Q
20  1021  -----+-----+-----+-----+-----+-----+ 1080
      ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
      CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTTCCTGCAGGGCCAGTCAG
      S I G T S L H W Y Q Q R T N G S P R L L
25  1081  -----+-----+-----+-----+-----+-----+ 1140
      SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
      AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAATGGTTCCTCCAAGGCTTCTC
      M K Y A S E S I S G I P S R F S G S G S
30  1141  -----+-----+-----+-----+-----+-----+ 1200
      MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
      ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
      G T D F T L T I N S V E S E D I A D Y Y
35  1201  -----+-----+-----+-----+-----+-----+ 1260
      GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
      GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
      C Q Q S H G W P F T F G S G T K L E I K
40  1261  -----+-----+-----+-----+-----+-----+ 1320
      CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
      TGTCAACAAAGTCATGGCTGGCCATTACGTTTCGGCTCGGGGACAAAGTTGGAAATAAAA
      CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTTGTTCTGTTTGGGTAGCTTGTGT
      1321  -----+-----+-----+-----+-----+-----+ 1380
      GAATTTGTGATATTT
45  1381  -----+----- 1395
      (III).

```

50 24. Verfahren nach Anspruch 21 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel III, worin ein oder mehrere Nukleotide durch andere Nukleotide ersetzt sind außerhalb der Nukleotidsequenzen der Formel III von Position 1069-1102, 1147-1167 und 1263-1291.

55 25. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für eine variable Region der schweren Kette der Maus kodiert, die spezifisch ist für Human-CEA, das aus der genomischen DNA der Zelllinie CE 25 herrührt, mit der Hinterlegungsnummer CNCM I-719.

26. Verfahren nach Anspruch 18 oder 25 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für das Polypeptid der Formel II kodiert, das gegebenenfalls Introns enthält.
27. Verfahren nach Anspruch 18, 25 oder 26 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für das Polypeptid der Formel II kodiert, worin FR₅, FR₆, FR₇ und FR₈ entsprechende Polypeptidreste der Formel IIA, IIB, IIC und IID sind, das gegebenenfalls Introns enthält.
28. Verfahren nach einem der Ansprüche 18, 25-27 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel

```

10  AAGCTTGTCTCTGTTACATGCAAGGAGGGAACTAAACTGAGTATGGTGAATCCCTAACC
1  -----+-----+-----+-----+-----+-----+-----+ 60
    AAAGGGAAAAAATGAACTACAATATGTTTCAAATGCTGTAAGTAAATCTGGTTTTTTG
15 61 -----+-----+-----+-----+-----+-----+-----+ 120
    ATGCCITTATACTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCAGAGCATGGTAT
121 -----+-----+-----+-----+-----+-----+-----+ 180
    AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCATGAAAACACCTCGGCCCTGACCC
20 181 -----+-----+-----+-----+-----+-----+-----+ 240
    TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTGAGTTCCTCACATTACAGTGATGAGC
241 -----+-----+-----+-----+-----+-----+-----+ 300
                                     M N F G F S L I F L V L V
                                     MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
25  ACTGAACACAGACACCTCACCATGAACTTCGGGTTCAGCTTGATTTTCCTTGTCTTGT
301 -----+-----+-----+-----+-----+-----+-----+ 360
    L K G
    LeuLysGly
30  TTAAAAGGTAATTTATTGAGAAGAGATGACATCTATTTACGCACATGAGACAGAAAAAA
361 -----+-----+-----+-----+-----+-----+-----+ 420
                                     V Q
                                     ValG1
35  TGTGGTTTGTGTTTGTAGTGACAGTTTCCAACCAGTTATTCTCTGTTTGTAGGTGTCCA
421 -----+-----+-----+-----+-----+-----+-----+ 480

```

```

      C E V K L V E S G G G L V K P G G S L K
nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA
481 -----+-----+-----+-----+-----+ 540
5
      L S C A A S G F T F R T Y A M A W V R Q
sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgGl
ACTCTCCTGTGCAGCCTCTGGGTTCACCTTCAGGACCTATGCCATGGCTTGGGTTCGCCA
541 -----+-----+-----+-----+-----+ 600
10
      T P E K R L E W V T S I S S G G T T Y Y
nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
GACTCCAGAGAAGAGGCTGGAGTGGGTCACATCCATTAGTAGTGGTGGTACCACCTACTA
601 -----+-----+-----+-----+-----+ 660
15
      P D S V K G R F T I S R D N A R N I L Y
rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA
661 -----+-----+-----+-----+-----+ 720
20
      L Q V S S L R S E D T A I Y Y C A R G F
rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGGTTT
721 -----+-----+-----+-----+-----+ 780
25
      Y D G Y L Y V V D Y W G Q G T S L T V S
eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
CTATGATGGTTACCTCTATGTTGTGGACTACTGGGCTCAAGGAACCTCACTCACCGTCTC
781 -----+-----+-----+-----+-----+ 840
30
      S
rSer
CTCAGGTAAGAATGGCC
841 -----+----- 857

```

(IV).

29. Verfahren nach Anspruch 26 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel IV, worin ein oder mehrere Nukleotide durch andere Nukleotide ersetzt sind außerhalb der Nukleotidsequenzen der Formel IV von Position 575-595, 629-680 und 776-805.
30. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für eine variable Region der leichten Kette der Maus fusioniert mit einer Humanen-konstanten Region α oder λ kodiert.
31. Verfahren nach Anspruch 30 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel III, fusioniert an eine Humane-konstante Region α .
32. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, umfassend ein Insert, das für eine variable Region der schweren Kette der Maus fusioniert mit einer Humanen-konstanten Region $\gamma 1$, $\gamma 2$, $\gamma 3$ oder $\gamma 4$ kodiert.
33. Verfahren nach Anspruch 32 zur Herstellung einer rekombinanten DNA, umfassend ein Insert der Formel IV fusioniert mit einer Humanen-konstanten Region $\gamma 4$.
34. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, die ein Hybridvektor ist, umfassend ein Insert, kodierend für eine chimäre Maus/Human-leichte Kette, hergestellt durch ein

Verfahren gemäß Anspruch 31 und/oder eine chimäre Maus/Human-schwere Kette, hergestellt nach einem Verfahren gemäß Anspruch 33, ein vollständiges Replikon und eine oder mehrere dominante Markersequenzen, gegebenenfalls an Expressionssteuerungssequenzen gebunden.

- 5 35. Verfahren nach Anspruch 18 zur Herstellung einer rekombinanten DNA, die ein Hybridvektor ist, umfassend ein Insert, kodierend für eine chimäre Maus/Human-leichte Kette, hergestellt nach einem Verfahren gemäß Anspruch 32 und/oder eine chimäre Maus/Human-schwere Kette, hergestellt nach einem Verfahren gemäß Anspruch 34, ein vollständiges Replikon und eine oder mehrere dominante Markersequenzen, gegebenenfalls an Expressionssteuerungssequenzen gebunden.
- 10 36. Verfahren nach Anspruch 34 oder 35 zur Herstellung einer rekombinanten DNA, die ein für Säuger-Wirte geeigneter Hybridvektor ist.
37. Verfahren nach Anspruch 34, 35 oder 36 zur Herstellung einer rekombinanten DNA, die ein Hybridvektor ist, worin der Vektor aus dem Plasmid pSV abgeleitet ist.
- 15 38. Verfahren nach Anspruch 37 zur Herstellung einer rekombinanten DNA, die ein Hybridvektor ist, worin der Vektor aus dem Plasmid pSV2gpt oder aus dem Plasmid pSV2neo abgeleitet ist.
- 20 39. Wirtszelle, transformiert mit rekombinanten DNAs, hergestellt nach einem Verfahren gemäß einem der Ansprüche 30 bis 38.
40. Wirtszelle nach Anspruch 39, die eine Säugerzelle lymphoiden Ursprunges ist.
- 25 41. Wirtszelle nach Anspruch 39, die eine Zelle ist, abgeleitet aus der Ig nicht-sekretierenden Maus-Hybridoma-Zelllinie Sp2/O (ATCC CRL 1581).
42. Wirtszelle nach Anspruch 39 oder 41, die mit einem oder zwei Vektoren transformiert ist, die nach einem Verfahren gemäß einem der Ansprüche 35 bis 38 hergestellt sind.
- 30 43. Wirtszelle nach Anspruch 42, die eine Zelle der Zelllinie EFVIII/γ4Na75-75/CxGa5-6 ist (CE 75-5-6 mit der Hinterlegungsnummer CNCM I-720).
44. Wirtszelle nach Anspruch 42, die eine Zelle der Zelllinie EFIX-pCEA-Ig-(γ4;Cx) ist (CE 4-8-13 mit der Hinterlegungsnummer CNCM I-818).
- 35 45. Wirtszelle nach Anspruch 39, dadurch gekennzeichnet, daß sie chimäre monoklonale Antikörper sekretiert, die nach einem Verfahren gemäß Anspruch 1 hergestellt sind.
- 40 46. Verfahren zur Herstellung einer Wirtszelle nach Anspruch 39 oder 45, dadurch gekennzeichnet, daß eine geeignete Zelle mit einem oder zwei Vektoren durch Elektroporation, Calciumbehandlung, Mikroinjektion oder Protoplastenfusion transformiert wird.
47. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, enthaltend einen chimären monoklonalen Antikörper oder Derivate davon, hergestellt nach einem Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß der monoklonale Antikörper mit einem pharmazeutischen Träger vermischt wird.
- 45

Revendications

50 **Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Anticorps monoclonal chimérique constitué de régions variables d'origine murine et de régions constantes d'origine humaine, qui reconnaît des épitopes d'antigène carcinoembryonnaire humain (CEA) non-présents sur les antigènes à réaction croisée non-spécifiques NCA₅₅ et NCA₉₅, sur la glycoprotéine biliaire, ou sur les granulocytes, et leurs dérivés.
- 55 2. Anticorps monoclonal chimérique et ses dérivés selon la revendication 1 ayant une affinité d'au moins $2,1 \times 10^{10}$ litres/mole pour le CEA humain.

3. Anticorps monoclonal chimérique et ses dérivés selon la revendication 1 ou 2, comprenant des régions variables à chaîne légère de formule

5 FR₁-Arg-Ala-Ser-Gln-Ser-Ile-Gly-Thr-Ser-Leu-His-FR₂-
└────────────────── CDR1L ─────────────────┘

Tyr-Ala-Ser-Glu-Ser-Ile-Ser-FR₃-Gln-Gln-Ser-His-Gly-Trp-Pro-Phe-Thr-FR₄
└────────── CDR2L ─────────┘ └────────── CDR3L ─────────┘
 (I),

10

dans laquelle FR₁ est un résidu polypeptide comprenant 23-28 acides aminés naturels, FR₂ est un résidu polypeptide comprenant 14-16 acides aminés naturels, FR₃ est un résidu polypeptide comprenant 30-34 acides aminés naturels et FR₄ est un résidu polypeptide comprenant 9-11 acides aminés naturels, et où l'acide aminé cys peut être à l'état oxydé, formant des ponts S-S.

15

4. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1 à 3 comprenant des régions variables à chaîne légère de formule I, où les résidus polypeptides des régions d'ossature FR₁, FR₂, FR₃ et FR₄ sont ceux qui apparaissent de préférence dans les anticorps murins.

20

5. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1 à 4 comprenant des régions variables à chaîne légère de formule I, où FR₁ est un résidu polypeptide de formule

25

A-Gly-Asp-Ile-Leu-Leu-Thr-Gln-Ser-Pro-Ala-Ile-Leu-Ser-Val-Ser-Pro-
 Gly-Glu-Arg-Val-Thr-Phe-Ser-Cys

30

(IA),

dans laquelle A est un hydrogène, un acyle, ou le résidu Ala-Ser-Arg, Ser-Arg ou Arg, FR₂ est le résidu polypeptide

35

Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

40

(IB),

FR₃ est le résidu polypeptide

45

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
 Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

50

(IC),

et FR₄ est le résidu polypeptide

55

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

5

(ID).

et où l'acide aminé cys peut être à l'état oxydé, formant des ponts S-S.

10 6. Anticorps monoclonal chimérique et ses dérivés selon la revendication 3 comprenant des régions variables à chaîne légère de formule I, où FR₁, FR₂, FR₃ et FR₄ sont des résidus polypeptidiques de formules IA, IB, IC et ID, respectivement, où un ou plusieurs acides aminés isolés sont remplacés par d'autres acides aminés en dehors des régions CDR1L, CDR2L, et CDR3L, et où l'acide aminé cys peut être à l'état oxydé, formant des ponts S-S.

15

7. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-6 comprenant des régions variables à chaîne lourde de formule

20 FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
 |----- CDR1H -----| |-----
 Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
 ----- CDR2H -----| |----- CDR3H -----|
 (II),

25

dans laquelle FR₅ est un résidu polypeptide comprenant 32-36 acides aminés naturels, FR₆ est un résidu polypeptide comprenant 14-16 acides aminés naturels, FR₇ est un résidu polypeptide comprenant 32-34 acides aminés naturels et FR₈ est un résidu polypeptide comprenant 12-14 acides aminés naturels, et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

30

8. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-7 comprenant des régions variables à chaîne lourde de formule II, où les résidus polypeptides des régions d'ossature FR₅, FR₆, FR₇ et FR₈ sont ceux que l'on trouve de préférence dans les anticorps murins.

35

9. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-8 comprenant des régions variables à chaîne lourde de formule II, où FR₅ est un résidu polypeptide de formule

40

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Arg

45

(IIA).

dans laquelle B est un hydrogène ou un acyle,
FR₅ est le résidu polypeptide

50

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

55

(IIB).

FR₇ est le résidu polypeptide

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
 Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
 Ala-Arg

(IIC),

et FR₈ est le résidu polypeptide

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

10. Anticorps monoclonal chimérique et ses dérivés selon la revendication 7, comprenant des régions variables à chaîne lourde de formule II, où FR₅, FR₆, FR₇ et FR₈ sont des résidus polypeptides de formule IIA, IIB, IIC et IID, respectivement, où un ou plusieurs acides aminés isolés sont remplacés par d'autres acides aminés en dehors des régions CDR1H, CDR2H et CDR3H, et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.
11. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-10 comprenant des régions constantes humaines à chaîne légère α ou λ .
12. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-11 comprenant des régions constantes humaines à chaîne lourde γ 1, γ 2, γ 3, ou γ 4.
13. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-12, comprenant des régions constantes à chaîne légère et des régions constantes humaines α à chaîne lourde γ 4.
14. Anticorps monoclonal chimérique et ses dérivés selon l'une quelconque des revendications 1-13 avec des régions variables à chaîne légère de formule I où FR₁, FR₂, FR₃ et FR₄ sont des résidus polypeptides de formule IA, IB, IC et ID, et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S, une région constante humaine à chaîne légère α , une région variable à chaîne lourde de formule II, où FR₅, FR₆, FR₇ et FR₈ sont des résidus polypeptides de formules IIA, IIB, IIC, et IID, respectivement, et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S et une région constante humaine à chaîne lourde γ 4.
15. Dérivé d'un anticorps monoclonal chimérique selon l'une quelconque des revendications 1-14 qui est un fragment.
16. Dérivé d'un anticorps monoclonal chimérique selon l'une quelconque des revendications 1-14 qui est un conjugué avec une enzyme, un marqueur fluorescent, un chélate métallique, une substance cytostatique ou cytotoxique, l'avidine ou la biotine.
17. Dérivé d'un anticorps monoclonal chimérique selon l'une quelconque des revendications 1-14 qui est radioactivement marqué.
18. Procédé de préparation d'anticorps monoclonaux chimériques et de leurs dérivés selon la revendication 1, caractérisé en ce qu'on multiplie in vitro des cellules de mammifère produisant de tels anticorps monoclonaux chimériques et, si on le désire, en ce qu'on transforme des anticorps monoclonaux chimériques résultants en leurs dérivés.

19. Procédé de préparation d'anticorps monoclonaux chimériques et de leurs dérivés selon la revendication 1, caractérisé en ce qu'on multiplie *in vivo* des cellules de mammifère produisant de tels anticorps monoclonaux chimériques et, si on le désire, on transforme les anticorps monoclonaux chimériques résultants en leurs dérivés.

5

20. ADN recombinant comprenant un insert codant pour une région variable murine à chaîne légère et/ou pour une région variable murine à chaîne lourde d'anticorps monoclonaux chimériques selon la revendication 1.

- 10 21. ADN recombinant selon la revendication 20 comprenant un insert codant pour une région variable murine à chaîne légère spécifique du CEA humain qui provient de l'ADN génomique de la lignée cellulaire CE 25, ayant le n° d'accès au dépôt CNCM I-719.

- 15 **22. ADN recombinant selon la revendication 20 ou 21 comprenant un insert codant pour le polypeptide de**
formule I, contenant facultativement des introns.

23. ADN recombinant selon l'une quelconque des revendications 20-22 comprenant un insert codant pour les polypeptides de formule I, où FR₁, FR₂, FR₃ et FR₄ sont des polypeptides de formule IA, IB, IC et ID, respectivement, contenant facultativement des introns.

20

- 24. ADN recombinant selon l'une quelconque des revendications 20-23 comprenant un insert de formule**

25

TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT

I **60**

TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTTGGAAAGATATGCAAG

[illegible]

AAGCACTATTTGGCTATTATTTGGAAAGTGCTATAATGTATTTTGATATCTCAACCTCTG

[illegible]

AAATTCTTCTGTATGTTGGCAGATTGTAAACCTTTACAAGGCTTTCATTCTCTTCTCTGG

181 240

AGAAAAATGTCTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA

24} -----+-----+-----+-----+-----+ 200

GTGTGATATCACTTTAGTTTTCATGTGTTGTTATGCTTCATGTAATGTTAAGAAAGTTAAA

301 360

GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTGAG

361 -----+-----+-----+-----+-----+ 420

ATGCTCTTTATTTCAAACACTGAATATATCTTAGAGATTTCTTTAGACTGTGTTAAATA

421 -----+-----+-----+-----+-----+-----+-----+ 480

TGTAACCATTTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA

481 -----+-----+-----+-----+-----+-----+-----+ 540

ACAAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT

541 -----+-----+-----+-----+-----+-----+-----+ 600

TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTCTTTCTTCTAATGTCCCTGC

601 -----+-----+-----+-----+-----+-----+-----+ 660

CTCTTAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTCATGGTCCACACAAAAATAGG

661 -----+-----+-----+-----+-----+ 720

N V S T P O F L V F L L F W I P

MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro

GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGTATTTTTGCTTTTCTGGATTCCA

721 -----+-----+-----+-----+-----+-----+**780**

781 GGTAATGACTGTTTGGGTGTGGCAAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT 840
 841 TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTTCAGTTTAAAGAAATTGATAC 900
 5 AATAAAAGTCATTTATTTTCTAAGTTGTTTAGAAGTGACTTTCATATTCAGTGTTATGA 960
 901
 A S R G D I L L T Q S
 AlaSerArgGlyAspIleLeuLeuThrGlnSer
 10 TCGACTAATGTATCTTCCATTTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT 1020
 961
 P A I L S V S P G E R V T F S C R A S Q
 ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
 15 CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTTCTCCTGCAGGCCAGTCAG 1080
 1021
 S I G T S L H W Y Q Q R T N G S P R L L
 SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
 20 AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTC 1140
 1081
 M K Y A S E S I S G I P S R F S G S G S
 MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
 25 ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA 1200
 1141
 G T D F T L T I N S V E S E D I A D Y Y
 GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
 30 GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC 1260
 1201
 C Q Q S H G W P F T F G S G T K L E I K
 CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
 35 TGTCAACAAAGTCATGGCTGGCCATTACGTTTCGGCTCGGGGACAAAGTTGGAATAAAA 1320
 1261
 CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTGGTTCTGTTTGGGTAGCTTGTGT
 35 1321 1380
 GAATTTGTGATATT
 1381 1395
 (III).

25. ADN recombinant selon la revendication 22 comprenant un insert de formule III où un ou plusieurs nucléotides isolés sont remplacés par d'autres nucléotides en dehors des séquences nucléotidiques de formule III à partir des positions 1069-1102, 1147-1167, et 1263-1291, respectivement.

26. ADN recombinant selon la revendication 20 comprenant un insert codant pour une région variable murine à chaîne lourde spécifique du CEA humain qui provient de l'ADN génomique de la lignée cellulaire CE 25, ayant le N° d'accès au dépôt CNCM I-719.

27. ADN recombinant selon la revendication 20 ou 26 comprenant un insert codant pour le polypeptide de formule II, contenant facultativement des introns.

28. ADN recombinant selon la revendication 20, 26 ou 27, comprenant un insert codant pour le polypeptide de formule I, où FR₅, FR₆, FR₇ et FR₈ sont des résidus polypeptides de formule IIA, IIB, IIC et IID, respectivement, contenant facultativement des introns.

29. ADN recombinant selon l'une quelconque des revendications 20, 26-28, comprenant un insert de formule

1 AAGCTTGTTCCTGTTTCACATGCAAGGAGGGAAACTAAACTGAGTATGGTGAATCCCTAACC 60
 5 61 -----+-----+-----+-----+-----+-----+ 120
 AAAGGGAAAAAATGAAACTACAATATGTTTCAAATGCTGTAAGTCAAATCTGGTTTTTTG
 121 -----+-----+-----+-----+-----+-----+ 180
 ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCAGAGCATGGTAT
 181 -----+-----+-----+-----+-----+-----+ 240
 10 AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCATGAAAACACCTCGGCCCTGACCC
 241 -----+-----+-----+-----+-----+-----+ 300
 TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTTGAGTTCCTCACATTTCAGTGATGAGC
 301 -----+-----+-----+-----+-----+-----+ 360
 15 M N F G F S L I F L V L V
 MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
 ACTGAACACAGACACCTCACCATGAACTTCGGGTTTCAGCTTGATTTTCCTTGTCTTGT
 361 -----+-----+-----+-----+-----+-----+ 420
 L K G
 LeuLysGly
 20 TTAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA
 361 -----+-----+-----+-----+-----+-----+ 420
 V Q
 ValG1
 25 TGTGGTTTGTGTTTGTAGTGACAGTTTTCCAACCAGTTATTCTCTGTTTGTAGGTGTCCA
 421 -----+-----+-----+-----+-----+-----+ 480
 C E V K L V E S G G G L V K P G G S L K
 nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
 30 481 GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAA 540
 -----+-----+-----+-----+-----+-----+

L S C A A S G F T F R T Y A M A W V R Q
 sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgGl
 ACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGGACCTATGCCATGGCTTGGGTTCCGCA
 541 -----+-----+-----+-----+-----+-----+-----+ 600
 5 T P E K R L E W V T S I S S G G T T Y Y
 nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
 GACTCCAGAGAAGAGGCTGGAGTGGCTCACATCCATTAGTAGTGGTGGTACCACCTACTA
 601 -----+-----+-----+-----+-----+-----+-----+ 660
 10 P D S V K G R F T I S R D N A R N I L Y
 rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
 TCCAGACAGTGTGAAGGGCCGATTACCACTCTCCAGAGATAATGCCAGGAACATCCTGTA
 661 -----+-----+-----+-----+-----+-----+-----+ 720
 15 L Q V S S L R S E D T A I Y Y C A R G F
 rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
 CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGGTTT
 721 -----+-----+-----+-----+-----+-----+-----+ 780
 20 Y D G Y L Y V V D Y W G Q G T S L T V S
 eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
 CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACCCTCTC
 781 -----+-----+-----+-----+-----+-----+-----+ 840
 25 S
 rSer
 CTCAGGTAAGAATGGCC (IV).
 841 -----+-----+-----+-----+-----+-----+-----+ 857

- 30
30. ADN recombinant selon la revendication 27 comprenant un insert de formule IV dans lequel un ou plusieurs nucléotides isolés sont remplacés par d'autres nucléotides en dehors des séquences nucléotidiques de formule IV provenant des positions 575-595, 629-680 et 776-805, respectivement.
- 35
31. ADN recombinant selon la revendication 20 comprenant un insert codant pour une région variable murine à chaîne légère fusionnée à une région constante humaine α ou λ .
32. ADN recombinant selon la revendication 31 comprenant un insert de formule III fusionné à une région constante humaine α .
- 40
33. ADN recombinant selon la revendication 20 comprenant un insert codant pour une région variable murine à chaîne lourde fusionnée à une région constante humaine $\gamma 1$, $\gamma 2$, $\gamma 3$ ou $\gamma 4$.
- 45
34. ADN recombinant selon la revendication 33 comprenant un insert de formule IV fusionné à une région constante humaine $\gamma 4$.
- 50
35. ADN recombinant selon la revendication 20 qui est un vecteur hybride comprenant un insert codant pour une chaîne légère murine/humaine chimérique selon la revendication 31 et/ou une chaîne lourde murine/humaine chimérique selon la revendication 33, un réplicon complet et une ou plusieurs séquences marqueuses dominantes, liées de manière opératoire à des séquences de commande d'expression.
- 55
36. ADN recombinant selon la revendication 20 qui est un vecteur hybride comprenant un insert codant pour une chaîne légère murine/humaine chimérique selon la revendication 32, et/ou une chaîne lourde murine/humaine chimérique selon la revendication 34, un réplicon complet et une ou plusieurs séquences marqueuses dominantes, liées de façon opératoire à des séquences de commande d'expression.


37. ADN recombinant qui est un vecteur hybride selon la revendication 35 ou 36 approprié à des hôtes mammifères.
38. ADN recombinant qui est un vecteur hybride selon la revendication 35, 36 ou 37, dans lequel le vecteur est dérivé du plasmide pSV.
39. ADN recombinant qui est un vecteur hybride selon la revendication 38, dans lequel le vecteur hybride est dérivé du plasmide pSV2gpt ou du plasmide pSV2neo.
40. Procédé de préparation d'ADN recombinant selon la revendication 20 dans lequel on cultive un hôte transformé.
41. Procédé selon la revendication 40 comprenant les étapes de
 - a) isolement d'ADN murins provenant d'une lignée cellulaire d'hybridome appropriée, sélection des ADN désirés codant pour les régions variables des anticorps monoclonaux dirigés contre le CEA humain en utilisant des sondes d'ADN,
 - b) isolement des ADN humains à partir d'une bibliothèque génomique, sélection des ADN désirés codant pour les régions constantes des anticorps monoclonaux en utilisant des sondes d'ADN,
 - c) construction de gènes murins/humains chimériques par incorporation des ADN des étapes a) et b) dans des vecteurs hybrides appropriés,
 - d) transfert des vecteurs hybrides obtenus chez un hôte récepteur, et
 - e) sélection et culture de l'hôte transformé.
42. Cellule hôte qui est transformée avec les ADN recombinants selon l'une quelconque des revendications 31-39.
43. Cellule hôte selon la revendication 42 qui est une cellule de mammifère d'origine lymphoïde.
44. Cellule hôte selon la revendication 42 qui est une cellule dérivée de la lignée cellulaire d'hybridome de souris non-sécrétrice d'Ig Sp2'0 (ATCC CRL 1581).
45. Cellule hôte selon la revendication 42 ou 44 qui est transformée avec un ou deux vecteurs selon l'une quelconque des revendications 36-39.
46. Cellule hôte selon la revendication 45 qui est une cellule de la lignée cellulaire EFVIII/ γ 4Na75-75/C $\times$ Ga5-6 (CE 75-5-6) ayant le numéro d'accès au dépôt CNCM I-720.
47. Cellule hôte selon la revendication 45 qui est une cellule de la lignée cellulaire EFIX-pCEA-Ig-(γ 4;C $\times$) (CE 4-8-13), ayant le numéro d'accès au dépôt CNCM I-818.
48. Cellule hôte selon la revendication 42, caractérisée en ce qu'elle sécrète des anticorps monoclonaux chimériques selon la revendication 1.
49. Procédé de préparation d'une cellule hôte selon la revendication 42 ou 48, caractérisé en ce qu'on transforme une cellule appropriée avec un ou deux vecteurs par électroporation, traitement au calcium, microinjection ou fusion de protoplaste.
50. Anticorps monoclonaux chimériques et leurs dérivés selon la revendication 1 pour utilisation dans le traitement de l'homme et pour le diagnostic.
51. Utilisation d'anticorps monoclonaux chimériques et de leurs dérivés selon la revendication 1 pour le diagnostic in vitro du cancer.
52. Application d'anticorps monoclonaux chimériques et de leurs dérivés selon la revendication 1 pour la détermination qualitative ou quantitative in vitro du CEA humain.
53. Application selon la revendication 51 d'anticorps monoclonaux chimériques et de leurs dérivés dans un radioimmunos dosage ou un immunodosage enzymatique.

54. Nécessaires expérimentaux pour la détermination qualitative et quantitative de CEA humain contenant des anticorps monoclonaux chimériques selon la revendication 1 et/ou leurs dérivés et, facultativement, d'autres anticorps monoclonaux ou polyclonaux et/ou additifs.

- 5 55. Composition pharmaceutique contenant un anticorps monoclonal chimérique ou un de ses dérivés selon la revendication 1.


Revendications pour les Etats contractants suivants : ES, GR

- 10 1. Procédé de préparation d'un anticorps monoclonal chimérique constitué de régions variables d'origine murine et de régions constantes d'origine humaine, qui reconnaît des épitopes d'antigène carcinoembryonnaire humain (CEA), non-présent sur les antigènes à réaction croisée non-spécifiques NCA₅₅ et NCA₉₅, sur une glycoprotéine biliaire ou sur des granulocytes, et de ses dérivés, caractérisé en ce qu'on multiplie in vivo ou in vitro les cellules de mammifère produisant de tels anticorps monoclonaux chimériques et, si on le désire, en ce qu'on transforme l'anticorps monoclonal chimérique résultant en leurs dérivés.
- 15 2. Procédé selon la revendication 1 de préparation d'un anticorps monoclonal chimérique et de ses dérivés ayant une affinité d'au moins $2,1 \times 10^{10}$ litres/mole pour le CEA humain.
- 20 3. Procédé selon la revendication 1 ou 2 de préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne légère de formule



dans laquelle FR₁ est un résidu polypeptide comprenant 23-28 acides aminés naturels, FR₂ est un résidu polypeptide comprenant 14-16 acides aminés naturels, FR₃ est un résidu polypeptide comprenant 30-34 acides aminés naturels et FR₄ est un résidu polypeptide comprenant 9-11 acides aminés naturels et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

- 35 4. Procédé selon l'une quelconque des revendications 1-3 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne légère de formule I, où les résidus polypeptides des régions d'ossature FR₁, FR₂, FR₃ et FR₄ sont celles que l'on trouve de préférence dans les anticorps murins.
- 40 5. Procédé selon l'une quelconque des revendications 1-4 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne légère de formule I, où FR₁ est un résidu polypeptide de formule



(IA),

où A est un hydrogène, un acyle, ou le résidu Ala-Ser-Arg, Ser-Arg ou Arg,
55 FR₂ est le résidu polypeptide

Trp-Tyr-Gln-Gln-Arg-Thr-Asn-Gly-Ser-Pro-Arg-Leu-Leu-Met-Lys

(IB).

FR₃ est le résidu polypeptide

Gly-Ile-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-
Thr-Ile-Asn-Ser-Val-Glu-Ser-Glu-Asp-Ile-Ala-Asp-Tyr-Tyr-Cys

(IC).

et FR_4 est le résidu polypeptide

Phe-Gly-Ser-Gly-Gly-Thr-Lys-Leu-Glu-Ile-Lys

(ID).

et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

6. Procédé selon la revendication 3 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne légère de formule L, où FR₁, FR₂, FR₃ et FR₄ sont des résidus polypeptides de formules IA, IB, IC et ID, respectivement, où un ou plusieurs acides aminés isolés sont remplacés par d'autres acides aminés en dehors des régions CDR1L, CDR2L et CDR3L et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.
7. Procédé selon l'une quelconque des revendications 1-6 pour la préparation d'un anticorps monoclonal chimérique ou de ses dérivés comprenant des régions variables à chaîne lourde de formule

FR₅-Thr-Tyr-Ala-Met-Ala-Trp-Val-FR₆-Ser-Ser-Gly-Gly-Thr-Thr-Tyr-Tyr-Pro-
 └────────── CDR1H ─────────┘ └──┘
 Asp-Ser-Val-Lys-Gly-FR₇-Gly-Phe-Tyr-Asp-Gly-Tyr-Leu-Tyr-Val-Val-FR₈
 └── CDR2H ──┘ └────────── CDR3H ─────────┘

(II).

- dans lequel FR₅ est un résidu polypeptide comprenant 32-36 acides aminés naturels, FR₆ est un résidu polypeptide comprenant 14-16 acides aminés naturels, FR₇ est un résidu polypeptide comprenant 32-34 acides aminés naturels et FR₈ est un résidu polypeptide comprenant 12-14 acides aminés naturels, et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.
8. Procédé selon l'une quelconque des revendications 1-7 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne lourde de formule II, où les résidus polypeptides des régions d'ossature FR₅, FR₆, FR₇ et FR₈ sont celles que l'on trouve de préférence dans les anticorps murins.
9. Procédé selon l'une quelconque des revendications 1-8 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne lourde de formule II, où FR₅ est un résidu polypeptide de formule

B-Gly-Val-Gln-Cys-Glu-Val-Lys-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-
Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-
Thr-Phe-Arg

(IIA),

où B est un hydrogène ou un acyle,
FR₆ est le résidu polypeptide

Arg-Gln-Thr-Pro-Glu-Lys-Arg-Leu-Glu-Trp-Val-Thr-Ser-Ile

(IIB),

FR₇ est le résidu polypeptide

Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Arg-Asn-Ile-Leu-Tyr-
Leu-Gln-Val-Ser-Ser-Leu-Arg-Ser-Glu-Asp-Thr-Ala-Ile-Tyr-Tyr-Cys-
Ala-Arg

(IIC),

et FR₈ est le résidu polypeptide

Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Ser-Leu-Thr-Val-Ser-Ser

(IID),

et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

10. Procédé selon la revendication 7 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions variables à chaîne lourde de formule II dans laquelle FR₅, FR₆, FR₇ et FR₈ sont des résidus polypeptides de formules IIA, IIB, IIC et IID, respectivement, où un ou plusieurs acides aminés isolés sont remplacés par d'autres acides aminés en dehors des régions CDR1H, CDR2H et CDR3H et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S.

11. Procédé selon l'une quelconque des revendications 1-10 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions constantes humaines à chaîne légère α ou λ .

12. Procédé selon l'une quelconque des revendications 1-11 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions constantes humaines à chaîne lourde γ 1, γ 2, γ 3 ou γ 4.

13. Procédé selon l'une quelconque des revendications 1-12 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés comprenant des régions constantes humaines à chaîne légère et des régions constantes humaines à chaîne lourde γ 4;

14. Procédé selon l'une quelconque des revendications 1-13 pour la préparation d'un anticorps monoclonal chimérique et ses dérivés avec des régions variables à chaîne légère de formule I dans laquelle FR₁, FR₂, FR₃ et FR₄ sont des résidus polypeptides de formules IA, IB, IC et ID, respectivement et où

l'acide aminé cys peut être à l'état oxydé formant des ponts S-S, une région constante humaine à chaîne légère χ , une région variable à chaîne lourde de formule II dans laquelle FR₅, FR₆, FR₇ et FR₈ sont des résidus polypeptides de formule IIA, IIB, IIC et IID, respectivement et où l'acide aminé cys peut être à l'état oxydé formant des ponts S-S et une région constante humaine à chaîne lourde γ 4.

5

15. Procédé selon l'une quelconque des revendications 1-14 pour la préparation d'un dérivé d'un anticorps monoclonal chimérique, caractérisé en ce que l'anticorps monoclonal est clivé de façon enzymatique ou chimique en un fragment.

10

16. Procédé selon l'une quelconque des revendications 1-14 pour la préparation d'un dérivé d'un anticorps monoclonal chimérique, caractérisé en ce que l'anticorps monoclonal est conjugué avec une enzyme, un marqueur de fluorescence, un chélate métallique, une substance cytostatique ou cytotoxique, l'avidine ou la biotine.

15

17. Procédé selon l'une quelconque des revendications 1-14 pour la préparation d'un dérivé d'un anticorps monoclonal chimérique, caractérisé en ce que l'anticorps monoclonal est radioactivement marqué.

20

18. Procédé de préparation d'un ADN recombinant comprenant un insert codant pour une région variable murine à chaîne légère et/ou pour une région variable murine à chaîne lourde d'anticorps monoclonaux chimériques préparés selon la revendication 1, caractérisé en ce que ledit procédé comprend la culture d'un hôte transformé.

25

19. Procédé selon la revendication 18 de préparation d'un ADN recombinant, caractérisé en ce que ledit procédé comprend les étapes de

a) isolement d'ADN murins provenant d'une lignée cellulaire d'hybridome appropriée, sélection des ADN désirés codant pour les régions variables des anticorps monoclonaux dirigés contre le CEA humain en utilisant des sondes d'ADN,

b) isolement des ADN humains à partir d'une bibliothèque génomique, sélection des ADN désirés codant pour les régions constantes des anticorps monoclonaux en utilisant des sondes d'ADN,

30

c) construction de gènes murins/humains chimériques par incorporation des ADN des étapes a) et

b) dans des vecteurs hybrides appropriés,

d) transfert des vecteurs hybrides obtenus chez un hôte récepteur, et

e) sélection et culture de l'hôte transformé.

35

20. Procédé selon la revendication 18 ou 19 pour la préparation d'un ADN recombinant comprenant un insert codant pur une région variable murine à chaîne légère spécifique du CEA humain qui provient de l'ADN génomique de la lignée cellulaire CE 25, ayant le numéro d'accès au dépôt CNCM I-719.

40

21. Procédé selon la revendication 18, 19 ou 20, de préparation d'un ADN recombinant comprenant un insert codant pour le polypeptide de formule I, contenant facultativement des introns.

45

22. Procédé selon l'une quelconque des revendications 18-21, de préparation d'un ADN recombinant comprenant un insert codant pour le polypeptide de formule I dans lequel FR₁, FR₂, FR₃ et FR₄ sont des polypeptides de formule IA, IB, IC et ID, respectivement, contenant facultativement des introns.

50

23. Procédé selon l'une quelconque des revendications 18-22 de préparation d'un ADN recombinant comprenant un insert de formule

55

TCTAGACTGCTGTGGTCTTTTAAGTAGCATGAAAAACATCTGCTAAAGAAGGAATTAGTT
 1 -----+-----+-----+-----+-----+-----+ 60
 TGAACATGCTAGAAATACATCTGTGATACTCTCATCACTCTTGTTGGAAAGATATGCAAG
 5 61 -----+-----+-----+-----+-----+-----+ 120
 AAGCACTATTTGGCTATTATTTGCAAAGTGCTATAATGTATTTTGATATCTCAACCTCTG
 121 -----+-----+-----+-----+-----+-----+ 180
 AAATTCTTCTGTATGTTGGCAGATTGTAAACCTTTACAAGGCTTTTCATTCTCTTCTCTGG
 10 181 -----+-----+-----+-----+-----+-----+ 240
 AGAAAAATGCTTTTGTAGGCAATCCAGAATTTCTTATTTCTTGCTAATGAAATCTCCTCA
 241 -----+-----+-----+-----+-----+-----+ 200
 GTGTGATATCACTTTAGTTTTCATGTGTTGTTATGCTTCATGTAATGTTAAGAAAGTTAAA
 15 301 -----+-----+-----+-----+-----+-----+ 360
 GATGCTCCAATCCATATTGTAAGAAACATTCCAAGCCATGGAATAAGGCATGGATTTGAG
 361 -----+-----+-----+-----+-----+-----+ 420
 ATGCTCTTTATTTCAAACACTACTGAATATACTTAGAGATTTCTTTAGACTGTGTTAAATA
 20 421 -----+-----+-----+-----+-----+-----+ 480
 TGTAACCATTTAAGTAGGAGTCAAGTCTCCTTTAAATCTCAACAGCTCTTCAGGTAACCA
 481 -----+-----+-----+-----+-----+-----+ 540
 ACAAAGGATAAATATTCTAATAAGTCACTAGGAGCATGCTCTTCTGACCAGGTCTTTCT
 25 541 -----+-----+-----+-----+-----+-----+ 600
 TATAAGCAACATGAAGACAGTATGATTTGCATAAGTTTTCTTTCTTCTAATGTCCCTGC
 601 -----+-----+-----+-----+-----+-----+ 660
 CTCTTAGAGTATTATAAGAAGATCTTTCTAGGGATGTGTGTCATGGTCCACACAAAAATAGG
 30 661 -----+-----+-----+-----+-----+-----+ 720

 M V S T P Q F L V F L L F W I P
 MetValSerThrProGlnPheLeuValPheLeuLeuPheTrpIlePro
 GAAAGTGTGAAGATGGTATCCACACCTCAGTTCCTTGTATTTTGGCTTTTCTGGATTCCA
 35 721 -----+-----+-----+-----+-----+-----+ 780
 GGTAATGACTGTTTGGGTGTGGCAAAAAGTGGAGATGTTATTTAAATACAAAATTTTCT
 781 -----+-----+-----+-----+-----+-----+ 840
 TGCTTTATTTGGAAGCCAATGTCACATGGGAATTGACTTTTCAGTTTAAAGAAATTGATAC
 40 841 -----+-----+-----+-----+-----+-----+ 900
 AATAAAAGTCATTTATTTTCTAAGTTGTTTAGAAGTGAATTCATATTCAGTGTTATGA
 901 -----+-----+-----+-----+-----+-----+ 960

 A S R G D I L L T Q S
 AlaSerArgGlyAspIleLeuLeuThrGlnSer
 TCGACTAATGTATCTTCCATTTTTCCAGCCTCCAGAGGTGACATCTTGCTGACTCAGTCT
 45 961 -----+-----+-----+-----+-----+-----+ 1020

 P A I L S V S P G E R V T F S C R A S Q
 ProAlaIleLeuSerValSerProGlyGluArgValThrPheSerCysArgAlaSerGln
 50 CCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCACTTTCTCCTGCAGGGCCAGTCAG
 1021 -----+-----+-----+-----+-----+-----+ 1080

S I G T S L H W Y Q Q R T N G S P R L L
 SerIleGlyThrSerLeuHisTrpTyrGlnGlnArgThrAsnGlySerProArgLeuLeu
 AGCATTGGCACAAGCTTACACTGGTATCAGCAAAGAACAAATGGTTCTCCAAGGCTTCTC
 1081 -----+-----+-----+-----+-----+-----+ 1140
 5 M K Y A S E S I S G I P S R F S G S G S
 MetLysTyrAlaSerGluSerIleSerGlyIleProSerArgPheSerGlySerGlySer
 ATGAAGTATGCTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTGGATCA
 1141 -----+-----+-----+-----+-----+-----+ 1200
 10 G T D F T L T I N S V E S E D I A D Y Y
 GlyThrAspPheThrLeuThrIleAsnSerValGluSerGluAspIleAlaAspTyrTyr
 GGGACAGATTTTACTCTTACCATCAATAGTGTGGAGTCTGAAGATATTGCAGATTATTAC
 1201 -----+-----+-----+-----+-----+-----+ 1260
 15 C Q Q S H G W P F T F G S G T K L E I K
 CysGlnGlnSerHisGlyTrpProPheThrPheGlySerGlyThrLysLeuGluIleLys
 TGTCAACAAAGTCATGGCTGGCCATTACGTTTCGGCTCGGGGACAAAGTTGGAAATAAAA
 1261 -----+-----+-----+-----+-----+-----+ 1320
 CGTAAGTGGACTTTTGTTCATTTACTTGTGACGTTTTGGTTCTGTTTGGGTAGCTTGTGT
 20 1321 -----+-----+-----+-----+-----+-----+ 1380
 GAATTTGTGATATTT
 1381 -----+----- 1395
 (III).

25

24. Procédé selon la revendication 21 de préparation d'un ADN recombinant comprenant un insert de
 formule III dans lequel un ou plusieurs nucléotides isolés sont remplacés par d'autres nucléotides en
 dehors des séquences de nucléotides de formule III à partir des positions 1069-1102, 1147-1167 et
 1263-1291, respectivement.

30

25. Procédé selon la revendication 18 de préparation d'un ADN recombinant comprenant un insert codant
 pour une région variable murine à chaîne lourde spécifique du CEA humain qui provient de l'ADN
 génomique de la lignée cellulaire CE 25, ayant le numéro d'accès au dépôt CNCM I-719.

35

26. Procédé selon la revendication 18 ou 25, de préparation d'un ADN recombinant comprenant un insert
 codant pour le polypeptide de formule II, contenant facultativement des introns.

27. Procédé selon la revendication 18, 25 ou 26 de préparation d'un ADN recombinant comprenant un
 insert codant pour le polypeptide de formule II dans laquelle FR₅, FR₆, FR₇ et FR₈ sont des résidus
 polypeptides de formule IIA, IIB, IIC et IID, respectivement, contenant facultativement des introns.

40

28. Procédé selon l'une quelconque des revendications 18,25-27 de préparation d'un ADN recombinant
 comprenant un insert de formule

45

50

55

```

AAGCTTGTTCCTGTTACATGCAAGGAGGGAACTAACTGAGTATGGTGAATCCCTAACC
1  -----+-----+-----+-----+-----+-----+ 60
AAAGGGAAAAAATGAAACTACAATATGTTTCAAATGCTGTAAGTGAATCTGGTTTTTTTG
5  61  -----+-----+-----+-----+-----+-----+ 120
ATGCCTTATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACCCAGAGCATGGTAT
121 -----+-----+-----+-----+-----+-----+ 180
AGCAGGAAGACATGCAAATAAGTCTTCTCTCTGCCCATGAAAACACCTCGGGCCCTGACCC
10 181 -----+-----+-----+-----+-----+-----+ 240
TGCAGCTCTGACAGAGGAGGCCAGTCCATGGATTTGAGTTCCTCACATTCAGTGATGAGC
241 -----+-----+-----+-----+-----+-----+ 300

          M N F G F S L I F L V L V
          MetAsnPheGlyPheSerLeuIlePheLeuValLeuVal
15  ACTGAACACAGACACCTCACCATGAACTTCGGGTTTCAGCTTGATTTTCCTTGTCCTTGTT
301 -----+-----+-----+-----+-----+-----+ 360

L K G
LeuLysGly
20  TTAAGGTAATTTATTGAGAAGAGATGACATCTATTTTACGCACATGAGACAGAAAAAA
361 -----+-----+-----+-----+-----+-----+ 420

          V Q
          ValG1
25  TGTGGTTTGTGTTTGTAGTGACAGTTTTCCAACCAGTTATTCTCTGTTTGTAGGTGTCCA
421 -----+-----+-----+-----+-----+-----+ 480

C E V K L V E S G G G L V K P G G S L K
nCysGluValLysLeuValGluSerGlyGlyGlyLeuValLysProGlyGlySerLeuLy
30  GTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTCAA
481 -----+-----+-----+-----+-----+-----+ 540

```

35

40

45

50

55

```

      L S C A A S G F T F R T Y A M A W V R Q
sLeuSerCysAlaAlaSerGlyPheThrPheArgThrTyrAlaMetAlaTrpValArgGl
ACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGGACCTATGCCATGGCTTGGGTTGCGCA
5 541 -----+-----+-----+-----+-----+-----+-----+ 600

      T P E K R L E W V T S I S S G G T T Y Y
nThrProGluLysArgLeuGluTrpValThrSerIleSerSerGlyGlyThrThrTyrTy
GACTCCAGAGAAGAGGCTGGAGTGGGTCACATCCATTAGTAGTGGTGGTACCACCTACTA
601 -----+-----+-----+-----+-----+-----+-----+ 660

      P D S V K G R F T I S R D N A R N I L Y
rProAspSerValLysGlyArgPheThrIleSerArgAspAsnAlaArgAsnIleLeuTy
TCCAGACAGTGTGAAGGGCCGATTACCATCTCCAGAGATAATGCCAGGAACATCCTGTA
661 -----+-----+-----+-----+-----+-----+-----+ 720

      L Q V S S L R S E D T A I Y Y C A R G F
rLeuGlnValSerSerLeuArgSerGluAspThrAlaIleTyrTyrCysAlaArgGlyPh
CCTGCAAGTGAGCAGTCTGAGGTCTGAGGACACGGCCATTTATTACTGTGCAAGAGCTTT
721 -----+-----+-----+-----+-----+-----+-----+ 780

      Y D G Y L Y V V D Y W G Q G T S L T V S
eTyrAspGlyTyrLeuTyrValValAspTyrTrpGlyGlnGlyThrSerLeuThrValSe
CTATGATGGTTACCTCTATGTTGTGGACTACTGGGGTCAAGGAACCTCACTCACCGTCTC
781 -----+-----+-----+-----+-----+-----+-----+ 840

      S
rSer
CTCAGGTAAGAATGGCC
841 -----+-----+-----+-----+-----+-----+ 857

```

(IV).

29. Procédé selon la revendication 26 de préparation d'un ADN recombinant comprenant un insert de
 35 formule IV dans lequel un ou plusieurs nucléotides isolés sont remplacés par d'autres nucléotides en
 dehors des séquences de nucléotides de formule IV à partir des positions 575-595, 629-680 et 776-
 805, respectivement.
30. Procédé selon la revendication 18 de préparation d'un ADN recombinant comprenant un insert codant
 40 pour une région variable murine à chaîne légère fusionnée à une région constante humaine α ou λ .
31. Procédé selon la revendication 30 de préparation d'un ADN recombinant comprenant un insert de
 formule III fusionné à une région constante humaine α .
- 45 32. Procédé selon la revendication 18 de préparation d'un ADN recombinant comprenant un insert codant
 pour une région variable murine à chaîne lourde fusionnée à une région constante humaine $\gamma 1$, $\gamma 2$, $\gamma 3$,
 ou $\gamma 4$.
33. Procédé selon la revendication 32 de préparation d'un ADN recombinant comprenant un insert de
 50 formule IV fusionné à une région constante humaine $\gamma 4$.
34. Procédé selon la revendication 18 de préparation d'un ADN recombinant qui est un vecteur hybride
 comprenant un insert codant pour une chaîne légère murine/humaine chimérique préparé par un
 procédé selon la revendication 31, et/ou une chaîne lourde murine/humaine chimérique préparée par un
 55 procédé selon la revendication 33, un réplicon complet et une ou plusieurs séquences marqueuses
 dominantes, liées de façon opératoire à des séquences de commande d'expression.

35. Procédé selon la revendication 18 de préparation d'un ADN recombinant qui est un vecteur hybride comprenant un insert codant pour une chaîne légère murine/humaine chimérique préparée par un procédé selon la revendication 32 et/ou une chaîne lourde murine/humaine chimérique préparée par un procédé selon la revendication 34, un réplicon complet et une ou plusieurs séquences marqueuses dominantes, liées de façon opératoire à des séquences de commande d'expression.
36. Procédé selon la revendication 34 ou 35 de préparation d'un ADN recombinant qui est un vecteur hybride approprié à des hôtes mammifères.
37. Procédé selon la revendication 34, 35 ou 36 de préparation d'un ADN recombinant qui est un vecteur hybride dans lequel le vecteur est dérivé du plasmide pSV.
38. Procédé selon la revendication 37 pour la préparation d'un ADN recombinant qui est un vecteur hybride dans lequel le vecteur est dérivé du plasmide pSV2gpt ou du plasmide pSV2neo.
39. Cellule hôte qui est transformée avec les ADN recombinants préparés par un procédé selon l'une quelconque des revendications 30-38.
40. Cellule hôte selon la revendication 39, qui est une cellule de mammifère d'origine lymphoïde.
41. Cellule hôte selon la revendication 39, qui est une cellule dérivée de la lignée cellulaire d'hybridome de souris non-sécrétante d'Ig Sp2/0 (ATCC CRL 1581)
42. Cellule hôte selon la revendication 39 ou 41 qui est transformée avec un ou deux vecteurs préparés par l'un des procédés selon les revendications 35-38.
43. Cellule hôte selon la revendication 42 qui est une cellule de la lignée cellulaire EFVIII/γ4Na75-75/CxGa5-6 (CE 75-5-6), ayant le numéro d'accès au dépôt CNCM I-719.
44. Cellule hôte selon la revendication 42 qui est une cellule de la lignée cellulaire EFIX-pCEA-Ig-(γ4;Cx) (CE 4-8-13), ayant le numéro d'accès au dépôt CNCM I-818.
45. Cellule hôte selon la revendication 39, caractérisée en ce qu'elle sécrète des anticorps monoclonaux chimériques préparés par un procédé selon la revendication 1.
46. Procédé de préparation d'une cellule hôte selon la revendication 39 ou 45, caractérisé en ce qu'on transforme une cellule appropriée avec un ou deux vecteurs par électroporation, traitement au calcium, microinjection ou fusion de protoplaste.
47. Procédé de préparation d'une composition pharmaceutique contenant un anticorps monoclonal chimérique et ses dérivés préparé par un procédé selon la revendication 1, caractérisé en ce qu'on mélange l'anticorps monoclonal avec un support pharmaceutique.

FIGURE 1A




FIGURE 1B




FIGURE 2




FIGURE 3




FIGURE 4




Figure 5




Figure 6





Figure 7

REGISTER ENTRY FOR EP0323806

European Application No EP88810898.2 filing date 28.12.1988

Priorities claimed:

05.01.1988 in United Kingdom - doc: 8800077

24.08.1988 in United Kingdom - doc: 8820099

Designated States BE CH DE ES FR GB GR IT LI LU NL SE AT

Title NOVEL CHIMERIC ANTIBODIES.

Applicant/Proprietor

CIBA-GEIGY AG, Klybeckstrasse 141, CH-4002 Basel, Switzerland

[ADP No. 50706951002]

Inventors

DR. NORMAN HARDMAN, Gstaltenrainweg 67/3, CH-4125 Riehen, Switzerland

[ADP No. 56682032001]

DR. LAURA LEE GILL, Gstaltenrainweg 67, CH-4125 Riehen, Switzerland

[ADP No. 56682040001]

DR. RONALD F.J. DE WINTER, Holly Tree Cottage Flewton End, Milton Ernest
Bedfordshire, United Kingdom

[ADP No. 56682057001]

KATHRIN WAGNER, Sundgauerstrasse 12, CH-4055 Basle, Switzerland

[ADP No. 56682065001]

DR. CHRISTOPH HEUSSER, Im Bertschenacker 21, CH-4103 Bottmingen,
Switzerland

[ADP No. 53594586001]

Classified to

C12N A61K C12P G01N

Address for Service

CIBA-GEIGY PLC, Patent Department, Central Research, Hulley Road,
MACCLESFIELD, Cheshire, SK10 2NX, United Kingdom

[ADP No. 00000521002]

Publication No EP0323806 dated 12.07.1989

Publication in English

Examination requested 30.12.1988

Patent Granted with effect from 17.03.1993 (Section 25(1)) with title NOVEL
CHIMERIC ANTIBODIES.

06.07.1989 A publication Title truncated by UK Office - for full Title see EPO
Bulletin.

Entry Type 10.1 Staff ID. TH1 Auth ID. EO

18.07.1989 THE APPLICANT HAS FILED A STATEMENT IN ACCORDANCE WITH RULE 28(4)
EPC (ISSUE OF A SAMPLE ONLY TO AN EXPERT). ACCESSION NUMBER(S) OF
THE DEPOSIT(S): 1-720 AND 1-818.

Entry Type 10.1 Staff ID. TH1 Auth ID. EO

04.01.1993 CIBA-GEIGY PLC, Patent Department, Central Research, Hulley Road,
MACCLESFIELD, Cheshire, SK10 2NX, United Kingdom
[ADP No. 00000521002]
registered as address for service
Entry Type 8.11 Staff ID. SS1 Auth ID. AA

15.02.1993 Notification from EPO of change of Inventor details from
DR. NORMAN HARDMAN, Gstaltnrainweg 67/3, CH-4125 Riehen,
Switzerland [ADP No. 56682032001]

DR. LAURA LEE GILL, Gstaltnrainweg 67, CH-4125 Riehen, Switzerland
[ADP No. 56682040001]

DR. RONALD F.J. DE WINTER, Holly Tree Cottage Flewton End, Milton
Ernest Bedfordshire, United Kingdom [ADP No. 56682057001]

KATHRIN WAGNER, Sundgauerstrasse 12, CH-4055 Basle, Switzerland
[ADP No. 56682065001]

DR. CHRISTOPH HEUSSER, Im Bertschenacker 21, CH-4103 Bottmingen,
Switzerland [ADP No. 53594586001]
to

DR. NORMAN HARDMAN, Gstaltnrainweg 67/3, CH-4125 Riehen,
Switzerland [ADP No. 56682032001]

DR. LAURA LEE GILL, Gstaltnrainweg 67, CH-4125 Riehen, Switzerland
[ADP No. 56682040001]

DR. RONALD F.J. DE WINTER, Holly Tree Cottage, Flewton End, Milton
Ernest, Bedfordshire, United Kingdom [ADP No. 60681947001]

KATHRIN WAGNER, Sundgauerstr. 12, CH-4055 Basle, Switzerland
[ADP No. 60681954001]

DR. CHRISTOPH HEUSSER, Im Bertschenacker 21, CH-4103 Bottmingen,
Switzerland [ADP No. 53594586001]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

01/06/95 11:21:34
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER

EP0323806

PROPRIETOR(S)

CIBA-GEIGY AG, Klybeckstrasse 141, CH-4002 Basel, Switzerland

DATE FILED

28.12.1988

DATE GRANTED

17.03.1993

DATE NEXT RENEWAL DUE

28.12.1995

DATE NOT IN FORCE

DATE OF LAST RENEWAL

24.11.1994

YEAR OF LAST RENEWAL

07

STATUS

PATENT IN FORCE

**** END OF REPORT ****